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Expression, Purification and Characterisation of 
Protoporphyrinogen Oxidases from Diverse Species 
This work involved the characterisation of protoporphyrinogen oxidase (PPO), the penultimate 
enzyme in haem biosynthesis, from Bacillus subtilis, Myxococcus xanthus, and human. A defect 
in human PPO causes variegate porphyria, an autosomal dominant disorder characterised by skin 
photosensitivity and propensity towards acute neurovisceral crises. At the beginning of this 
project little information was available on the kinetic and biophysical properties of isolated PPOs 
due largely to difficulties associated with their purification from natural sources. 
Recombinant PPOs of B. subtilis, M xanthus and human, expressed in E. coli cells were purified 
to apparent homogeneity by a rapid metal chelate affmity chromatography procedure. These PPOs 
with subunit molecular weights ranging from 52000 to 54000 Da were shown to be F AD­
containing flavoproteins. Optimal oxidation of the substrate, protoporphyrinogen-IX by the B. 
subtilis and M xanthus PPOs occurred at pH 8.7 and 8.1, respectively. Whilst both the human 
and M xanthus PPOs were highly specific for protoporphyrinogen-IX as substrate, the B. subtilis 
enzyme utilised both mesoporphyrinogen-IX and coproporphyrinogen-III as well. The fatty acids, 
oleic and palmitic, stimulated M xanthus PPO activity, whereas the B. subtilis enzyme was 
inhibited. Inhibition studies enabled us to establish the inhibitor profiles of these PPOs. 
Acifluorfen and methylacifluorfen, which strongly inhibited both human and M xanthus PPOs 
were ineffective against the B. subtilis enzyme. Human PPO was weakly inhibited by hemin and 
biliverdin, which strongly inhibited both B. subtilis and M xanthus enzymes. At 100 J.lM bilirubin 
did not inhibit human and M xanthus PPOs, whilst approximately 95% inhibition of the B. 
subtilis enzyme was observed. This revealed interspecies differences in the behaviour of PPOs 
towards various compounds. In all cases effective inhibitors produced a competitive mode of 
inhibition with respect to protoporphyrinogen-IX. 
Phylogenetic analysis using 28 different PPO protein sequences was perf?rmed, and interesting 
divergences amongst the prokaryotic forms of this protein were revealed. Immunocharacterisation 
studies with a polyclonal antibody raised against human PPO were used to demonstrate the 
differential expression of PPO in various human tissues/organs. Immunogold labelling and 
electron microscopy studies on human hepatocytes confirmed predominant location of PPO in 
mitochondria and also demonstrated cytosolic forms of PPO in these cells. 
Kwanele Bennett Siziba 
MRC/UCT Liver Research Centre 
Department ofMedicine. UCT Medical School 











ABBREVIATIONS AND SYMBOLS 

g gram °c degrees centigrade 
mg milligram O.D. optical density 
~g microgram A absorbance 
ng nanogram kb kilobases 
L litre bp base pairs 
ml millilitre Da Daltons 
~l microlitre G centrifugal force 
M molar (moles/litre) rpm revolutions per minute 
mM millimolar vol volume 
~M micromolar a alpha 
nM nanomolar p beta 
nmol nanomole B delta 
N nonnality infinityct.) 
n number ofvalues used BSA bovine serum albumin 
sec second V volts 
min minute kV kilovolts 
h hour rnA milliAmperes 
cm centimetre W Watts 
mm millimetre Rf relative migration value 
mm3 cubic millimetre Me relative molecular weight 












SDS-PAGE Sodium dodecyl sulphate 
polyacrylamide gel electrophoresis 
FAD flavin adenine dinucleotide 
FMNflavin mononucleotide 
RFU relative fluorescence unit 
A angstrom 
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LB Luria-Bertani medium 
PBS Phosphate buffered saline 
EDT A Ethylenediethylaminetetra­
acetic acid 
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Haem is an iron-containing complex of protoporphyrin which associates with several 
proteins and is central to virtually all biological oxidations. In all living organisms 
haem is synthesised via a specific pathway involving a series of chemical reactions 
and modifications ofvarious porphyrin intermediates (see below). 
While this work is primarily concerned with detailed study of one specific protein, the 
penultimate enzyme of haem biosynthesis, protoporphyrinogen oxidase (PPO), this 
chapter serves to describe the context within which PPO can be viewed. It will cover 
general aspects of haem biosynthesis, the enzymes of haem biosynthesis and the 
porphyrias (especially variegate porphyria). PPO itself is reviewed in necessary detail 
in Chapter 2. 
Haem Biosynthetic Pathway 
Historical Background 
An historical perspective of the porphyrins nd haem biosynthesis allows some useful 
insight into the processes which have resulted in the development of knowledge in 
this area. The existence of porphyrins was first alluded to by Scherer in 1841 when he 
showed that iron was not responsible for the red colour of blood. He demonstrated the 
existence of the red colour following the washing away of precipitated iron from the 
solution. Similar demonstrations were done in experiments conducted by other 
researchers (Lecanu, 1837; Berzelius, 1840; Mulder, 1844). The substance 
responsible for the red colour was subsequently named "cruentine" by Thudichum 
(1867) who also defined its visible spectrum. The iron-free "purple-red fluid" 
described by Mulder (1844) in his experiments was later found by Hoppe-Seyler 
(1871) to consist mainly of a substance he called "hematoporphyrin". Hoppe-Seyler 
(1879) rediscovered the red fluorescence in his study of the porphyrin in chlorophyll, 
and he named it phylloporphyrin. The word porphyrin is derived from the Greek word 
porphuros, viz. purple. 
Schultz (1874) described a 33 year old patient suffering from skin photosensitivity 
from the age of three, who passed wine red urine. On investigation the urine was 
found to contain a pigment with a spectrum similar to that of hematoporphyrin 
(Baumstark, 1874). Importantly, in the interpretation of these findings Baumstark 
(1874) suggested that these urinary porphyrin pigments were originating from an 
"error of synthesis", a fact which was confirmed fifty years later. A dark pigment 
isolated from a rheumatic patient treated with salicylates was described by MacMunn 
(1880) and he named it "urohematin", and he later renamed it "urohematoporphyrin" 
because of its striking resemblance to haematoporphyrin (MacMunn, 1885). 
Subsequently, this pigment was found in association with several other diseases as 










2 Chapter I 
Nencki and Sieber (1888) showed that haematoporphyrin was a dicarboxylic 
porphyrin which could undergo esterification at carboxyl groups. Coproporphyin was 
first prepared from urine by Saillet (1896) and was named "urospectrine". This 
compound was later correctly named by Fischer and Zerweck (1924). Protoporphyrin 
was also identified around this time (Laidlaw, 1904). Subsequently, the correct 
tetrapyrrole structure of haem was proposed by Kuster (1912). However, at that time 
other scientists had reservations about the stability of such a large ring structure. The 
remarkable work by Fischer (1915) and other workers resulted in the differentiation of 
the natural haem from haematoporphyrin which was correctly named, protoporphyrin. 
The terminology used for the tetrapyrrole biosynthetic pathway intermediates, the 
porphyrins, was applied to the description of diseases of the haem pathway in 1937 ­
they became known as "the porphyrias" (Waldenstrom, 1937). 
The isolation of crystalline porphobilinogen (PBG) from the urine of acute 
intermittent porphyria patients was another important milestone in the understanding 
of this pathway (Westall, 1952). Cookson and Rimington (1954) elucidated the 
monopyrrole structure ofPBG. This compound (PBG) was shown to be enzymatically 
converted into uroporphyrinogen when incubated with chicken red cell haemolysate 
(Falk et aI, 1953). Attempts to study the tetrapyrrole biosynthetic pathway using 
uroporphyrin-III which had been prepared from turacin (a copper complex of 
uroporphyrin-III found in the feathers of a bird species, the Cape Loerie) by the 
removal of the bound copper ions were not successful (Rimington, 1939). The reasons 
for this only became clear when it was realised that the actual intermediate substrates 
of the tetrapyrrole pathway reactions were porphyrinogens, the reduced forms of 
porphyrins (Bogorad, 1955). 
Studies carried out in suitable animal models provided important information on the 
systematic biochemical description of the haem (tetrapyrrole) biosynthetic pathway. 
Various investigators studied the incorporation of radio labelled precursors at different 
steps of the pathway during the formation of the haem molecule. Initial studies 
described how CSN]glycine and C4C]glycine were incorporated into haem in humans 
and other animals (Shemin and Rittenberg, 1946; Shemin et aI, 1955; Gray, 1952; 
Grinstein et aI, 1950; Muir and Neuberger, 1950). Labelling studies with C4C]acetate 
(Shemin and Wittenberg, 1951) and in vitro experiments in avian erythrocyte 
preparations established that succinyl-CoA was the 4-carbon compound from the 
tricarboxylic acid cycle which provided some of the carbon atoms in the haem 
macrocycle (Gibson et aI, 1958). Subsequently, it was demonstrated that 5­
aminolaevulinic acid (ALA) was the committed precursor leading to the synthesis of 
all the porphyrin intermediates (Shemin and Russell, 1953; Neuberger and Scott, 
1953). During this same period it was shown that PBG is the monopyrrole precursor 
for all the tetrapyrrole synthesis in this pathway (Falk et aI, 1953). Thus, the porphyrin 
biosynthetic pathway was established by the mid-50's and was shown to be virtually 










Chapter J 3 
Structure and Chemistry of Porphyrins and Porphyrinogens 
The structural and physical chemistry of porphyrins is covered in several earlier 
reviews (Burnham, 1968; Marks, 1969; Adler, 1973; Smith, 1975; Dolphin, 1979; 
Meissner, 1990; Moore, 1990; McDonagh and Bissell, 1998). Essentially, porphyrins 
are tetrapyrroles which consist of four weakly aromatic pyrrole rings that are linked 
. by four methene bridges (-CH=). The four pyrrole rings have been designated A, B, 
C, and D, starting at the top and proceeding clockwise (figure 1.1) (Falk, 1964). 
The four methene bridges are designated a, B, y, and 0 in the same order as the rings 
(Fischer and Orth, 1934). The porphyrinogen macrocycle is a rigid planar structure 
with eight positions where substituents (side chains) can be attached. Irradiation of 
the porphyrins with ultraviolet light at a wavelength of approximately 400nm results 
in red fluorescence, indicating the high degree of conjugation of these macro cycles. 
This property of the porphyrins was first described for haemoglobin by Soret (1883), 
and this absorption band is referred to as the Soret band. The side chain substituents 
attached to the rings are important in determining the physical characteristics of the 
porphyrins. As biological intermediates, the porphyrins exist as the unconjugated, less 
stable reduced forms, the porphyrinogens. Oxidation of a porphyrinogen will produce 
the corresponding porphyrin. Porphyrinogens are relatively non-aromatic compounds, 
with less rigid structural properties (Smith, 1975), and they do not fluoresce under 
ultraviolet light. Indeed, the oxidation of protoporphyrinogen to protoporphyrin is 




Figure 1.1 The tetrapyrrole structure of porphyrins showing the four pyrrole rings joined by methene 
bridges. 
An important property of the porphyrin macrocyc1e is the availability of ligand 
binding sites. This gives these compounds the ability to bind metals; particularly iron 
to form haem, magnesium to form chlorophylls and cobalt to form vitamin B 12 via the 
corrins (Scott et aI, 1972; Battersby and McDonald, 1975; Jones, 1976; Bissell and 
Schmid, 1987). In all living organisms the porphyrin biosynthetic pathway leads to 










4 Chapter I 
mentioned in the introduction, haem (figure 1.2) associates with several proteins and 
is central to virtually all biological oxidations. Haem, by virtue of it's ferrous iron 
being coordinately bound within the tetrapyrrole ring, plays specific roles in oxygen 
binding, electron transport, reduction of oxygen and transfer of oxygen for 
hydroxylation reactions. 
These roles are in turn determined by the structure of the protein moiety of each 
specific haemoprotein, their substrates, and the intracellular milieu within which it 
functions (Bottomley and Muller-Eberhard, 1988). Chlorophylls, on the other hand, 
(figure 1.3) are magnesium-porphyrin complexes which are central in the utilisation 





Figure 1.2 The tetrapyrrole structure of the haem molecu/~showing the ferrous iron (Fe +) in the 













Figure 1.3 The structure ofchlorophyll at with the magnesium ion in the centre of the tetrapyrrole ring. 











Chapter 1 5 
Enzymology of Haem Biosynthesis 
Haem biosynthesis can be viewed in the most general terms as consisting of a series 
of "pyrrolic" chemical reactions and modifications catalysed and linked by the so­
called haem biosynthetic enzymes, forming an irreversible, unbranched metabolic 
pathway. The enzymes of the pathway are located sequentially in the mitochondria, 
cytoplasm, and finally mitochondria (Dailey, 1990). The synthesis of chlorophyll on 
the other hand occurs exclusively within the plastids (Beale and Wenstein, 1990) as 
demonstrated by the experiments which showed the synthesis of chlorophyll in 
isolated chloroplasts from [14C]ALA or [14C]glutamate (Fuesler et ai, 1984; Gomez­
Silva et ai, 1985; Huang and Castelfranco, 1988). 
In a wide variety of organisms the sequence of reactions in this pathway is highly 
conserved after the initial reactions leading to ALA synthesis (figure 1.4) (Jordan, 
1990). Both photosynthetic and non-photosynthetic organisms share a common 
pathway and generally have identical enzymes from ALA to the formation of 
protoporphyrin-IX. In animals ALA, the first committed precursor, is synthesized in a 
single reaction from glycine and succinyl-CoA by the mitochondrial matrix enzyme 
ALA synthase [E.C. 2.3.1.37]. In plants and some algae ALA is synthesized from the 
intact carbon skeleton of glutamate in three sequential enzymic steps via what is 
referred to as the Cs pathway (Beale and Castelfranco, 1974a; Gough et aI, 1976; Oh­
hama et ai, 1982; Porra et ai, 1983; Wang et ai, 1981; Kannangara et ai, 1988). 
The enzymic description of the haem biosynthetic pathway drew much interest when 
in the mid-50's Goldberg et al (1956) described ferrochelatase, the enzyme which 
catalyses the incorporation of ferrous iron into the protoporphyrin macro cycle to form 
protohaem. PPO, which catalyses the penultimate step in the haem synthesis pathway, 
was the last enzyme of the pathway to be described (Jackson et aI, 1974; Poulson and 
Polglase, 1975) and it is the least characterised of these enzymes, motivating, at least 
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scoli PORPHYRINOGEN·III 6C01i PORPHYRINOGEN·III 7COli PORPHYRINOGEN-lil 
Figure 1.4 Haem biosynthesis involves eight enzyme catalysed "pyrrolic" reactions which are located 
sequentially, in the mitochondria, cytosol and finally mitochondria. M =methyl (-CHa), V =vinyl (­
CH=CH21, P =propionate (-CH2CH2COOH), and A = acetate (-OCHJJ. 1: ALA Synthase; 2: ALA 
Dehydratase; 3: PSG Deaminase; 4: Uroporphyrinogen Cosynthase; 5: Uroporphyrinogen 










7 Chapter 1 
1. ALA Synthase [EC2.3. 1.37] 
The first reaction of the haem biosynthesis pathway takes place in the mitochondrion. 
This involves the condensation of succinyl-CoA and glycine to form 5­
aminolaevulinic acid (ALA) (151 reaction, figure 1.4), and is considered the rate­
controlling step of the pathway (Gibson et aI, 1958; Kikuchi et al, 1958a, b; Granick, 
1963; Kappas et aI, 1989). 
This reaction is catalysed by the enzyme ALA synthase which is loosely bound to the 
inner mitochondrial membrane (McKay et aI, 1969). In some early studies small 
amounts of this enzyme were found in the cytosol and were presumed to be newly 
synthesized protein destined for mitochondrial import (Hayashi et aI, 1969; Patton 
and Beattie, 1973). Studies following this showed that the ALA synthase protein is 
encoded by nuclear DNA and synthesized in cytoplasmic ribosomes as a larger 
precursor protein before its final insertion into the mitochondrial membrane. There it 
is located as a modified smaller mature protein (Hayashi et aI, 1970, 1976; 1983; 
Whiting and Elliott, 1972; Yamauchi et aI, 1980; Borthwick et aI, 1985; Urban­
Grimal et aI, 1986). Studies carried out on mitoplasts using specific enzyme markers, 
and in vitro investigations of the rat enzyme showed existence of this protein in the 
mitochondrial matrix (Scotto et aI, 1983). 
This protein has been purified from several sources including Rhodobacter 
sphaeroides (Warnick and Burnham, 1971); rat liver (Ohashi and Kikuchi, 1979); 
chicken liver (Borthwick et aI, 1983); Euglena gracilis (Dzelzkalns et aI, 1982) and 
yeast (Volland and Felix, 1984). The isolated proteins exist as homodimers with 
subunit molecular weights ranging from 40 000 to 70 000 Da, although it is now 
accepted that the mature mitochondrial forms of human erythroid and housekeeping 
ALA synthases have molecular weights of 59 500 Da and 64 600 Da, respectively 
(Cox et aI, 1991). 
This enzyme requires pyridoxal phosphate as an essential cofactor for actiVIty 
(Granick and Sassa, 1971, Jordan and Shemin, 1972). The proposed mechanism of 
action is that glycine, bound through pyridoxal phosphate as a stable Schiff-base 
carbanion on the enzyme surface, can react with the electrophilic carbonyl group of 
succinyl CoA to produce an a-amino-p-keto adipic acid with the release of coenzyme 
A, which is then de carboxylated to ALA (Moore et aI, 1987). Studies on the mouse 
enzyme have demonstrated a Schiff base linkage between the pyridoxal phosphate 
cofactor and a lysine residue (Lys-313) in the protein (Ferreira et aI, 1993). Site­
directed studies revealed that this lysine residue was essential for catalytic activity of 
the enzyme, and mutant proteins were shown to be able to bind the pyridoxal 
phosphate cofactor, although this binding was found to be non-covalent (Ferreira et 
aI, 1995). 
Application of molecular biology techniques has resulted in the cloning and 
sequencing of ALA synthase genes from several sources which include chick liver 
(Borthwick et aI, 1985; Maguire et aI, 1986; Yamamoto et aI, 1985); yeast 
(Saccharomyces cerevisiae) (Urban-Grimal et aI, 1986); human liver (Bawden et aI, 
1987); mouse (Schoenhaut and Curtis, 1986); B. japonicum (McClung et aI, 1987); E. 
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(Elliott, 1989); Aspergillus nidulans (Bradshaw et al, 1993); rat liver (Yomogida et ai, 
1993); Rhodobacter sphaeroides (Neidle and Kaplan, 1993) and Chlorobium 
virbrioforme (Majumdar et al, 1991). Interestingly, comparison of the primary 
sequences of the human with the rat and chicken sequences revealed 83% and 87% 
similarities, respectively, but only 43% similarity with the mouse sequence (Jordan, 
1990). The cDNA encoding the human enzyme had an N-terminalleader sequence of 
56 amino acids (Bawden et ai, 1987). 
It is now recognised that there are two separate genes encoding ALA synthase. There 
is an ubiquitously expressed "housekeeping" (nonerythroid) isoenzyme (ALA-Sl) and 
an erythroid-specific isoenzyme (ALA-S2) (Riddle et al 1989; Bishop, 1990; Cox et 
aI, 1992; Conboy et al, 1992). Although the ALA-Sl and ALA-S2 isoforms share 
over 50% amino acid identity, they are localized to chromosomes 3p21 and Xpl1.21, 
respectively (Bishop et aI, 1990). 
It was proposed that the reduced activity of ALAS2 in X-linked sideroblastic anaemia 
could be due to mutations in the erythroid-specific ALA synthase (ALAS2) gene 
(Bishop et aI, 1990). Indeed, this was confirmed in a patient with X-linked 
sideroblastic anaemia by the identification of a T>A transition (codon 4711exon 9, a 
" highly conserved region) causing an Ile>Asn substitution which interrupted 
contiguous hydrophobic residues (Cotter et ai, 1992). The amino acid substitution was 
apparently in the putative pyridoxal 5' -phosphate binding site and structural 
prediction suggested that it caused a transformation of beta-sheet structure into 
random-coil structure. The mutant construct expressed in prokaryotic cells Was shown 
to have low levels of enzymatic activity which required higher concentrations of 
pyridoxal phosphate to reach maximal activity compared to the normal enzyme. A 
number of mutations have been identified in the ALAS2 gene of different patients 
with pyridoxine-responsive, X-linked sideroblastic anaemia (Cotter et ai, 1994, 1995; 
1999, Edgar et aI, 1997, 1998; Edgar and Wickramasinghe, 1998; Furuyama et aI, 
1997,1998; Harigae et ai, 1999a, and 1999b). Addition of pyridoxal 5'-phosphate in 
vitro to the purified mutant recombinant enzymes caused their activation and/or 
stabilisation, a fact consistent with the observed pyridoxine-responsive sideroblastic 
anaemia in vivo (Cotter et aI, 1995). 
The synthesis of ALA in plants, algae and some photosynthetic bacteria occurs by a 
different pathway involving the carbon skeleton of glutamate (Beale and Castelfranco, 
1974a; Beale et aI, 1975). This reaction occurs via the formation of an intermediate, 
glutamate I-semialdehyde which is transformed into ALA by an aminotransferase 
(Houen et ai, 1984) (figure 1.5). It has been proposed that in plant systems glutamate 
I-semialdehyde undergoes transformation into another intermediate; 4,5­
dioxovalerate (DOVA) before the final formation of ALA (Beale et ai, 1975; Breu et 
aI, 1988; Breu and Dornemann, 1988). This intermediate (which has also been found 
in bovine liver extracts (Varticovski et ai, 1980)) is converted by the enzyme 4,5­
DOV A transaminase into ALA (Morton et aI, 1981). The three enzymes involved in 
transforming glutamate into ALA have been characterised, and they are glutamate­
tRNA ligase (Bruyant and Kannangara, 1987), NADPH-dependent enzyme (Houen et 
aI, 1984), and glutamate I-semialdehyde aminotransferase (Hoober et ai, 1988). It is 
widely accepted that the primary mechanism of regulation of haem synthesis IS 
























Figure 1.5 Formation of aminolaevulinic acid in plants and green algae showing the various reactions 
and intermediate products. 
Regulation of Haem Biosynthesis in Non-erythroid and Erythroid 
tissue 
Haem synthesis is nonnally an extremely efficient, tightly controlled process; efficient 
because less than 2.5% of the ALA entering the pathway is lost (Elder, 1982) and 
tightly controlled because the amount of haem produced closely matches the needs of 
the body. This implies that enzymes involved in haem synthesis are nonnally able to 
use all of the substrate presented to them, that they can handle an increased flux 
through the pathway, and that the pathway may be subject to some fonn of 
"feedback" control. Indeed, there is much evidence to suggest that, at least in the liver 
and all non erythroid tissue, haem itself modulates its own rate of production, 
principally at the level of ALA synthase, which is considered the rate-detennining 
enzyme of the pathway. This tight regulation of liver cell haem occurs by several 
mechanisms. 
First, haem regulates it's own synthesis by controlling the amount of ALA-S1 mRNA. 
In mammalian systems this occurs primarily at the transcriptional level (Srivastava et 
aI, 1988; Yamamoto et aI, 1988) but studies in avian systems suggest the effect may 
also be on mRNA stability (Drew and Ades, 1989; Hamilton et aI, 1991). The haIf­
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life of the protein in mitochondria is even shorter (Kikuchi and Hayashi, 1981). This 
is an important mechanism as many, but not all drugs, that induce cytochrome P 450 
activity also induce transcription of ALA-S1 in mammalian systems. It is suggested 
that this may be via haem depletion that would accompany the synthesis of P450 
haemoprotein. 
Secondly, haem regulates the translocation of ALA synthase from cytosol to 
mitochondria (Yamauchi et aI, 1980, Srivastava et aI, 1983). This is mediated by two 
cysteine-containing haem regulatory motifs in the leader sequence (Lathrop and 
Timko, 1993; Dailey, H. A. - personal communication). 
In contrast the mechanisms of controlling erythroid ALA synthase activity are 
different (Ponka, 1997). Transcription of ALA-S2 is controlled primarily by 
erythroid-specific transcription factors interacting with noncoding regions of the gene 
(Cox et al, 1991; May et aI, 1995). Interestingly, the same factors are responsible for 
induction of globin synthesis but this only occurs following the induction of haem 
synthesis, indicating the importance ofhaem per se as a regulatory molecule. 
Post-transcriptional regulation of ALA-S2 also occurs differently to that of ALA-S 1. 
There is a cis-acting regulatory iron element in the 5' untranslated region (Cox et aI, 
1991), similar to the stem-loop structure occurring in the 5' untranslated region of 
ferritin mRNAs (Klausner et aI, 1993). A protein that binds to the iron regulatory 
element inhibits translation of the mRNA, but in the presence of iron the protein 
dissociates and the mRNA binds to ribosomes and is translated (Melefors et aI, 1993). 
In this way the translation ofALA-S2 mRNA is coupled to the availability of iron. 
Although haem does not appear to play a major role in the transcription and 
translation of ALA-S2, there are identical cysteine-containing haem regulatory motifs 
to those found in the ALA-Sl gene, in the leader sequence of ALA-S2, and in vitro 
experiments suggest a haem-mediated inhibitory effect (Lathrop and Timko, 1993). 
Thus translocation of ALA synthase to the mitochondrion may also be a controlled 
event in erythroid tissue. 
2. ALA Dehydratase lEe 4.2.1.24J (Porphobilinogen Synthase) 
The next step in the haem biosynthetic pathway takes place in the cytosol and it 
involves the condensation of two ALA molecules in a series of stages involving an 
aldol condensation and formation of a Schiff-base (Shemin, 1976) with the 
elimination of two water molecules, to form the monopyrrole, porphobilinogen (2nd 
reaction, figure 1.4) (Jordan and Seehra, 1980). An important role of enzyme catalysis 
in this reaction is to ensure that the two ALA molecules form the correct product 
because 2-aminoketones like ALA are intrinsically reactive, and can easily form other 
products such as the dehydropyrazine formed in the non-enzymatic dimerization. This 
is the first committed step of the tetrapyrrole synthetic pathway. This reaction is 
catalysed by the multi subunit cytoplasmic enzyme, ALA dehydratase (Eiberg et aI, 
1983; Beaumont et aI, 1984). Initial evidence for the existence of this enzyme came 
from studies on ox liver extracts (Gibson et aI, 1955) and avian erythrocytes (Schmid 
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This protein has been purified from a variety of sources which include yeast (De 
Barreiro, 1967); R. sphaeroides (Nandi et aI, 1968); human erythrocytes (Anderson 
and Desnick, 1979; Gibbs et aI, 1985); bovine liver (Bevan et aI, 1980; Jordan and 
Seehra, 1986); and spinach (Liedgens et aI, 1983). These enzymes exist as octamers 
with molecular weights of up to 280 000 Da consisting of identical subunits of 
approximately 35 000 Da each (Jordan, 1990). The human enzyme is a homo-octamer 
with subunits of 36274 Da (Wetmur et aI, 1986). The E. coli ALA dehydratase was 
purified and also shown to be a homo-octamer composed of identical 36 554 Da 
subunits (Spencer and Jordan, 1993). ALA dehydratase of the unicellular green algae, 
Scenedesmus obliquus was identified as a 282 000 Da native protein consisting of six 
42 000 Da subunits arranged in a ring (Stolz and Dornemann, 1996). 
The genes encoding ALA dehydratases have been sequenced and their cDNAs and 
protein products characterised from several sources such as human (Wetmur et aI, 
1986); rat (Bishop et ai, 1986); E. coli (Echelard et ai, 1988); Chlamydomonas 
reinhardtii (Matters and Beale, 1995); soybean (Kaczor et aI, 1994); Bradyrhizobium 
japonicum (Chauhan and O'Brian, 1993); pea (Pisum sativum L.) (Boese et ai, 1991); 
and Pseudomonas aeruginosa (Frankenberg et aI, 1998). T o tissue-specific forms of 
ALA dehydratase exist which are encoded by a single gene which contains separate 
erythroid and housekeeping promoters and can undergo alternative splicing (Kaya et 
aI, 1994; Bishop et aI, 1996). It has been proposed that this· novel expression of 
erythroid-specific and housekeeping transcripts apparently evolved to ensure that 
there is enough supply of haem for high-level tissue-specific haemoglobin production 
(Bishop et aI, 1996). 
In the case of human ALA dehydratase the holoenzyme contains four catalytic sites 
and can be viewed as a tetramer of dimers with one active site per dimer. Each active 
site binds two molecules of ALA at two distinct positions, the A-site and P-site 
(Shoolingin-J ordan et aI, 1996, 1997, Shoolingin-J ordan, 1998). The ALA molecule 
contributing the acetate group and the amino-methyl group of PBG binds at the A­
site. The ALA contributing the propionate side chain and the pyrrolic nitrogen binds 
at the P-site. There is an ordered binding in which the keto group of the ALA 
contributing the propionate side chain forms a transient covalent bond with a 
conserved lysine (human Lys-252) in the P-site first. Once there is bound substrate at 
the P-site with an available 5-amino group binding of the second ALA molecule onto 
the enzyme at the A-site may occur. The amino-nitrogen is then incorporated into the 
pyrrole ring ofPBG. 
Binding of the second substrate at the A-site is dependent on the presence of a 
divalent metal ion, and removal of these divalent ions prevent binding at the A-site 
resulting in loss of activity but has no effect on ALA binding at the P-site (Norton et 
aI, 1998). Typically, the required metals are Zn2 + or Mg2 + (Abdulla and Haeger­
Aronsen, 1971, Senior et aI, 1996b). Thus in mammalian systems up to a maximum 
of eight Zn2 + ions can bind onto an ALA dehydratase octarner (Wu et aI, 1974; 
Tsukamoto et ai, 1980), four being required for catalysis (at the A-site) and four not. 
Although the binding of the latter four metal ions at the P-site may appear non­
essential they probably play a role in conformational stabilisation of the enzyme 











E. coli ALA dehydratase and are tenned the alpha and beta sites (Spencer and Jordan, 
1994a; 1995). . 
The B japonicum ALA dehydratase was found to be similar to the plant enzymes in 
that it required Mg2+ ions for activity (Chauhan and O'Brian, 1993). A putative Mt+ 
binding domain was identified in the cloned Chlamydomonas reinhardtii ALA 
dehydratase, which had approximately 60% amino acid sequence identity to higher 
plants (Matters and Beale, 1995). Other Mg2+ -dependent ALA dehydratases were also 
identified from Scenedesmus obliquus, a unicellular green algae (Stoltz and 
Domemann, 1996) and Pseudomonas aeruginosa (Frankenberg et aI, 1998). Although 
the E. coli ALA dehydratase was shown to be a Zn2+ -dependent enzyme, in contrast to 
the other known prokaryotic ALA dehydratases which are Mg2+- dependent; when a 
Zn2+ ion was present at the beta site, a Mg2+ ion could bind at the alpha site and yield 
an active enzyme (Spencer and Jordan, 1994a, b). 
Cloning has allowed the development of expression systems for various fonns of 
ALA dehydratase and ultra-pure preparations of the recombinant enzyme have yielded 
the protein as a crystal, sometimes suitable for X-ray diffraction (Senior et aI, 1996; 
1997). The crystallisation and initial X-ray characterisation of the ALA dehydratases 
from E. coli and Saccharomyces cerevisiae of around 2A have been reported (Erskine 
et aI, 1997) as well as a more detailed structur  down to 1.67 A for Pseudomonas 
aeruginosa ALA dehydratase (Frankenberg et aI, 1999). In all cases the best crystals 
were obtained when these proteins were covalently bound to laevulinic acid. The X­
ray structures have confinned that ALA dehydratase is a homo-octamer with each of 
its subunits adopting a "TIM" barrel fold with an N-tenninal arm of 30 amino acid 
residues (Erskine et aI, 1999a). The monomers fonned asymmetric dimers with their 
"arms" wrapped around each other, and four of these dimers interact to fonn octamers 
with their active sites located on the surface .. 
In the E. coli enzyme Lys-247 (equivalent of the essential Lys-252 at the P-site in 
human ALA dehydratase) fonned a Schiff-base link with the bound laevulinic acid at 
the active site. This is also the case in the yeast ALA dehydratase where X-ray 
analysis shows the fonnation of a Schiff-base with Lys-263 (also equivalent to human 
Lys-252) (Erskine et aI, 1999b). 
Pseudomonas aeruginosa ALA dehydratase structural analysis reveals that in each 
dimer the monomers differed from one another by having a "closed" and an "open" 
active site pocket (Frankenberg et aI, 1999). Whereas no metal ions were found in the 
active site of both monomers, a single well-defined and highly hydrated Mg2+ was 
identified only in the closed fonn, about 14A away from the Schiff base fonning 
nitrogen atom of the active site lysine. Based on this infonnation a structure-based 
mechanism of action involving Mg2+ allosteric binding at the active site and rate 
enhancement has been proposed (Frankenberg et aI, 1999). 
Several ALA dehydratase inhibitors have clinical significance. The enzyme is highly 
sensitive to lead, which is believed to displace the Zn2+ ions. The clinical symptoms 
of lead poisoning are similar to those described in hereditary ALA dehydratase 
deficiency (table 1.2), suggesting that ALA dehydratase inhibition is responsible for 
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similar symptoms. In these cases a deficiency in the enzyme 4-fumarylacetoacetate 
hydrolase causes accumulation of succinylacetone, which is a potent inhibitor of ALA 
dehydratase (Sassa and Kappas, 1983). 
3. PSG Deaminase lEe 4.3.1.8] (Hydroxymethylbilane Synthase) 
Formation of the basic porphyrinogen tetrapyrrole is initiated in the cytosol by the 
assembly of four PBO molecules via a stepwise deamination and head-to-tail 
polymerization into a chemically reactive linear tetrapyrrole, hydroxymethylbilane by 
the enzyme PBO deaminase (Battersby et aI, 1979) (3 rd reaction, figure 1.4). 
PBO deaminase has been purified from many sources, often as a complex together 
with the next enzyme in the pathway, uroporphyrinogen-III cosynthase. (Sancovich et 
aI, 1969; Llambias and Batlle, 1970; Frydman and Fenstein, 1974) (see next section). 
Purification is reported from both eukaryotic and prokaryotic sources such as spinach 
(Higuchi and Bogorad, 1975); human erythrocytes (Anderson and Desnick, 1980; 
Corrigall et aI, 1991); Rhodobacter spheroides (Jordan and Shemin, 1973; Davies and 
Neuberger, 1973); and E. coli (Hart and Battersby, 1985). The purified protein exists 
as a 35 000 to 44 000 Da monomer, with optimal activities at pH 8.0-8.5 (Jordan, 
1990). 
PBO deaminase is unique in that it contains a covalently attached dipyrromethane 
cofactor at the active site which binds substrate molecules during the sequential 
assembly of the linear tetrapyrrole molecule (Jordan and Warren, 1987). The structure 
of the dipyrromethane cofactor and its sites of attachment to the enzyme have been 
characterised (Jordan et aI, 1988; Jordan, 1990). The PBO deaminase apoenzyme 
catalyses the deamination and polymerisation of two molecules of PBO at its active 
site (Awan et aI, 1997). The resultant dipyrrole is covalently linked via a thioether 
linkage to the enzyme through a conserved cysteine (E. coli Cys-242) (Jordan et aI, 
1988; Louie et ai, 1996). This dipyrrolic cofactor then acts as a primer which gets 
elongated in a stepwise mechanism, one PBO unit at a time, through enzyme 
intermediate complexes, ES (with one PBO attached); ES2 (two PBOs attached); ES3 
(three PBOs attached), and finally ES4 (four PBOs attached) from which the 
tetrapyrrole product, hydroxymethylbilane, is released by hydrolytic cleavage, 
regenerating the enzyme-dipyrromethane intact (Jordan, 1994; Luke and Shoolingin­
Jordan, 1998). Thus, the two proximal PBOs (ie. the dipyrromethane cofactor) remain 
covalently linked to the enzyme and are not turned over. The precise mechanisms by 
which the enzyme carries out this sequential manipulation of the four substrates and 
how the tetrapyrrole product is specifically cleaved leaving the intact dipyrromethane 
cofactor covalently attached to the enzyme, have not been fully elucidated. 
PBO deaminase was the first of the haem biosynthetic enzymes to benefit from the 
application of modem recombinant DNA technological investigation (Orandchamp et 
aI, 1984). Presumably this was primarily driven by investigators attempting to derive 
diagnostic benefit in the realm of the clinically important, diagnosis of acute 
intermittent porphyria (see below). Consequently the gene for PBO deaminase has 
been sequenced and characterised from both prokaryotic and eukaryotic sources 
(Orandchamp et aI, 1984; Thomas and Jordan, 1986; Sasarman et aI, 1987; Jordan et 
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protein structures of PBG deaminases from various sources reveal a considerable 
degree of conservation of this enzyme during evolution, as demonstrated by the 60% 
similarity between the human and the E. coli enzymes (Shoolingin-Jordan, 1998). 
In mammals there is a single PBG deaminase gene consisting of 15 exons extending 
over lOkb of DNA (Deybach and Puy, 1995). In humans the gene has been mapped to 
chromosome 11 q23 and two different transcripts, differing at their 5' ends, are 
produced from the single gene (Namba et aI, 1991, Deybach and Puy, 1995). The first 
is a ubiquitous, "housekeeping" mRNA transcript produced in all cells in which exon 
1 is spliced to exon 3. The second form is specific to erythroid cells and initiates by 
alternate splicing at exon 2 (Grandchamp et aI, 1987). Exon 2 does not contain an 
AUG translation-initiating codon, and translation of the erythroid-specific mRNA is 
initiated at an AUG located in exon 3 (Chretien et ai, 1988). Exon 1 contains an 
AUG, which is spliced into the same reading frame as the AUG in exon 3. Thus, 
translation of the "housekeeping" mRNA produces a protein that differs from the 
erythroid form by the absence of 17 amino acids (encoded by exon 1) at its N­
terminus (Grandchamp et aI, 1987). 
Activation of transcription of PBG deaminase is controlled by two separate 
promoters. The "housekeeping" promoter lies upstream f exon 1 and contains motifs 
commonly associated with "housekeeping" genes (Grandchamp et aI, 1987, Chretien 
et ai, 1988). The erythroid promoter lies between exon 1 and 2. The two promoters 
appear to be regulated independently, even though when RNA polymerase initiates at 
the "housekeeping" promoter it must transcribe the entire erythroid promoter 
(Chretien et aI, 1988). The erythroid-specific promoter contains at least three classes 
of transcription factor binding sites characteristic of erythroid promoters, viz. the 
GATA, NF-E2 and the CACCC motifs (Mignotte et aI, 1989). In keeping with other 
erythroid promoters, activation of transcription requires an interaction between the 
factors bound at the GATA site and factors bound at either NF-E2 or the CACCC 
sites (Mignotte et aI, 1989). 
In addition to the cloning and large scale expression of recombinant E. coli PBG 
deaminase (Jordan et aI, 1988; 1992) allowing characterisation of the dipyrromethane 
cofactor, crystallisation of the protein was facilitated and the X-ray crystal structure of 
the E. coli PBG deaminase determined to 1.76A resolution (Louie et aI, 1992; 1996). 
The high resolution structure revealed a protein folded into three alphalbeta domains 
of approximately 100 amino acids each, linked to one another by flexible strands 
(Lambert et aI, 1994; Louie et aI, 1996; Shoolingin-Jordan, 1998; Luke and 
Shoolingin-Jordan, 1998). Domains 1 and 2, which have similar overall topology 
form a cleft at their interface. The dipyrromethane cofactor is bound by extensive 
contacts, including salt bridges and hydrogen bonds between these two domains in 
this cleft. Site-directed mutagenesis experiments have demonstrated that several of 
the salt bridges between arginine and the pyrrole acetates and propionates are 
important for enzymatic activity (Lambert et aI, 1994, Jordan, 1994). Domain 3, 
which is an open-faced anti-parallel sheet of three strands containing the cysteine to 
which the cofactor is covalently bound, is situated deep within the cleft between 
domains 1 and 2. Deamination of PBG and formation of the methene bridge occurs 
here. Thus domain 3 can be considered as containing the single catalytic site. 
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which would allow confonnational changes that accommodate each added PBG 
pyrrole until the tetrapyrrole (hydroxymethylbilane) is synthesised. 
4. Uroporphyrinogen Cosynthase lEC 4.2.1.75] 
The regularly· substituted linear tetramer, hydroxymethylbilane, is converted to an 
asymmetrically substituted cyclic tetramer, uroporphyrinogen-III, by 
uroporphyrinogen co synthase (4th reaction, figure 1.4). In the absence of this enzyme 
hydroxymethylbilane cyclizes spontaneously to fonn uroporphyrinogen-I instead of 
the III isomer which, as noted above, is required for further processing to haem 
(Jordan, 1994). Thus cyclization of hydroxymethylbilane by uroporphyrinogen 
cosynthase critically involves intramolecular inversion of the tenninal D ring of the 
substrate. This inversion probably occurs via a chiral spiro intennediate (Leeper, 
1994; Spivey et ai, 1996). Considering the requirement for uroporphyrinogen 
co synthase to act in concert with its "partner", PBG deaminase, and the fact that the 
two enzymes may be co-purified, it has been suggested that they may exist in a 
cytosolic complex (Tsai et aI, 1987). 
Uroporphyrinogen cosynthase has been isolated and purified to homogeneity from 
many sources (Higuchi and Bogorad, 1975; Kohashi et al, 1984; Smythe and 
Williams, 1988; Hart and Battersby, 1985; AlwaD and Jordan, 1988) including human 
erythrocytes (Tsai et aI, 1987). They all appear to exist as monomeric subunits with 
molecular weights around 30 000 Da (Jordan, 1990) and are extremely thennolabile. 
Because of this instability the protein has not been well characterised. There is no 
evidence for a cofactor of any sort and the human enzyme has an isoelectric point of 
5.5, and a pH optimum of 7.4. Activity measurements show it to be present in excess 
over PBG deaminase, favouring the synthesis of the uroporphyrinogen-III over the 
series I isomeric fonn (Tsai et aI, 1987, Desnick et aI, 1998). 
The genes/cDNAs encoding this enzyme have been isolated from several sources 
. including animals and bacteria (Stamford et ai, 1995; Amillet and Labbe-Bois, 1995; 
Xu et aI, 1995; Tsai et aI, 1988; Jordan et ai, 1988). The human uroporphyrinogen 
co synthase gene has been isolated, sequenced and mapped to chromosome 10q25.3 
(Astrin et al, 1991), and the cDNA expressed in E. coli (Tsai et ai, 1988). In both the 
human and mouse there are 5' and 3' untranslated regions and an open reading frame 
spanning 10 exons and encoding a polypeptide of 265 amino acids. The mouse gene 
shares an 80% nucleotide and 78% amino acid identity with that of the human gene 
(Xu et aI, 1995). 
5. Uroporphyrinogen Decarboxylase lEC 4.1.1.37] 
Uroporphyrinogen decarboxylase, a soluble cytoplasmic protein, catalyses the 
decarboxylation of four acetyl side-chains in the 8-carboxylic (-COOH) 
uroporphyrinogen-III molecule. The reaction proceeds in a stepwise manner through 
fonnation of 7-, 6-, and 5-COOH intennediates resulting in the fonnation of the 4­
COOH coproporphyrinogen-III (Mauzerall and Granick, 1958; Jackson et ai, 1976) 
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In theory, the successive removal of all four acetate carboxyl groups could occur by 
24 possible routes involving fourteen intennediates (McDonagh and Bissell, 1998). 
Nevertheless evidence suggests that, at physiologic substrate concentrations, this 
reaction occurs in an orderly manner with the carboxyl groups removed in a 
clockwise direction starting at ring D and proceeding through A, B, and C before the 
final fonnation of coproporphyrinogen-III (Jackson et aI, 1976; Luo and Lim, 1993). 
The intennediates fonned in this reaction are relatively stable porphyrinogen species 
which are detectable in vivo. Each intennediate acts as the substrate for further 
decarboxylation until the requisite coproporphyrinogen-III is fonned. Both the series I 
and III uroporphyrinogen isomers fonned are suitable substrates for this enzyme, but 
the series III isomer is more rapidly de carboxylated (Granick and Mauzerall, 1958; 
Smith and Francis, 1981). 
This enzyme has been purified from human erythrocytes (de Verneuil et aI, 1983; 
Elder et aI, 1983; Mukerji and Pimstone, 1992; Roberts and Elder, 1997); bovine liver 
(Straka and Kushner, 1983); chicken erythrocytes (Kawanishi et aI, 1983; Seki et aI, 
1986); Euglena gracilis (Juknat et aI, 1989); Saccharomyces cerevisiae (Felix and 
Brouillet, 1990) and Rhodobacter sphaeroides (Jones and Jordan, 1993). Most fonns 
of the protein have been reported to be monomeric with molecular weights reported 
from 40 000 Da (Elder et aI, 1983) to 46 000 Da (de Verneuil et aI, 1983). The 
chicken enzyme, on the other hand is reported to exist as a dimer composed of two 40 
000 Da subunits (Kawanishi et aI, 1983). 
The cDNAs for the gene encoding this protein in humans and rat have been cloned, 
sequenced and characterised (Romeo et ai, 1986; Romana et aI, 1987a). The two 
uroporphyrinogen decarboxylase gene sequences are very similar with 85% and 90% 
homology at the DNA and protein levels, respectively. The cDNA for the mouse gene 
encoding this enzyme has 88% and 90% nucleotide and amino acid sequence identity, 
respectively, with the human enzyme (Wu et aI, 1996). The isolated human 
uroporphyrinogen decarboxylase gene is made up of 10 exons and two transcriptional 
start sites were identified (Romana et ai, 1987b). The human gene encodes a 367 
amino acid residues polypeptide (predicted molecular weight approximately 41 000 
Da), is present as a single copy containing 10 exons within about 3 kb of DNA and 
has been mapped to chromosome 1 p34 (de Vernueil et aI, 1983; Dubart et aI, 1986; 
Romeo et al 1986). Two transcriptional start sites separated by six nucleotides have 
been identified (Romana et al, 1987b) but the same polyadenylation site is used in all 
tissues and it seems that both sites are used in the same proportion in both erythroid 
and nonerythroid cells. Two isofonns of this enzyme were identified in human 
erythrocytes by Murkeji and Pimstone (1987). 
cDNAs from other species have also been analysed and compared. Sequence analysis 
of S. cerevisiae (Garey et aI, 1992; Diflumeri et aI, 1993) and Synechoccus (Kiel et aI, 
1992) uroporphyrinogen decarboxylase revealed approximately 50% and 32% 
respectively identity with the human enzyme. In addition a full length cDNA for the 
tobacco plant (Nicotiana tabacum L.) uroporphyrinogen decarboxylase gene and a 
partial cDNA for the barley (Hordeum vulgare L.) gene have been cloned and 
sequenced (Mock et aI, 1995). Overall, in tenns of protein size, amino acid 
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decarboxylases compared from all these different sources (bacteria, yeast, plants, 
mammals) are fundamentally similar (Elder and Roberts, 1995). . 
Various inhibitor studies using human uroporphyrinogen decarboxylase suggest that 
cysteine and histidine residues are important for enzyme activity especially free thiols 
and various conserVed histidines, lysines and arginines (Whitby et aI, 1998). 
However, site-directed mutagenesis experiments indicate that no single cysteine is 
absolutely critical for the integrity of the catalytic site, as activity in all cysteine 
mutants was essentially maintained at a significant level. Three histidine mutants also 
retained significant enzyme activity but one (human H339N) has been identified as 
important in imparting isomer specificity (Wyckoff et al, 1996). 
A recombinant human uroporphyrinogen decarboxylase, expressed with a histidine 
tag in E. coli for purification purposes, was crystallized and initial data collected at a 
3.oA resolution (Phillips et al, 1997; Laterriere et aI, 1997). Subsequently, the crystal 
structure has been determined at 1.60A resolution (Whitby et aI, 1998). This enzyme 
is a dimer in solution and this dimer also appears to be formed in the crystal (Whitby 
et aI, 1998). 
6. Coproporphyrinogen Oxidase lEC 1.3.3.3J 
At this point the synthesis of haem re-enters the mitochondria, where the enzyme 
coproporphyrinogen-III oxidase, located in the intermembrane space and loosely 
associated with the inner mitochondrial membrane on the intermembrane space side 
(Sano and Granick, 1961 Batlle et aI, 1965; Poulson and Polglase, 1974; Elder and 
Evans, 1978; Grandchamp et aI, 1978), catalyses the oxidative decarboxylation of 
coproporphyrinogen-III to form protoporphyrinogen-IX (6th reaction, figure 1.4). 
The two propionate residues (P) on rings A and B of the tetrapyrrole molecule are 
converted into vinyl groups (-CH=CH2) in a clockwise fashion, proceeding via a 
tricarboxylic porphyrinogen, tripropionate monovinyl porphyrinogen (trivially known 
as harderoporphyrinogen). It is a stepwise decarboxylation with the decarboxylation 
of the position 2 propionate side chain proceeding first and at a faster rate than that of 
position 4 (Martasek, 1998). Under normal circumstances free harderoporphyrinogen 
is not generated and thus does not appear in physiological porphyrin analytical 
profiles. Two molecules of CO2 are produced and the reaction requires molecular 
oxygen as an electron acceptor. This oxygen-dependent reaction probably involves p- . 
hydroxypropionate which is then decarboxylated and at least one protein tyrosine 
group(s) may be involved in this part of the catalytic mechanism (Yoshinaga and 
Sano, 1980b). In an alternative scheme it has been suggested that a hydroxylation 
reaction does not take place, but the reaction proceeds via a hydride removal during 
the decarboxylation (Seehra et ai, 1982). It is possible that both schemes may occur 
naturally depending on the nature of the organism (Dailey, 1990). Indeed, in 
prokaryotes there appears to be two forms of coproporphyrinogen oxidase based on 
their oxygen requirements, and in the case of Salmonella typhimurium two genes, 
encoding an oxygen-dependent and oxygen-independent coproporphyrinogen-III 











Coproporphyrinogen oxidase has been purified from a number of sources including 
rat (BatlIe et aI, 1965), bovine (Yoshinaga and Sano, 1980a; Kohno et aI, 1993) and 
mouse liver (Bogard et aI, 1989) and Saccharomyces cerevisiae (Camadro et al, 
1986). Early studies reported molecular weights in the region of 70 - 80 000 Da 
(BatlIe et aI, 1965; Yoshinaga and Sano, 1980a), and later studies indicate a dimeric 
protein consisting of approximately 35 000 Da molecular weight subunits (Camadro 
et al, 1986; Bogard et aI, 1989; Kohno et aI, 1993). cDNA data has confirmed this. 
The cDNA sequence of the human gene encoding coproporphyrinogen-III oxidase has 
been cloned, sequenced and characterised (Taketani et al, 1994; Martasek et al, 1994; 
Delfau-Larue et aI, 1994; Medlock and Dailey, 1996). Analysis of the cDNA and the 
cloned gene from a number of oxygen-dependent species as well as the N-terminal 
amino acid sequence from mouse liver has led workers to suggest that newly 
synthesised coproporphyrinogen-III oxidase has an N-terminal mitochondrial­
targeting peptide which is cleaved during transport into the mitochondria. Although 
the length of this leader sequence was initially proposed to be 31 amino acid residues 
in length (Kohno et ai, 1993, Taketani et ai, 1994) other workers have reported an 
unusually long leader sequence of 110 amino acids (Delfau-Larue et ai, 1994, 
Martasek et al, 1994). 
In humans there appears to be a single copy of the gene with multiple transcriptional 
initiation sites. The human gene spans approximately 14 kilobases, and consists of 
seven exons and six introns (Delfau-Larue et ai, 1994). This gene has been mapped to 
chromosome 3q12 of the human genome (Cacheux et al, 1994). Potential regulatory 
elements have been identified in the GC-rich promoter region (six Spl, one CACCC 
and four GATA sites) and it is suggested that a single promoter may be differentially 
regulated in erythroid and non-erythroid tissue (Martasek et aI, 1994, Taketani et ai, 
1994). Coproporphyrinogen-III oxidase transcripts are induced during erythroid cell 
differentiation (Conder et ai, 1991, Taketani et aI, 1995a). The gene contains two 
polyadenylation signals separated by 126 base pairs and it is possible that these two 
signals, differently utilised, may play a role in tissue-specific expression of 
coproporphyrinogen-III oxidase mRNA (Martasek et al, 1997). 
Kohno et al (1993) isolated the full length cDNA sequence of the mouse 
coproporphyrinogen oxidase gene from a mouse erythroleukemia cell cDNA library. 
Sequence analysis revealed that the mouse gene encodes a 40647 Da (354 amino acid 
residues) protein precursor with a putative cleavable leader peptide of 31 amino acid 
residues, which was modified into a 37 255 Da (323 amino acid residues) mature 
protein. The post-translational modification of the mouse enzyme was very similar to 
the human form. Localisation experiments revealed that the enzyme activity was 
mainly found in mitochondria. Metal analysis and site-directed mutagenesis 
experiments indicated that the mouse enzyme was a metalloprotein associated with 
Cu2 + ions as essential cofactors for the enzyme activity (Kohno et aI, 1996). 
The cDNA encoding human coproporphyrinogen oxidase gene was expressed in E. 
coli cells and purified to apparent homogeneity (Medlock and Dailey, 1996). Metal 
analysis of this purified protein by u.v.!visible spectroscopy, inductively coupled 
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spectroscopy revealed that the human enzyme did not have a metal centre and there 
was no in vitro stimulation by either Fe2+ or Cu2• 
In prokaryotes there appears to be two forms of coproporphyrinogen oxidase, based 
on their oxygen requirements. The genes for these coproporphyrinogen oxidase forms 
viz., hemF and hemN code for the oxygen-dependent and oxygen-independent 
enzymes, respectively. Xu and Elliot (1993) reported the cloning and sequencing of 
the hemF gene which encodes an oxygen-dependent coproporphyrinogen oxidase 
from the facultative bacterium, Salmonella typhimurium. The predicted protein 
sequence had 44% amino acid identity to the yeast coproporphyrinogen oxidase 
encoded by hem13 gene (Zagorec et aI, 1988). Subsequently, these workers cloned 
and sequenced the hemN gene which encodes the oxygen-independent enzyme (52 
800 Da) from the same organism (S. typhimurium) (Xu and Elliot, 1994). This protein 
had 38% identity to a putative anaerobic coproporphyrinogen oxidase (hemN) of 
Rhodobacter sphaeroides which had previously been cloned and sequenced (Coomber 
et ai, 1992). The two genes encoding the aerobic (hemF) and anaerobic (hemN) 
coproporphyrinogen oxidase isoforms of E. coli were also cloned and characterised 
(Troup et ai, 1994; 1995). An open reading frame (hemN) cloned from B. subtilis was 
also identified to be coding for an oxygen-independent coproporphyrinogen-III 
decarboxylating protein (Hippler et aI, 1997). Detailed investigation for the hemF 
(oxygen-dependent) gene in the B. subtilis genomic DNA, and alignment with all 
known sequences, could not identifY this gene in this organism (Hippler et aI, 1997). 
Zagorec et al (1988) isolated the hem13 gene of Saccharomyces cerevisiae by 
:functional complementation of a hem13 mutant. The encoded protein had a calculated 
molecular weight of 37 673 Da (328 amino acid residues) which was in agreement 
with that predicted for the previously purified aerobic native enzyme (Camadro et aI, 
1986). The yeast coproporphyrinogen oxidase is different from others in that, it exists 
as a cytoplasmic rather than a mitochondrial protein. The cDNA for the gene 
encoding coproporphyrinogen oxidase of soybean plant was isolated and its primary 
structure was determined (Madsen et aI, 1993). The gene encodes a polypeptide with 
a predicted molecular weight of 43 000 Da which has 50% amino acid sequence 
similarity to the yeast coproporphyrinogen oxidase. A 67 amino acid residue 
extension at the N-terminus of the protein, which is different to the other 
coproporphyrinogen oxidase sequence, is thought to be a leader peptide required for 
transit across membranes. This protein was shown to be highly expressed in soybean 
root nodules. 
7. Protoporphyrinogen Oxidase (PPO) lEe 1.3.3.4} 
In the penultimate step of the haem biosynthesis pathway protoporphyrinogen-IX is 
oxidised to protoporphyrin-IX by protoporphyrinogen oxidase (7th reaction, figure 
1.4). 
This was the last enzymatic reaction to be described in haem biosynthesis and is the 
least characterised. Initial evidence which indicated the enzymatic oxidation of 
protoporphyrinogen-IX first emerged when Sano and Granick (1961) demonstrated 
the in vitro increase in the rate of this reaction on addition of liver cell mitochondrial 











extracts (Porra and Falk, 1961). Subsequent studies showed that oxygen was the 
acceptor of the electrons which were released during the oxidation of 
protoporphyrinogen-IX to fonn protoporphyrin-IX (porra and Falk, 1964). 
Important breakthroughs in describing the enzymatic catalysis of this reaction came 
from the work done by Poulson and Polglase (1975), and Poulson (1976) which 
provided much of the evidence which showed that a protein associated with 
mitochondrial membranes was involved in this reaction. The detailed localisation 
studies done by Deybach et al (1985) continned the mitochondrial location of this 
protein and further provided evidence showing that this enzyme was intrinsically 
associated with the inner mitochondrial membrane. The work by Ferreira et al (1988) 
further confinned these findings and they proposed that the tenninal three enzymes of 
the haem biosynthesis pathway that is, coproporphyrinogen oxidase; 
protoporphyrinogen oxidase; and ferrochelatase, could possibly exist in some fonn of 
an enzyme complex which would facilitate the channelling of substrate intennedites 
between the different enzymes. Thus far the existence of such a complex has not been 
verified. 
In the next few of years great effort was put into trying to characterise this protein 
from various sources. For many years scientists were dogged by difficulties in trying 
to purify the protein from membranes using conventional chromatographic 
techniques. PPOs are hydrophobic membrane bound proteins which require 
detergents for solubilisation. Repeated purification attempts in different laboratories 
around the world resulted in partial characterisation of the enzyme from several 
sources such as rat (Poulson, 1976); Saccharomyces cerevisiae (Poulson and Polglase, 
1975; Camadro et aI, 1994); Rhodopseudomonas spheroides (Jacobs and Jacobs, 
1981) barley (Jacobs and Jacobs, 1987; Jacobs et al, 1989); Desulfovibrio gigas 
(Klemm and Barton, 1987); mouse (Dailey and Karr, 1987; Ferreira and Dailey, 1988; 
Proulx and Dailey, 1992) and bovine (Siepker et ai, 1987). 
More detail and progress made in characterising PPOs is presented separately, later in 
this review. 
8. Ferrochelatase (FC) lEC 4.99.1.1J 
The last step in haem biosynthesis involves the incorporation of ferrous iron (Fe2+) 
into the protoporphyrin-IX macrocycle by ferrochelatase to fonn haem (protohaem) 
(Goldberg et aI, 1956) (8th reaction, figure 1.4). This reaction has been extensively 
studied and is well characterised in humans. Ferrochelatase is an intrinsic protein of 
the inner mitochondrial membrane (McKay et aI, 1969; Jones and Jones, 1969; 
Harbin and Dailey, 1985). Initial attempts at purifying this protein to homogeneity 
were hampered by difficulties in stabilizing the enzyme during the purification 
process. Relentless efforts by various laboratories resulted in the purification of the 
protein from various sources such as rat liver (Mailer et ai, 1980; Taketani and 
Tokunaga, 1981), Rhodopseudomonas sphaeroides (Dailey, 1982), bovine liver 
mitochondria (Taketani and Tokunaga, 1982; Dailey and Fleming, 1983; Siepker et 
aI, 1987). The bovine enzyme with a reported molecular weight of 40 000 Da was 
purified and shown to be cross-reacting with antibodies raised against the purified 











The structural gene for Saccharomyces cerevisiae ferrochelatase (hem15) was isolated 
by functional complementation ofa mutant yeast strain (Labbe-Bois, 1990). This gene 
encodes a protein precursor with a putative 31 amino acid residues leader sequence 
and the mature enzyme is a 40 900 Da (362 amino acid residues) protein. Eldridge 
and Dailey (1992) described the production of large amounts of the yeast 
ferrochelatase from a baculovirus expression system. Investigation of several 
invariant amino acid residues in the yeast ferrochelatase protein by site-directed 
mutagenesis revealed that Glu-314 was critical for catalysis, for metal binding His­
235 was essential, and Asp-246 and Tyr-248 were also involved synergestically in this 
function (Gora et al, 1996). 
Mouse ferrochelatase gene cDNA was isolated by immunoscreening of a cDNA 
library from mouse erythroleukemia (MEL) cells with a polyclonal antibody (Taketani 
et aI, 1990). This gene encodes a ferrochelatase precursor of 47 130 Da (420 amino 
acid residues) with a putative presequence of 53 amino acid residues which on 
cleavage during importation into the mitochondrial inner membrane is modified into a 
mature protein of 41 692 Da (367 amino acid residues). Brenner and Frasier (1991) 
also reported the isolation of a mouse ferrochelatase gene from libraries screened with 
an oligonucleotide probe, and found similar features to those reported by Taketani et 
al (1990). The deduced amino acid sequence had 47% identity with the cloned yeast 
ferrochelatase. A single chromosomal gene was demonstrated by Southern blotting, 
whilst Northern blotting showed existence of two transcripts in all tissues (Brenner 
and Frasier, 1991). The cDNA of the gene encoding mouse ferrochelatase was 
overexpressed in E. coli and this facilitated the purification of the enzyme, but no 
further characterisation was performed (Ferreira, 1994). Purification of large amounts 
of the mammalian ferrochelatase and characterisation was reported by Dailey et al 
(1994b). 
The characterisation of the mouse ferrochelatase gene facilitated the cloning and 
sequencing of the human gene (Nakahashi et al, 1990). This human ferrochelatase 
gene was isolated from a placental cDNA library using a radiolabelled mouse cDNA 
fragment. This enzyme was synthesized as a 47 833 Da (423 amino acid residues) 
protein precursor which was modified into a smaller mature protein of 42 158 Da by 
cleavage of a putative leader sequence of 54 amino acid residues. Analysis of the 
primary sequence of this protein showed identities of 88% and 46% to the mouse and 
yeast ferrochelatases, respectively. Human ferrochelatase gene was mapped to 
chromosome 18q22 by hybridisation of the cDNA to sorted chromosomes and by 
fluorescence in situ hybridisation with a human ferrochelatase genomic clone 
(Whitcombe et ai, 1991; Taketani et aI, 1992, Brenner et aI, 1992). The cloned mature 
forms of the human and mouse ferrochelatases were expressed, purified and 
characterised (Dailey et ai, 1994b, c). In this study this group demonstrated the 
intriguing presence of a singIe.labile iron-sulphur (2Fe-2S) cluster at the caboxyl end 
of the purified mature human ferrochelatase using uv/visible spectral analysis, 
variable temperature magnetic circular dichroism (MeD) and electron paramagnetic 
resonance (EPR). The labile [2Fe-2S] cluster was shown to be disappearing gradually 
over 24 hours, with concomittant loss of enzyme activity when stored aerobically at 
4°C. Investigation of the purified mouse natural and recombinant ferrochelatases 
using EPR and Mossbauer spectroscopy also confirmed the presence of the [2Fe-2S] 












the prokaryotic, yeast, and plant ferrochelatase gene cDNAs revealed a lack of the 
putative binding site for the iron sulphur cluster. The destruction or loss of this cluster 
from the mammalian ferrochelatases resulted in loss of enzyme catalytic activity 
(Sellers et aI, 1996). In that study EPR and uv/visible spectroscopy was applied to 
demonstrate the destruction of the [2Fe-2S] cluster by nitric oxide (NO) in both the 
human and mouse ferrochelatases. Interestingly, NO had no effect on the yeast 
ferrochelatase which lacks the [2Fe-2S] cluster, or other enzymes such as spinach 
ferrodoxin which also has the [2Fe-2SJ cluster. Further investigations involving site­
directed mutagenesis and spectroscopic characterisation of the human enzyme 
revealed that three cysteines at the carboxyl terminal; Cys-403, Cys-406 and Cys-411 
(which are conserved in many of the known ferrochelatase sequences) were involved 
in the ligation of the [2Fe-2SJ cluster to the protein (Crouse et ai, 1996). Another 
cysteine, Cys-196, has been identified as the fourth ligand of the [2Fe-2SJ onto human 
ferrochelatase (Sellers et aI, 1998). The precise function of the iron~sulphur centre 
remains to be elucidated. But since this centre appears to be absent in bacterial and 
yeast ferrochelatases, it was proposed that this [2Fe-2SJ centre may be involved in a 
regulatory role in the mammalian enzymes (Sellers et aI, 1998). 
Recent studies have revealed the presence of the [2Fe~2SJ cluster in several non~ 
mammalian ferrochelatases (Sellers et ai, 1998; Day et ai, 1998). EPR and uv/visible 
spectroscopy were applied in identifying the [2Fe~2SJ cluster in the cloned 
Drosophila melanogaster ferrochelatase (Sellers et aI, 1998). The conserved cysteines 
196, 403, 406 and 411 were also identified in this enzyme. Day et al (1998) reported 
the cloning of the chicken (Gallus gallus) and amphibian (Xenopus laevis) 
ferrochelatases, and the expressed (in E. coli) and purified proteins were both found to 
contain [2Fe-2SJ clusters which were readily destroyed by NO. 
The gene for a prokaryotic ferrochelatase was identified and characterised from the 
aerobic bacterium Bacillus subtilis (Hansson and Hederstedt, 1994a). In this organism 
this gene forms part of the hemEHY gene cluster which encodes uroporphyrinogen 
(hemE), protoporphyrinogen oxidase (hemY) and ferrochelatase (hemH) (Hansson and 
Hederstedt, 1992, 1994b). The purified protein encoded by hemH was shown to be a 
water-soluble, 35 000 Da monomeric protein which could incorporate Fe2+, Zn2 + and 
Cu2 + into the protoporphyrin-IX macrocycle. A single cysteine residue appeared to be 
required for catalytic activity of this enzyme. Hansson and AI-Karadaghi (1995) 
expressed the B. subtilis ferrochelatase as a soluble protein in E. coli cells and 
purified it for crystallisation studies. Subsequently, the three dimensional crystal 
structure of this protein was determined at 1.9A resolution by a method of multiple 
isomorphous replacement, and characterised (AI~Karadaghi et aI, 1997). This protein 
was folded into two similar domains each with a four-stranded parallel beta sheet 
flanked by alpha helices. The two domains formed a cleft with several of the amino 
acids which are invariant in many ferrochelatase species. It was proposed that the 
porphyrin substrate binds in this cleft and that the metal-binding site was also found 












The porphyrias are a heterogeneous group of metabolic disorders associated with 
specific clinical syndromes. They are characterised by a derangement of the haem 
biosynthetic pathway resulting from inherited deficiencies of the enzymes catalysing 
the reactions in this biochemical pathway (Kappas et ai, 1989). Thus, each of the 
different porphyrias is characterised by a defect in a specific haem synthetic enzyme 
(table 1.1). 
Table 1.1 A summary of the porphyria syndromes and the haem synthetic enzymes affected in each of 
these conditions. 
Enzyme involved Haem synthetic Porphyria syndrome 
athwav 
Glycine + Succinyl CoA 
ALA synthase u 
5-aminolaevulinic acid 
ALA dehydratas'e . U ALA dehydratase deficiency 
Porphobilinogen 
Porphobilinogen deaminase u Acute intermittent porphyria 
Hydroxymethylbilane 
Uroporphyrinogen cosyntbase u Congenital erythropoietic porphyria 
Uroporphyrinogen-III 
Uroporphyrinogen decarboxylase u Porphyria cutanea tarda 
Coproporphyrinogen-III 
Coproporphyrinogen oxidase u Hereditary coproporphyria 
Protoporphyrinogen-IX 
Protoporphyrinogen oxidase u Variegate porphyria 
Protoporphyrin-IX 
Ferrochelatase u Erythropoietic porphyria 
Haem 
The defect is often identifiable as decreased catalytic activity in that enzyme 
(Waldenstrom, 1957; Brodie et aI, 1977b; Elder, 1982; Rimington, 1985). The focus 
of this dissertation, PPO, is associated with variegate porphyria (VP). In rare 
circumstances more than one enzyme may be affected (Day et aI, 1982; Martasek et 
al, 1983; Sturrocket aI, 1989). Deficiencies in the enzyme activities are either due to 











1987). At the biochemical level, the type of porphyria is identified by the 
characteristic excretion pattern of porphyrin intermediates present in urine, stool and 
blood from patients, which reflects the enzyme deficiency, and this is sometimes 
accompanied by an elevation of the porphyrin precursors, 5-aminolaevulinic acid 
(ALA) and porphobilinogen (PBG) in the acute porphyrias (Moore et al, 1987; 
Dailey, 1990; Kappas et al, 1989). 
The inherited porphyrias appear to be of variable clinical penetrance. In some studies 
only about 10% of subjects who carry a particular defective enzyme develop clinical 
symptoms or other biochemical changes associated with the disorder (Moore et aI, 
1987; Hindmarsh, 1993; Elder, 1993; Elder et ai, 1997). In other studies the, 
penetrance may be in the range of 40 - 60 % (Kauppinen and Mustajoki, 1992). 
Generally, the prevalence of overt cases of the porphyrias is much lower than the 
defective gene frequencies. 
Porphyrias have a worldwide distribution, but certain types have exceptionally high 
frequencies in some countries. This is demonstrated by the relatively high frequency 
of VP in the South African population which has been attributed to a founder gene 
effect (Dean, 1971; Meissner et aI, 1987, 1996). More recent work has established a 
molecular basis for this. The gene defect apparently responsible for the VP founder 
effect in South Africa, is termed R59W and was found in over 90% of VP cases that 
were studied (Meissner et aI, 1996). This is reviewed in more detail later. Similarly in 
Northern Sweden a single mutation termed Trp 1985top, which is presumably 
responsible for a founder effect of acute intermittent porphyria (AlP) in that country 
appears to be responsible for the high prevalence (111500 people) of this disease in 
that area of that country (Kauppinen and Mustajoki, 1992). 
Classification of Porphyrias 
The diseases of porphyrin metabolism were first classified by Gunther (1911; 1922). 
Several classifications followed and the general aim of these was to provide a clinical 
basis that was consistent with the biochemical changes. A useful classification of the 
porphyrias groups these disorders into acute and non-acute forms on the basis of their 
main clinical presentation. Such a classification takes ,into account the combination of 
clinical manifestations and biochemical changes associated with these disorders and 
allows for differential diagnosis of the different porphyrias (Moore, 1990; Meissner, 
1990). The clinical disease state ofporphyrias involves several different body systems 
which may include the skin, nervous system, digestive system, and liver, depending 
on the type and level of expression of porphyria (Brodie et aI, 1977a; Elder, 1982; 
Rimington, 1985). As it is not the purpose of this dissertation to discuss all the 
porphyrias in detail I have included table 1.2 which classifies the porphyrias as acute 
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Table 1.2: A classification of the porphyrias. 
5-ALA-D deficiency =5-amino/aevulinic acid dehydratase deficiency porphyria; 
AlP =Acute intermittent porpyria; CEP = Congenital erythropoietic porphyria; 
PCT = Porphyria cutanea tarda; HCP = Hereditary coproporphyria; 
VP = Variegate porphyria; EP =Erythropoietic protoporphyria. 
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The Acute Porphyrias 
5-ALA-D deficiency I5~ALA dehydratase IRecessive 1 9q34 
Comment: 
ALA dehydratase porphyria results from a homozygous 5-ALA deficiency. and heterozygotes with a genetic defect 
usually do not show clinical changes (Sassa. 1998). Diminished 5-ALA dehydratase activity was demonstrated in 
erythrocytes (Doss et al. 1982). It is the rarest form of porphyria (Kappas et al. 1995). Disease presents 
prepubertally. Is similar to lead poisoning, but lead poisoning is generally associated with elevated urinary ALA and 
coproporphyrin. Symptoms similar to AlP. but can be differentiated by its autosomal recessive inheritance, lack of 
PBG overproduction and markedly reduced ALA dehydratase activity (Sassa. 1998). No cutaneous photosensitivity. 
Molecular analysiS of the ALA dehydratase genetic defects revealed different mutations indicating the genetic 
heterogeneity of this condition (Ishida et ai, 1990; Plewinska et ai, 1991; ). Patients with ALA dehydratase genetic 
defects showed markedly elevated urinary ALA, but variation of the clinical disease ranging from asymptomatic to a 
severe porphyric syndrome (Sassa, 1998). 
AlP IPBG Deaminase ! Dominant !11Q24.1-24.2 
Comment: 
Autosomal dominant disorder in which the activity of PBG deaminase is reduced in circulating erythrocytes (Strand et 
al. 1972) and other cells such as liver (Miyagi, 1970). lymphocytes (Sass a et ai, 1978), fibroblasts (Meyer, 1973). and 
amniotic cells (Sassa et ai, 1975). Enzyme deficiency is detectable from birth. Most carriers of the defective gene 
remain asymptomatic throughout their lives (Lamon et ai, 1979; Tschudy et ai, 1980; Bottomley et ai, 1981 ; Kappas et 
ai, 1989). Most of the defective proteins have been shown in several studies to be inactive and variable in stability 
(Anderson et al. 1981; Desnick et ai, 1985). Several mutations responsible for the defective PBG deaminases have 
been reported (Nordmann et ai, 1990; Lee and Anvret, 1991; Grandchamp, 1998). Despite the genetic heterogeneity, 
the clinical phenotype of AlP is relatively uniform presenting with acute attacks only, and no cutaneous involvement. 
Usually manifests postpubertally, and degree of clinical expression is highly variable and dependant on additional 
precipitating factors. Excessive PBG and to a lesser extent ALA excretion in urine. Clinical syndrome more frequently 
manifests in females (Stein and Tschudy. 1970). The diagnosis of latent gene carriers and prognosis of the disease 
improved as a result of the better understanding of the genetic defects underlying the biochemical and clinical 
features of AlP. and it appears that the use of DNA analysis is a more reliable approach to diagnosis (Kauppinen and 
Mustajoki. 1992; Kauppinen et al. 1995; Puy et ai, 1997). 
HCP ICopro' gen Oxidase IDominant 13Q12 
Comment: 
Diminished coproporphyrinogen oxidase (CO) activity shown in leukocytes (Brodie et al. 1977b). liver (Hawk et al. 
1978). lymphocytes (Elder et ai, 1976; Grandchamp and Nordmann. 1977) and cultured fibroblasts (Elder et al. 
1976). Dominant inheritance. homozygous form and a variant with 10% CO activity (harderoporphyria) (Nordmann et 
al. 1983) have been described. Skin lesions with acute attacks in about one third of patients. In absence of acute 
attacks the skin lesions are rare. Characterised by excessive excretion of coproporphyrin in the stool and to a lesser 
extent in urine (Brodie et al. 1977a; Blake et al. 1992; Schoenfeld et al. 1995). Acute attacks are more common in 
females (Brodie et al. 1977b; Kappas et al. 1995). and these could easily be diagnosed by the typical red 
fluorescence of stools under ultraviolet light. The disease is genetically heterogeneous. and different mutations 
identified in the CO gene of HCP patients have been reported (Martasek. 1998. Susa et al. 1998). Expression of the 
defective CO genes in Epstein-Barr virus transformed Iymphoblasts revealed reduction in CO activity ranging from 
less than 5% to appproximately 50% of normal (Sassa et al. 1997). 
vp IProto'gen Oxidase IDominant 11Q22-23 
Comment: 
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The Non-acute Porphyrias 
CEP 1 Uro'gen Cosynthase IRecessive 1 10Q2s.2-26.3 
Comment: 

Uroporphyrinogen-III cosynthase activity is markedly reduced, demonstrated in erythrocytes and skin fibroblasts 

(Romeo and Levin, 1969). Manifests from infancy. Severely photomutilating (Nordmann and Deybach, 1982). 

Characterised by accumulation of uroporphyrin-I and coproporphyrinogen-I in erythrocytes, plasma, bone marrow, 

urine and stool (Desnick et ai, 1998). The type I isomers of the intermediate 7-, 6-, and 5-carboxylate porphyrins are 

also predominantly excreted. Anaemia and cutaneous involvement are the major debilitating features of this disease. 

Several mutations responsible for the defective uroporphyrinogen-III cosynthases have been identified in the genes 

of patients with CEP, and these have been reviewed by Desnick et al (1998). 

PCT 1 Uro'gen Decarboxylase I Dominant 11P34 
Comment: 
Is the most common porphyria worldwide which presents with cutaneous photosensitivity and is caused by the 
deficiency of uroporphyrinogen decarboxylase activity (Kushner et ai, 1976; Elder, 1998). Is broadly subdivided into 
two main types that is, sporadic (type I) and familial (type II) based on measurement of erythrocyte enzyme activity 
(De Verneul et ai, 1978). Main biochemical features are elevated urinary and plasma uroporphyrinogen and 
heptacarboxylic porphyrin. Hexa-, pentacarboxylic and coproporphyrin are elevated to a lesser extent. There is 
elevation of stool porphyrins in addition to a striking elevation of lsocoproporphyrin. The clinical and biochemical 
changes can be reversed by either iron depletion or low-dose chloroquine treatment. The disease can be classified 
into different forms based on the underlying cause for the reduced enzyme activity and the clinical presentation: 
I. Familial Form: 
Decreased uroporphyrinogen decarboxylase activity which is inherited in an autosomal dominant fashion was 
demonstrated in liver cells (Elder et ai, 1978) and erythrocytes (de Verneuil et ai, 1978; McManus et ai, 1988; 
Elder et ai, 1989; Held et ai, 1989; Koszo et ai, 1992). Low clinical penetrance, with less than 10% subjects 
developing symptoms even though uroporphyrinogen decarboxylase is half normal in all tissues (de Verneuil et 
ai, 1978; Elder et ai, 1989; Elder, 1998). Mutations responsible for the defective uroporphrinogen decarboxylase 
proteins have been identified in the gene sequence (Garey et ai, 1989; McManus et ai, 1996; Sorkin et ai, 1996; 
Moran-Gimenez et ai, 1996). Both homozygous and compound heterozygous forms exist (McManus et ai, 1996; 
Moran-Gimenez et ai, 1996). 
II. Hepatoerythropoeitic porphyria (HEP) 
There is reduction of uroporphyrinogen decarboxylase activity by at least 75%, and severe photosensitivity from 
childhood which results from sustained overproduction of porphyrins (Roberts et ai, 1995a; Moran-Gimenez et ai, 
1996). Different mutations have been identified in the uroporphyrinogen decarboxylase gene (Elder and Roberts, 
1994; Meguro et ai, 1994; McManus et ai, 1996; Moran-Jiminez et ai, 1996) and only one of these was reported 
to be associated with the overt clinical disease (Roberts et ai, 1995a). Patients are either homozygotes or 
compound heterozygotes for the uroporphyrinogen decarboxylase mutations. It has been proposed that the other 
mutations may be autosomal recessive (Meguro et ai, 1994; Roberts et ai, 1995). Presenting feature is elevated 
erythrocyte Zn-protoporphyrin (Smith, 1986). 
III. Acquired Forms: 
- Sporadic 
Appears as an unusual response to alcohol abuse, sex steroids and some forms of iron overload including 
"Bantu siderosis· (Pimstone, 1982). Reduced uroporphyrinogen decarboxylase activity appears to be restricted to 
the liver (Elder et ai, 1985). 
- Toxic 
Appears in response to certain toxic chemicals, particularly polyhalogenated hydrocarbons (Silbergeld and 
Fowler, 1987), includes "Turkish" porphyria (Schmid, 1960). Development of the disease appears to be a 
predictable and dose-related response to the absorption of a porphyrinogenic chemical (Elder, 1998). 
- Chronic renal failure 
Appears in a small number of patients with chronic renal failure on haemodialysis (Day and Eales, 1982). Must 
be distinguished from "pseudoporphyria" which resembles PCT clinically but without evidence of 
uroporphyrinogen decarboxylase deficiency (Moore et ai, 1987). 
EPP IFerrochelatase IDominant I18q21.3 
Comment: 
Diminished ferrochelatase activity found in all tissue types (Bloomer et ai, 1982). Dominant inheritance with partial 
penetrance (Went and Klasen, 1984). Highly variable clinical expression (poh-Fitzpatrick, 1985). Cutaneous 
involvement. Manifests from infancy. Association of the cutaneous involvement with progreSSive liver failure is more 
serious, and focal deposits of protoporphyrin were demonstrated in hepatocytes and thrombi within biliary canaliculi 
(Thompson et ai, 1973; Klatskin and Bloomer, 1974;Matilla and Molland, 1974; MacDonald et ai, 1981; Sarkanyand 
Cox, 1995). Outstanding biochemical feature is the elevated erythrocyte free protoporphyrin. Molecular analysis 
revealed several mutations associated with the deficiency of ferrocholatase activity, recently reviewed by Cox et al 
(1998). The fact that most of the affected individuals seem to possess unique mutations in the ferrochelatase gene 












VP is an autosomal dominant disorder of haem biosynthesis which results in 
decreased activity of PPO, the penultimate enzyme of this pathway. Tissues from VP 
patients such as fibroblasts (Brenner and Bloomer, 1980b); leukocytes (Viljoen et aI, 
1983; Deybach et al, 1981; Boyle et al, 1986; Moore et ai, 1987; Timonen et ai, 1990; 
Guo et aI, 1991); and Epstein-Barr virus transformed Iymphoblasts (Meissner et aI, 
1986; 1993) express approximately 50% of the enzyme activity. VP is characterised 
clinically by photosensitive skin disease and the propensity to develop a life 
threatening acute neurovisceral crisis. 
History and Prevalence of Variegate Porphyria in South Africa 
The history of acute porphyrias in South Africa dates back to a publication in 
I'nyanga (a journal of medical students) describing this condition, by two medical 
students, Eales and Chait (1939). Subsequently, a series of cases of this condition was 
described within the South African White population (Barnes, 1945; 1951; Dean and 
Barnes, 1958; 1959). Important characteristics of this condition were described in the 
meticulous genealogical investigations carried out by Dean (1971). In these studies 
Dean hypothesised that the South African VP subjects were descendants from the 
marriage between a Dutch couple which took place at the Cape of Good Hope in 
1688. Ariaantjie Adriaanse, an orphan from Rotterdam (Netherlands) arrived at the 
Cape in 1688 and married one of the Free Burghers, Gerrit Jansz van Deventer. Four 
of their eight children inherited the genetic defect which they passed on to 
approximately 50% of their offspring (Jenkins, 1997). It seems therefore that one 
individual was heterozygous for (or a carrier of) the gene for VP. 
Population growth theories suggest that in the 1960s approximately 10-20 000 
subjects were carrying the defective PPO gene introduced by this couple to the Cape 
(Dean, 1971; Eales et aI, 1980; Day, 1986). This gene had a high prevalence in this 
population due to the tendency to produce large families, which had resulted in the 
rapid expansion of this population during the 18th century from just over 1000 to 
17000 in 85 years (Jenkins, 1997). Furthermore, because of the isolation of this 
population, gene flow into it or immigration was relatively limited (Jenkins, 1997). 
Besides the White population, cases of VP have been encountered in the popUlation 
of mixed ancestry who are mainly descendent from the slave population imported by 
17th 18ththe Dutch to Cape Town in the and century, further modified by 
intermarriage with other indigenous and settler populations over the years. The 
exceptionally high prevalence of VP in the SA population is a typical example of 
random genetic drift (the operation of chance factors resulting in the high [or low] 
frequency of a gene in a popUlation) which is known as founder effect (Jenkins, 
1997). 
The extensive investigations carried out by Dean on the epidemic of inherited 
porphyrias in SA subjects with the so-called 'van Rooyen's skin' (referring to 
photosensitive skin) revealed some of the characteristics of VP (Dean, 1953; 1957; 
Barnes, 1951). Dean observed that all the porphyric patients were over 18 years of age 











and stools which were found to have elevated levels of porphyrins. Later the clinical 
and biochemical studies of acute porphyrias carried out by Eales (1961; 1963) 
clarified and confirmed the increase in the concentration of porphyrins as well as the 
precursors, ALA and PBa in the urine specimens of the disease during the acute 
phase. It was found that an average of 50% of children developed the porphyria when 
one of the parents was a porphyric, suggesting a classical Mendelian inheritance of 
this condition (Dean, 1971; Jenkins, 1990), It was also observed that females were 
more prone to the acute attacks than males, indicating a hormonal influence in the 
expression and severity of this disorder. 
The excellent work by Dean, Barnes and Eales in defining this disease condition 
culminated in them hosting the first International Conference on the Porphyrias in 
Cape Town, in 1963. This conference reached an important agreement on the 
classification of porphyrias (Proceedings of the International conference on the 
Porphyrias, 1963). 
Presentation and Diagnosis of Variegate Porphyria 
Clinical presentation 
Patients with the PPO defect do not normally present with the disease condition of VP 
before puberty (Dean, 1971, Kramer, 1980, Meissner and Hift, 1991). Clinically VP 
patients may present with photocutaneous lesions, acute neurovisceral crisis, or both 
(Eales et aI, 1980). A significant proportion of subjects with the underlying enzyme 
defect remain asymptomatic throughout life. A severe diffuse abdominal pain felt 
through the abdomen, and often the lower back, buttocks and thighs is the most 
common presenting feature. Vomiting, constipation, hypertension, tachycardia, and 
dehydration are the other common presenting features of this disorder. They may be 
accompanied by a peripheral neuropathy. Some patients may present with abnormal 
behaviour, confusion, and agitation, although in the majority of cases this is only 
during the acute attack in hyponatraemic patients on pethidine (Kauppinen and 
Mustajoki, 1992; Hift et aI, 1997; Elder et aI, 1997; Kirsch et aI, 1998). 
The porphyrin intermediates which accumulate in the upper layers of the dermis are 
assumed to cause a classical photodermatitis (Runge and Watson, 1962; Day, 1986). 
The common hypothesis, that porphyrins on exposure to light in the near ultraviolet 
range (±400nm) can cause the formation of singlet toxic oxygen species which may in 
turn be responsible for peroxidative destruction of cellular membranes, remains to be 
shown as being the primary pathogenic mechanism operative in VP. Thus other 
mechanisms may also contribute to the photo cutaneous sensitivity (Poh-Fitzpatrick, 
1998). In addition, an interesting specific observation in VP is that uro- and 
heptacarboxylic porphyrin rather than the predominant excreted proto- and 
coproporphyrin species are present in the skin (Day, 1986). 
The skin lesions are generally in the form of blisters, erosions, fragility, milia and 
abnormal pigmentation which eventually leads to thickening, grooving, hirsutes and 











such as the dorsa of the hand, forearm and feet; the face and nape of the neck (Elder et 
I 
aI, 1997; Kirsch et aI, 1998). 
Biochemical presentation and diagnosis 
The classical biochemical picture of VP is characterised by an increase in faecal 
protoporphyrin and to a lesser extent, coproporphyrin; and the urinary porphyrin 
precursors, ALA and PBG which are elevated during the acute attack (Eales et aI, 
1980; Day, 1986; Nordmann and Deybach, 1990; Kappas et aI, 1989; Hift et aI, 
1997). The porphyrin elevations are consistent with a partial block in the haem 
pathway at the level of PPO. There is evidence to suggest that the accumulation o[ 
ALA and PBG during the acute attack of VP, may be due to the allosteric inhibition 
of PBG deaminase by the accumulating protoporphyrinogen and coproporphyrinogen 
(Meissner et al, 1993). 
Thus biochemical diagnoses may be based on the quantitation and analysis of 
excreted porphyrins, and in the case of a suspected acute attack on the measurement 
of the porphyrin precursors. The experience of our laboratory also suggests that the 
finding of 5-COOH-porphyrin or "pseudo 5-COOH-porphyrin" compounds in VP 
patients is ofdiagnostic significance (Moore et aI, 1987; Hift et ai, 1997). 
In addition to the classical porphyrin extraction and chromatographic techniques, a 
plasma protein-porphyrin complex gives a characteristic peak of fluorescence 
emission between 621 and 627 nm at an excitation of 405 nm, and appears specific 
for VP diagnosis (Poh-Fitzpatrick, 1980; Long et al, 1993; Gregor et aI, 1994; Da 
Silva et ai, 1995). This method is fast replacing the more traditional porphyrin 
chromatographic techniques in many parts of the world. 
The enzyme assay on PPO activity, which can be performed on Epstein-Barr virus 
transformed Iymphoblasts (Meissner et aI, 1986) and fibroblasts (Brenner and 
Bloomer, 1980a) to demonstrate the 50% decrease in enzyme activity, is not suitable 
for diagnostic purposes due to the low levels of this activity in these cell types and the 
tediousness of the assay. 
While it is not perhaps relevant to review the finer intricacies of the diagnosis of VP 
in detail here, the following are interesting observations. 
1. The profile of excreted porphyrin varies widely between and within individual 
VP patients. Chromatographic analysis of porphyrin profiles may indeed be normal or 
near normal in some VP patients. About 30-40% of VP patients examined in our 
laboratory, either consistently or transiently, present with normal porphyrin excretory 
profiles (Kirsch et aI, 1998). The biochemistry of many of the older patients who . 
presented with elevated porphyrin excretion in early adult life sometimes return to 
normal levels. 
2. The stool porphyrin profile has been shown to be normal in some YP patients 
in the presence of elevated biliary porphyrin concentrations (Logan, et aI, 1991). Also, 
dissimilarities in stool and biliary porphyrin excretion profiles have been 











predominate in bile and stool, respectively (Hift R., unpublished data). This 
unexplained paradox may be due to the differential reabsorption of porphyrins in the 
small intestine or it may be due to bacterial metabolism within the colon. 
Genetic presentation and diagnosis 
The isolation of the cDNA (Nishimura et aI, 1995b; Dailey and Dailey, 1996b) and 
characterisation of the gene (Roberts et aI, 1995b) encoding human PPO has 
facilitated the identification of many mutations. Indeed, 81 mutations responsible for 
the defective PPO genes in VP have been reported worldwide to-date (Deybach et aI, 
1996; Meissner et aI, 1996; Wamich et aI, 1996a; Frank et aI, 1998a, b, c, d, e; 
Roberts et aI, 1996, 1998; Lam et aI, 1996, 1997; Puy et al, 1996; Corrigall et al, 
1998, 2000, de Rooij et al, 1997, Kauppinen et al, 1996, Whatley et aI, 1999). This 
has led to the development ofDNA diagnostic techniques, which have been applied in 
the management of families with this condition. Because VP has a variable clinical 
and biochemical expression, and the fact that the disease seldom manifests before 
puberty, its diagnosis is significantly enhanced by the use of mutational analysis. 
Indeed, in SA screening for the R59W mutation is useful as this defect appears to be 
accountable for over 90% ofVP in this country (Meissner et aI, 1996; Wamich et aI, 
1996a). However, a major limiting factor to the role of mutational analysis in the 
diagnosis of VP is the genetic heterogeneity of this condition in the rest of the world. 
Even in South Africa, in spite of the founder gene effect, nine different mutations 
have been identified to-date (Meissner et aI, 1996, Wamich et aI, 1996a, Hift et al, 
1997, Corrigall et aI, 1998, 2000). 
A small number of cases of apparently homozygous VP (HVP) have been reported 
worldwide including South Africa (Korda et aI, 1984, Murphy et aI, 1986, Mustajoki 
et al, 1987, Norris et al, 1990, Gandolfo et aI, 1991, Coakley et al, 1990, Hift et al, 
1993, Roberts et aI, 1998, Corrigall et aI, 2000). These individuals have a marked 
reduction of PPO activity [<25% of normal] (Hift et aI, 1993, Roberts et aI, 1998), 
and a severe phenotype with onset occuring mainly in infancy. However a case of late 
presentation (at age 19 years) has been documented (Corrigall et aI, 2000). Typical 
symptoms include growth retardation, brachydactyly, nystagmus, mental retardation 
and convulsions. Prior to the identification of the PPO gene many of these cases were 
thought to represent VP homozygosity, thus the syndrome became known as HVP. 
Nine of the thirteen cases of apparently homozygous VP, reported todate, have been 
investigated at a molecular level. Only two of these cases were homozygotes (Roberts 
et aI, 1998) while the remainder were compound heterozygotes (Roberts et aI, 1998, 
Meissner et aI, 1996, Frank et aI, 1998c, Kauppinen et aI, 1996, Corrigall et aI, 2000). 
Interestingly, in South Africa the gene frequency of the R59W mutation is such that 
homozygosity would have been expected to occur (Jenkins, 1996). No cases of R59W 
homozygosity have been reported todate. Thus, it would appear that homozygosity for 











On examination of the above it stands to reason that: 
1. Intensive screening of VP families which leads to identification of carriers, and 
the better education of both patients and doctors on factors precipitating acute attacks, 
should result in a significant reduction of the number of VP subjects who present with 
the life threatening acute attacks. 
2. When possible VP individuals should be described in terms of their genotype, 
biochemical activity, and clinical expression in order to allow easier comparison and 
critical understanding of data emanating from all parts of the world. 
General Comments 
On reading the above it is clear that the application of molecular biological techniques 
in the study of the haem biosynthetic proteins has yielded valuable information and 
facilitated their characterisation. The genes or cDNA sequences have now been 
isolated and characterised for all of the human enzymes involved in the haem . 
pathway. These have led to refinement of purification procedures enabling simple 
rapid purifications to be carried out with large protein yields, which in turn have 
allowed detailed characterisations, and in some cases, crystal structures to be 
determined. The new methodologies have also helped clarify some of the ambiguities 
. encountered when these proteins were purified by conventional chromatographic 
purification procedures. These advances have also facilitated the correct chromosomal 
mapping of some of these genes in the human genome, improving dramatically on 
previous methods used for this purpose. 
Importantly, these methods have become useful and additional tools in investigating 
the factors associated with the pathogenesis of porphyrias. Many mutations which are 
responsible for the defective enzymes in the inherited porphyrias have now been 
identified and characterised. 
Despite the advances mentioned above difficulties may still be encountered. Indeed, 
PPO is still difficult to purify to homogeneity despite its cloning and the use of 
affinity chromatography purification procedures. This has contributed to the lack of 
information on structure-function relationship of this enzyme. Continued interest in 
PPO is due to it's role in the pathogenesis of VP and the fact that PPO is the 
molecular target for several peroxidizing herbicides. This has raised much interest and 
stimulated a lot of research by the agricultural sector aimed at exploiting this property 
in crop control (Matringe et aI, 1989a, b; Witkowski and Halling, 1988). The next 












Literature Review Continued 
As this thesis is largely concerned with work on the protein PPO it is reviewed in 
relevant detail in this chapter. 
Protoporphyrinogen Oxidase (PPO) and the 
Conversion of Protoporphyrinogen-IX to 
Protoporphyri n -IX. 
ppo is the last enzyme common to both the haem and chlorophyll pathways (Jacobs. 
and Jacobs, 1981). At this, the penultimate step, the pathway leading to the formation 
of these two compounds diverges, with specific chelatases inserting either iron (Fe2+) 
or magnesium (Mi+) into the protoporphyrin tetrapyrrole to form haem and 
chlorophyll precursors, respectively (Beale and Weinstein, 1990). 
Briefly, during the six electron oxidation catalysed by PPO, the methylene bridges (­
CH-) in protoporphyrinogen-IX are converted into methenyl bridges (-CH=) and 
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Figure 2.1 The penultimate step of haem biosynthesis involves six electron oxidation of 
protoporphyrinogen-IX to protoporphyrin-IX by protoporphyrinogen oxidase. In the presence 
of air protoporphyrinogen-IX is auto-oxidised to protoporphyrin-IX. M =methyl, V =vinyl and P 
= propionate. 
It must be added that in the presence of oxygen protoporphyrinogen-IX is auto­
oxidised into the highly conjugated protoporphyrin-IX molecule in a light-dependent 
non-enzymatic (chemical) reaction, thus compounding the difficulties associated with 
work on this enzyme. This in vitro oxidation of protoporphyrinogen-IX occurs rapidly 
at neutral and acidic pH. However, under nonnal circumstances in cells this reaction 
requires enzymatic catalysis due to the reducing environment in the mitochondria 











Although all PPOs share a common feature in that they oxidise protoporphyrinogen­
IX to protoporphyrin-Ix, these proteins show inter· and sometimes intra-species 
diversity in their kinetic and other physicochemical properties. It must also be borne 
in mind that some of the apparent diversities could have arisen because of the 
differences between earlier and later more definitive reports. These can conceivably 
arise as early workers did not have the advantage of known and identifiable protein or 
cDNA sequence data. Thus some apparently discrepant reports could have been 
artefactual (eg. Some of the "PPO" apparently purified by Siepker et al (1987) was 
probably a.-I-antitrypsin - personal communication L. Siepker, S. Kramer). 
Early work on the yeast (Saccharomyces cerevisiae) reaction (Poulson and Polglase, 
1975) and subsequent work on the mammalian mitochondrial reaction (Poulson, 
1976) provided much of the information which supported the specific enzymatic 
catalysis of this step in haem and chlorophyll . biosynthesis. The isolation and 
subsequent characterisation of protoporphyrinogen-IX oxidising proteins from several 
sources such as yeast (Poulson and Polglase, 1975), rat livers (Poulson, 1976), the 
photosynthetic bacteriwn, Rhodopseudomonas spheroides (Jacobs and Jacobs, 1981), 
and barley (Jacobs and Jacobs, 1984a) provided conclusive evidence for the 
enzymatic catalysis of the penultimate step in haem biosynthesis. Jacobs and Jacobs, 
(1984b) demonstrated the existence of this protein in several prokaryotic and 
eukaryotic species such as rat, barley, spinach, Escherichia coli and R. spheroides. 
Anaerobic enzymatic oxidation of protoporphyrinogen-IX was demonstrated by the 
isolation of this protein from the obligate anaerobic bacteriwn, Desulfovibrio gigas 
(Klemm and Barton, 1985; 1987). PPO activity was solubilised from the plasma 
membranes of D. gigas and the protein was purified to apparent homogeneity (Klemm 
and Barton, 1987). 
Terminal Electron Acceptors in the Oxidation of 
Protoporphyrinogen-IX to Protoporphyrin-IX 
Consideration of the reaction catalysed by PPO, implies that there is an electron 
acceptor required for catalysis to occur. It appears that during aerobic oxidation of 
protoporphyrinogen-IX to protoporphyrin-IX, by both eukaryotic and prokaryotic 
PPOs, molecular oxygen is utilised as the terminal electron acceptor (Poulson, 1976; 
Deybach et al, 1985). Aerobic bacteria such as Bacillus subtilis (Dailey et aI, 1994a; 
Hansson and Hederstedt, 1994b) and Myxococcus xanthus (Dailey and Dailey, 
1996a), also utilise molecular oxygen as the final acceptor of the electrons. In some 
facultative prokaryotes such as E. coli, oxygen serves as the final acceptor of the 
electrons released from the aerobic reaction, but in the anaerobic oxidation alternative 
electron acceptors such as nitrate and fumarate are utilised (Jacobs and Jacobs, 1975; 
1976). Facultative organisms are defined as those organisms that can exist and 
survive well under either aerobic (in presence of oxygen) or anaerobic (in absence of 
oxygen) conditions. In these organisms it is proposed that the electrons removed from 
the oxidation of protoporphyrinogen-IX are transferred to the electron transport chain 
(Jacobs and Jacobs, 1977a); thus providing a source of energy regeneration. The 
coupling of the oxidation reaction to the nitrate/fumarate reductase system was shown 











However, different facultative organisms utilise different alternative terminal electron 
acceptors in the anaerobic reaction. Nitrate and fumarate were ineffective as electron 
acceptors in the anaerobic reaction of Staphylococcus epidermidis, which is a 
facultative anaerobe (Jacobs and Jacobs, 1976). It seems as if in this organism 
protoporphyrinogen-IX oxidation is strictly an oxygen-dependent process. The 
anaerobic oxidation of protoporphyrinogen-IX into protoporphyrin-IX in the obligate 
anaerobe, D. gigas, was also shown to be coupled to the reduction of several 
physiologic electron acceptors such as; NAD+, NADP+, FAD, FMN, nitrite, fumarate 
and ATP plus SUlphate (Klemm and Barton, 1985, 1989), and a non-physiologic 
compound, dichlorophenolindophenol (DCIP) (Klemril and Barton, 1987). In the 
photosynthetic bacterium, R. sphaeroides, the anaerobic reaction is similar to E. coli 
in that protoporphyrinogen-IX oxidation has been shown to be coupled to the electron 
transport chain utilising quinones as electron carriers (Jacobs and Jacobs, 1981). 
Due to the different conditions under which reactions take place in prokaryotes, on 
many occasions different isoforms of the same enzyme are often used in the catalysis 
of the same reaction. But such isoforms which differ on the basis of their oxygen 
requirements have not been unequivocally identified in PPOs. While, it has been 
suggested that the two PPOs identified in E. coli that is, hemG (Sasarman et aI, 1993, 
Nishimura et aI, 1995a) and hemK (Nakayashiki et al, 1995) could be PPO isoforms 
which operate under aerobic and non-aerobic conditions of protoporphyrinogen 
oxidation this appears not to be the case. 
pH Conditions for the Enzymatic Oxidation of Protoporphyrinogen­
IX 
Generally PPOs operate optimally at and above neutral pH. R. spheroides (Klemm 
and Barton, 1987), E. coli (Sasarman et aI, 1993), S. cerevisiae (Poulson and Polglase, 
1975), spinach, barley (Jacobs and Jacobs,1984a), potato and maize (Camadro et aI, 
1991) have pH optima in the range 7.0 to 7.5. Interestingly, the oxygen-independent 
D. gigas enzyme oxidised protoporphyrinogen-IX optimally over a wide pH range 
from 7.0 to 11 (Klemm and Barton, 1987). The fact that this PPO is a very large 
multi subunit protein complex may be contributing somehow to the pH tolerance over 
such a wide range. Thus, the interaction between the six subunits which comprise the 
active enzyme could provide some protective buffering effect which minimises the 
effects of pH change over this range on the enzyme's catalytic activity. 
Mammalian PPOs such as the rat (Poulson, 1975), bovine (Siepker et aI, 1987), human 
(Camadro et aI, 1985) and mouse (Dailey and Karr, 1987) have pH optima of 8.1-8.8; 
8.7; 7.2 and 7.1, respectively. The purified mitochondrial and etioplastic barley PPOs 
had the lowest reported pH optimum range of 5-6, which indicates preference for an 
acidic environment (Jacobs and Jacobs, 1987). Previously, optimum PPO activity for 
the crude sonicated barley enzyme preparation was achieved at pH 7.3 (Jacobs and 
Jacobs, 1984a). Considering the fact that undesirable auto-oxidation of 
protoporphyrinogen-IX would be fairly rapid at such a low pH range «6), it would be 
logical therefore to speculate that under physiological conditions pH 7.3 could be the 











Isolation and Purification of PPOs 
For many years researchers were dogged by difficulties in attempts at purification of 
this membrane bound protein using a variety of standard chromatographic methods. 
PPOs are hydrophobic membrane bound proteins requiring detergents for 
solubilisation and the various PPO forms behave differently in the presence of 
different detergents. Furthermore, these proteins show variable stability. In the 
presence of 0.2% octyl glucopyranoside purified human PPO may be stored for days 
at 4°C and even retains significant activity after overnight storage at room temperature 
(Dailey and Dailey, 1997a). In contrast, M xanthus PPO appears less stable and tends 
to precipitate out when stored at 4°C (personal observation). Prolonged storage (1 
month) of yeast mitochondrial membranes at -80°C resulted in degradation of PPO 
into immunologically detectable low molecular weight fragments. Proteolysis was 
however significantly less than when stored at -20°C (Camadro et aI, 1994). Finally 
the assay for PPO activity is extremely laborious requiring fresh preparation of the 
substrate which involves sodium amalgam reduction of protoporphyrin-IX and, since 
porphyrins are photo-degradable compounds, the PPO assay is performed in the dark. 
Despite these difficulties a number of laboratories managed to build up a considerable 
knowledge of this enzyme, even though the data was sometimes obtained using crude 
sonicated enzyme preparations, or partially purified preparations. 
Efforts by various researchers working on this protein paid off with achievements of 
partial and on very rare occasions homogeneous purification, and subsequent 
characterisation of PPOs from various sources such as rat (Poulson, 1976); S 
cerevisiae (Poulson and Polglase, 1975; Camadro et aI, 1994); R. sphaeroides (Jacobs 
and Jacobs, 1981) barley (Jacobs and Jacobs, 1987; Jacobs et aI, 1989); D. gigas 
(Klemm and Barton, 1987); mouse (Dailey and Karr, 1987; Ferreira and Dailey, 1988; 
Proulx and Dailey, 1992); bovine (Siepker et aI, 1987); spinach (Matringe et ai, 
1992a); and potato plant (Johnston et aI, 1998). In many of these efforts a 
combination of several different steps of standard chromatographic purification 
techniques were applied to improve purification of the protein. This resulted in long 
procedures and the protein yield was very low making it difficult to carry out lengthy 
characterisation studies. The rapid degradation of this protein under cold storage 
compounded this problem. 
More recently several PPO genes have been cloned and sequenced from various 
species. These are discussed later in this chapter. However, pertinent to this 
discussion is the fact that cloning of the various PPO genes and overexpression of this 
protein in E. coli cells has resulted in the establishment of simple rapid purification 
procedures enabling researchers to produce large amounts of the protein. This 
breakthrough facilitated confirmatory and further characterisation of this enzyme from 
various sources. In spite of this data, information on the protein structure, and in 












PPO Protein Size Range 
Most oxygen-dependent PPOs, such as the human (Nishimura et aI, 1995; Dailey and 
Dailey, 1996b); mouse (Taketani et aI, 1995a, Dailey et aI, 1995); M xanthus (Dailey 
and Dailey,1996a); B. subtiUs (Hansson and Hederstedt, 1992; Dailey et aI, 1994a); S. 
cerevisiae (Camadro et aI, 1994); A. thaliana (Narita et aI, 1996); bovine (Siepker et 
al, 1987); tobacco plant (Lermontova et aI, 1997); spinach (Matringe et aI, 1992); and 
potato plant (Johnston et aI, 1998) forms have reported molecular weights within the 
range 51 000-57 000 Da. The rat enzyme is the smallest reported mammalian PPO 
with a molecular weight of 33 000 Da determined by SDS-PAGE (Poulson, 1976). 
This is similar to the molecular weight of 36 000 Da reported for the purified barley 
PPO (Jacobs and Jacobs, 1987). Howevere, as both these are early reports they may 
well be spurious The 21 200 Da E. coli PPO (Sasarman et ai, 1993) and 148000 Da 
reported for the D. gigas multi subunit enzyme (Klemm and Barton, 1987) represent 
anaerobic eznymatic oxidation and are distinct from the oxygen-utilising forms of the 
enzyme. 
Subunit Composition of PPO Proteins 
Analysis of various purified PPOs suggest that most of these proteins exist as either 
monomers such as the B. subtiUs (Dailey et al, 1994a); S. cerevisiae (Camadro et aI, 
1994); and mouse (Dailey and Karr, 1987); or homodimers such as M xanthus 
(Dailey and Dailey, 1996a) and human PPOs (Nishimura et aI, 1995b; Dailey and 
Dailey, 1996b). The oxygen-independent D. gigas enzyme is a large multi-subunit 
protein complex of 148 000 Da. The active form of this protein is a hexamer 
composed of two of each of three different subunits of 12000 Da, 18500 Da, and 57 
000 Da which are held together by disulfide bonds (Klemm and Barton, 1987). 
PPO Cofactor Composition 
Evidence from spectral analysis and gene/protein sequence information shows that 
these enzymes are flavoproteins. Such evidence has come in the form of flavins 
extracted from various purified PPOs and the identification of the dinucleotide 
binding (~a~) motif near the N-terminal sequences of cloned PPO genes. Generally 
the flavin cofactors are non-covalently bound to these proteins. The bovine FAD 
(Siepker et aI, 1987) cofactor is an exception in that it appears to be covalently 
associated with the protein. 
When Poulson and Polglase (1975) first partially purified and characterised the yeast 
PPO they observed an absorption peak at 410 nm which seemed to indicate presence 
of a prosthetic cofactor. However, no flavins were detected in their enzyme 
preparations. Interestingly, studies of the oxidation of protoporphyrinogen-IX by the 
obligate anaerobic bacterium, D. gigas, showed that in the presence of several 
electron acceptors such as NAD+, NADP+, FAD, and FMN this reaction was 
significantly stimulated (Klemm and Barton, 1985). This suggested a role of these 
compounds in the enzymatic activity, but unfortunately this property was not 











Spectral analysis of a purified bovine PPO revealed a typical flavoprotein spectrum 
which was indicative of the association of this enzyme with a flavin cofactor (Siepker 
et aI, 1987). Subsequent characterisation of the extracted flavin cofactor indicated that 
it was FAD. The extraction of the cofactor required the use of hot mineral acids and 
trypsin digestion demonstrating that it was covalently bound to the protein. The use of 
exogenous flavins to try and stimulate the enzyme activity proved unsuccessful, and 
Siepker et al (1987) attributed this to the requirement for tight covalent binding of the 
cofactor by the enzyme. An unusual finding with the bovine PPO FAD cofactor was 
that it appeared to be present in a reduced form in the active enzyme (Siepker et aI, 
1987), a situation which would be expected to occur only when the electrons are 
released from the porphyrinogen during the catalysis of the reaction by the enzyme. 
On the other hand, Dailey and Karr (1987) did not find any evidence of a 
chromophoric cofactor from the ultraviolet/visible spectral analysis of the purified 
mouse PPO. A fluoroscence emission spectroscopy at an excitation wavelength of 
450 nm under both oxidizing and reducing conditions did not yield a typical flavin 
spectrum, suggesting that this purified PPO was not a flavoprotein. When the effects 
of several electron acceptors such as FAD were tested on this enzyme no significant 
stimulation could be detected (Dailey and Karr, 1987; Ferreira and Dailey, 1988). In a 
subsequent re-investigation of this property on this enzyme by the same laboratory a 
flavin moiety was identified in the purified protein from utraviolet/visible spectral 
analysis (Proulx and Dailey, 1992). This group used a shorter and more rapid scheme 
for the purification of the mouse PPO which gave higher protein yields than in 
previous procedures. Lack of any effect on oxidation of the purified enzyme 
preparation indicated that the cofactor was present in an oxidised state. The 
fluorescence emission spectrum of the isolated' cofactor gave the same emission 
maximum as an FMN standard, suggesting that this was the cofactor associated with 
this enzyme. This was also supported by data from HPLC analysis. Attempts to 
reconstitute the activity of this enzyme with exogenous flavins were not successfuL 
Later, the presence of the dinucleotide binding motif and identification of FAD as a 
cofactor in mammalian PPO were reported for the first time in the mouse (Dailey et 
aI, 1995) and human (Dailey and Dailey, 1996b) enzymes. 
During the cloning and characterisation of the B. subtilis hemY cDNA sequence 
Dailey et al (1994a) identified the dinucleotide binding domain in this PPO gene, 
suggesting association of this enzyme with flavins. Subsequent spectral analysis of 
the purified B. subtilis PPO revealed a typical flavoprotein spectrum (Hansson et aI, 
1997). 
At that time an improved purification of the yeast PPO by Camadro et al (1994) also 
revealed the presence of a flavin cofactor which was identified by its pH-dependent 
spectral shift to be FAD. The cofactor was present at a flavin-to-protein ratio of 1. 
Slightly later, sequence analysis of the cloned yeast hem14 gene coding for PPO, 
revealed a putative (3a(3 motif (Camadro and Labbe, 1996). A typical flavin 
absorption spectrum was obtained from spectrophotometric analysis of the purified 
protein and extracted cofactor. 
To further confirm the flavoprotein nature of the B. subtilis PPO Hansson et al (1997) 
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FAD-containing enzymes. In the presence of FAD the enzymatic activity was also 
stimulated 2-3 fold. This data suggested a role of the FAD cofactor in enzyme 
activity. The cloned PPO from another aerobic bacterium, M xanthus, was also 
reported to be a flavoprotein that was non-covalently associated with FAD (Dailey 
and Dailey, 1996a). Analysis of the PPO cDNA sequence from this organism also 
revealed the presence of the dinucleotide binding motif. In this protein the cofactor 
was reported to be present at a ratio of one FAD per homodimer or 0.5 FAD per 
protein subunit. 
Nishimura et al (1995a) had also identified the flavodoxin motif in the hemG cDNA 
sequence ofE. coli which suggested that this enzyme was a flavoprotein. 
Consideration of the. cDNA sequence data from many species reveal that human 
(Nishimura et ai, 1995b), mouse (Taketani et ai, 1995a), plant (Narita et ai, 1996), 
yeast (Camadro and Labbe, 1996) and some bacterial (Dailey and Dailey, 1996a, 
1998) PPO sequences share a high degree of homology near the amino terminus. This 
area corresponds to a typical dinucleotide binding (~a~) motif. This is a defined, 
conserved sequence which occurs in the form of a GXGXXG fingerprint, comprised 
of three glycine (G) residues and other amino acid (X) substituents which include an 
acidic residue, found near the N-termini of many NAD and flavin binding protein 
domains (Wierenga et ai, 1986). Both DNA sequence analysis for the dinucleotide 
binding motif and further extraction of these cofactors from purified proteins have 
facilitated the identification of PPOs as fl voproteins associated with either FAD or 
FMN as cofactors. 
Plant biologists followed a similar path of discovery. Fluorometric analysis of a crude 
plant PPO (barley) preparation looking for cofactors involved in the electron transfer 
process showed no association of this protein with any chromophoric compounds 
(Jacobs and Jacobs, 1987). On subsequent analysis of the purified barley PPO, using 
extraction procedures for either covalently or non-covalently bound cofactors, there 
was no evidence of a flavin cofactor association with this protein (Jacobs et ai, 1989), 
suggesting that the plant PPO was not a flavoprotein. This property appears either 
unique to the barley PPO or represents a conclusion based on a non-PPO protein, 
because recent cloning of the A. thaliana PPO and subsequent analysis of the cDNA 
sequence revealed the presence of the typical dinucleotide binding motif (Narita et aI, 
1996). More recently the presence of this dinucleotide binding domain has also been 
identified in the cloned and characterised plastidal and mitochondrial PPO isoforms 
of the tobacco plant (Lermontova et al, 1997) and potato (Johnston et al 1998). 
Although the physical analysis for the flavin association with these proteins has not 
been done, available sequence information indicates that plant PPOs are also 
flavoproteins. 
The identification of the flavin cofactors in association with PPOs has been an 
important discovery since this sheds light on the ability of the protein to transfer six 
electrons during the oxidation of protoporphyrinogen-IX. Sequence analysis revealed 
that, in addition to the dinucleotide binding motif, there is high similarity in an 
approximately 60 residue-long region that extends beyond this motif between PPOs, 
bacterial and plant phytoene desaturases (PHDs) and animal monoamine oxidases 











motif for an FAD superfamily containing PPOs, PHDs and animal MOAs as this 
region of similarity does not appear in any of the other proteins in current gene 
sequence databases. 
Substrate Specificity 
Naturally, PPOs catalyse the oxidation of protoporphyrinogen-IX into protoporphyrin­
IX. Some PPOs such as the barley and spinach (Jacobs and Jacobs, 1984a), B. subtilis 
(Dailey et aI, 1994a), rat (Poulson, 1975), mouse (Dailey and Karr, 1987), and human 
enzymes (Camadro et aI, 1985) also oxidise the non-physiological dicarboxylic 
mesoporphyrinogen-IX. Mesoporphyrinogen-IX is normally oxidised at a slower rate 
than protoporphyrinogen-IX, but some of the enzymes oxidise the two compounds at 
a similar rate, e.g. spinach and barley enzymes (Jacobs and Jacobs, 1984a). Both these 
compounds are dicarboxylic tetrapyrroles which are structurally similar and this 
explains their recognition as substrates by the same enzyme. 
The B. subtilis enzyme is exceptional to all the known PPO species in that, in addition 
to protoporphyrinogen-IX and mesoporphyrinogen-IX, it was shown to oxidise the 
four carboxylic coproporphyrinogen-III molecule (Hansson and Hederstedt, 1994; 
Dailey et al, 1994a), which is the substrate in the previous reaction of the haem 
synthetic pathway catalysed by coproporphyrinogen oxidase. The fact that B. subtilis 
PPO oxidises coproporphyrinogen-III into coproporphyrin-III (Hansson et aI, 1997) 
indicates that a true coproporphyrinogen oxidase, which catalyses the oxidative 
decarboxylation of coproporphyrinogen-III into protoporphyrinogen-IX, exists in this 
organism. Indeed, the recent cloning of the hemN gene from B. subtilis which encodes 
an oxygen-independent coproporphyrinogen-III decarboxylating protein (Hippler et al, 
1997) supports this. 
Besides protoporphyrinogen-IX, the PPO of the photosynthetic bacterium, R. 
sphaeroides was reported to utilise both mesoporphyrinogen-IX and 
uroporphyrinogen-I as substrates (Jacobs and Jacobs, 1981). However, broad substrate 
specificity is not a general prokaryotic PPO property as demonstrated by M xanthus 
protein (Dailey and Dailey, 1996a) which has high specificity for protoporphyrinogen­
IX. Despite its uniqueness the B. subtilis PPO is not a general porphyrinogen oxidase, 
because it did not oxidise the eight-carboxylic, uroporphyrinogen-III (Hansson and 
Hederstedt, 1994a). 
Sub-cellular Localisation and Translocation of PPO 
Several approaches were used in the localisation of PPO within the cells of various 
organisms. Investigation methods used can broadly be grouped into three, viz. 
1. Assaying PPO activity in subcellular or suborganellar fractions separated by 
differential centrifugation methods (Jacobs et aI, 1982; Deybach et aI, 1985). 
2. Identification of PPO in isolated subcellular or organellar fractions using specific 











3. in vitro translation and import of cloned PPO, expressed in E. coli cells, into 
isolated mitochondria and chloroplasts (Nishimura et aI, 1995b, Lermontova et al, 
1997). 
The work of Poulson and Polglase (1975) and Poulson (1976) demonstrated that both 
the yeast and mammalian PPO activities were associated with mitochondrial 
membranes and required detergents for solubilisation. In plants the enzyme activity 
was demonstrated in mitochondria as well as chloroplasts (Jacobs et aI, 1982). The 
extensive investigation carried out by Deybach et al (1985) on rat livers presented 
evidence which showed that PPO was an intrinsic protein of the inner mitochondrial 
membrane. This involved subfractionation of purified mitochondria using the 
digitonin method, tryptic digestion with and without detergent solubilisation, and 
chemical modification with diazo benzene sulfonate of intact and sonicated mitoplasts. 
Ferreira et al (1988) used a membrane-impermeable water soluble inhibitor of PPO, 
the ditaurine conjugate of bilirubin, and reported inhibition of rat liver PPO activity in 
intact mitochondria and mitoplasts, and also in sonicated mitochondria. These 
findings demonstrated that the PPO catalytic site was on the cytosolic side of the 
inner membrane since this membrane was impermeable to this inhibitor. 
Smith et al (1993) performed differential subfractionation of cells from pea leaves, 
into mitochondria and chloroplast fractions and showed that PPO activity was present 
in these organelles at a ratio of 1:2, respectively. Previously, Matringe et al (1992a) 
had shown that in subfractionated chloroplasts PPO activity was found in thylakoids 
and the total envelope membranes, but not in the stroma. The relative PPO activity 
per mg total protein was 7-8 times higher in the envelope membranes compared to 
thylakoids. Using subfractionated yeast mitochondria, Camadro et al (1994) also 
demonstrated that PPO activity was localised at the inner membrane of this organelle. 
The progress made in the identification and cloning of PPO genes allowed new 
methods to be applied in further confirming the localisation of these proteins within 
cells. These involved the in vitro transcription and translation of cloned PPO genes, 
and the import of the labelled translation products into isolated mitochondria and 
chloroplasts. The mitochondrial importation of these products was confirmed by the 
reisolation of the product from these organelles and comparing its properties with 
those of the known purified protein. Nishimura et al (1995b) performed an in vitro 
transcription of the human PPO gene and translated the mRNA in the rabbit 
reticulocyte lysate system in the presence of [35S]methionine to produce a labelled 
protein product. The labelled translation product was imported into isolated intact 
mouse mitochondria. Reisolation of the labelled protein yielded a protein with similar 
molecular weight to that predicted for the human PPO gene, suggesting that this 
protein did not undergo modification on insertion into the mitochondrial membrane .. 
Within the mitochondrial membrane this protein was protected against proteolytic 
digestion in the absence of detergents. On addition of 0.3% Triton X-lOO digestion of 
the protein occurred demonstrating the intrinsic association of this protein with the 
membrane lipid bilayer. 
In a similar study, Lermontova et al (1997) demonstrated the importation of the 
tobacco plant plastidal and mitochondrial PPO isoforms into intact chloroplasts and 











the plastidal PPO isofonn was processed from a 59 000 Da precursor protein into a 53 
000 Da mature fonn which was protected against protease degradation. No processing 
was observed in the mitochondrial isofonn which was also protected against protease 
degradation, indicating that these proteins were hidden within the membrane lipid 
bilayer. The correct targeting of these PPO isofonns was confinned by 
immunodetection in plastids and mitochondria using specific antibodies. 
Computer analysis of several PPO gene or protein sequences has revealed the lack of 
membrane targeting leader sequences or obvious internal targeting signals in these 
proteins (Dailey et aI, 1994a, Nishimura et aI, 1995, Dailey and Dailey, 1996a, b). The 
amino tenninal portion (28 amino acids) of human PPO contains features which are 
characteristic of a presequence in. that, it has 3 basic residues and no acidic residues 
(Nishimura et aI, 1995b). However, although this portion can fonn an alpha helix, it is 
not amphiphilic as the hydrophobic residues are not clustered on the opposite side of 
positively charged amino acids and the hydroxylated amino acids are scattered. 
Although these features may represent a mitochondrial targeting signal, human PPO 
may have another type of signal at its amino-tenninus which has not yet been 
identified. The only PPO species that have been demonstrated thus far to be 
synthesized as precursor proteins with amino-tenninal putative membrane targeting 
leader sequences are Arabidopsis thaliana (Narita et aI, 1996), and the plastidal 
isofonn of the tobacco plant enzyme (Lennontova et aI, 1997). Since it has been 
established that PPOs are membrane bound proteins associated with the inner 
mitochondrial membrane, it appears therefore that those proteins which lack the 
leader sequences apparently possess internal membrane targeting signals which have 
not yet been identified. 
Indeed, such unique internal targeting mechanisms have been proposed for other 
proteins destined for mitochondrial membranes (Lill et aI, 1996, Stuart and Neupert, 
1996). For example, the BCS 1 protein (involved in the assembly of complex III, that 
is, ubiquinol-cytochrome c reductase [bc1] of the mitochondrial respiratory chain), 
which spans the inner mitochondrial membrane, contains a stretch of positively 
charged amino acids (amphiphilic segment) after a transmembrane domain sequence, 
which were shown to function as the internal targeting signal through the fonnation of 
an amphipathic helix (Folsch et aI, 1996). It was suggested that such an amphipathic 
helix could react on its apolar side with the transmembrane domain and fonn· a 
hairpin loop which will penetrate the trans locating channel of the inner membrane to 
facilitate translocation. In addition to the membrane targeting sequences the inner 
mitochondrial membrane proteins are reported to possess so-called topogenic signals 
which detennine not only their correct import into the membranes but also their final 
. orientation. For instance, the cytochrome oxidase subunit Va, which spans the inner 
membrane, is reported to have such a topogenic signal which prevents its 
translocation across the inner membrane, by interacting with translocation 
components in the membrane, resulting in the arrest of its complete translocation 
(Stuart and Neupert, 1996). Since many PPOs lack any cleavable mitochondrial 
targeting signals their import into the membranes could be similar to that described 
for the BCS 1 protein. Such topogenic signals are therefore likely to exist in PPO 











Initially it was suggested that yeast PPO was synthesised as a high molecular weight 
precursor which was converted to a mature mitochondrial membrane-bound form 
(Camadro and Labbe, 1994). However, a later publication from this group (Camadro 
and Labbe, 1996) suggested that the hydropathy profile of yeast PPO demonstrated a 
moderately high hydrophobic protein with a single potential membrane-spanning 
segment (residues 13-33). Analysis revealed that this was not a transmembrane 
domain. There are several hydrophobic regions in yeast PPO but all are less than 15 
uncharged residues and are therefore unlikely to form membrane-spanning segments. 
While it is possible that shorter helical domains could be responsible for the insertion 
of PPO into the inner mitochondrial membrane another possibility is that PPO is 
anchored to the membrane by a mechanism such as acylation. Indeed a recent study 
has demonstrated that palmitoleic acid is a major component involved in modifying 
yeast PPO (Arnould et aI, 1999). This is compatible with a post-translational 
modification of the protein resulting in the electrophoretic mobility shift which was at 
first attributed to the cleavage ofa putative presequence. 
In plants, besides the mitochondria and chloroplasts, PPO activity has been found in 
other subcellular locations such as the plasma membrane (Jacobs et aI, 1991, Lee et 
aI, 1993), and the endoplasmic reticulum (Retzlaff and Boger, 1996). Interestingly, 
the plasma membrane associated PPO activity has been found to possess properties 
which are different from those of the mitochondrial and chloroplastic enzymes, such 
as its resistance to inhibition by the diphenyl ether herbicides which are strong 
inhibitors of many known and characterised PPO activities (Jacobs et aI, 1991) (see 
later in this chapter). 
Effects of Various Detergents and Lipids on PPO Activity 
PPOs are hydrophobic in na ure and are solubilised from membranes with solutions 
that contain detergents such as n-octyl B-d-glucopyranoside, Tween-20, Triton X-I00, 
and sodium cholate. In the absence of these detergents PPO tends to precipitate out of 
solution. The efficacy of the various detergents differs according to the PPO species 
solubilised. R. sphaeroides PPO activity was reportedly destroyed by solubilisation 
with Triton X-I00 (Jacobs and Jacobs, 1981). A similar effect was documented with 
the E. coli and barley PPO activities in the presence of sodium cholate and Tween-20, 
respectively (Jacobs and Jacobs, 1984a). 
Since PPOs are known to be membrane bound proteins, some workers have 
investigated the effects of various lipid (hydrophobic) environment on the activity of 
these enzymes. Jacobs and Jacobs (1984b) tested the effects of several lipids on the 
activities of the barley mitochondrial and etioplast PPO preparations, and showed that 
some of the lipids had a stimulatory effect on the activity of these enzymes. From 
several lipids tested, only oleic and linoleic acid had a significant stimulatory effect 
on these PPO activities, whilst others such as palmitic acid, phosphatidyl choline, p­
ethanolamine, and caprylic acid, did not affect the activity of these proteins. At 6 mM 
both these lipids caused optimal stimulation of the enzymatic oxidation of both 
protoporphyrinogen-IX, and the nonphysiologic mesoporphyrinogen-IX. Siepker et al 
(1987) also showed that in the presence of 1 mglml of oleic acid, protoporphyrinogen­











similar stimulatory effect which resulted in doubling of the oxidation rate of 
protoporphyrinogen by a purified barley PPO preparation was observed in the 
presence of 1 mg/ml of oleic acid, but this effect was not observed in the unpurified 
crude enzyme preparations from the same source (Jacobs and Jacobs, 1987). This 
suggested that the purification process had removed a lipid factor from the protein 
which could be substituted by addition of exogenous lipids. Importantly, Ferreira and 
Dailey (1987) demonstrated a decrease in mouse PPO activation energy and a 7-28 
fold reduction in Km when PPO was reconstituted into phospholipid vesicles. 
Analysis of the purified barley mitochondrial PPO for lipids, using quantitative thin 
layer chromatography and specific sprays, revealed that this protein was associated 
with various phospholipids, free fatty acids, and sterols which appeared to be 
important in stabilisation of the protein molecule (Jacobs et aI, 1989). 
It was shown that the creation of a hydrophobic environment with palmitate 
significantly enhanced the enzymatic oxidation of protoporphyrinogen-IX by barley 
and wheat etioplast PPOs (Han and Kim, 1996). Earlier Camadro et al (1994) 
demonstrated that the presence of 3 mM palmitate caused optimal activation of the 
purified yeast PPO, whilst the membrane bound PPO did not show this effect. 
Absence of this fatty acid in the enzyme preparation resulted in rapid loss of activity. 
This demonstrated that in a hydrophobic environment the protein molecule was more 
stable. This was in keeping with the fact that PPOs are intergral membrane proteins 
which are buried within the lipophilic core of the membrane lipid bilayer (Deybach et 
aI, 1985; Camadro et aI, 1994). 
Protoporphyrinogen Oxidase Inhibition Studies 
By the time PPOs were first identified as targets for inhibition by several chemically 
unrelated herbicidal compounds, many of these substances were already in 
commercialised use as herbicides in controlling crops and weeds. The mode of action 
of the various herbicides was only discovered when Matringe and Scalla (1987, 1988) 
demonstrated that the diphenyl ether herbicide, acifluorfen (AF), caused accumulation 
ofprotoporphrin-IX in treated plants. Importantly, they found that the accumulation of 
protoporphyrin was due to the inhibition of protoporphyrinogen oxidase by this 
herbicide (Matringe et aI, 1989a & b). The abnormal accumulation of protoporphyrin­
IX in tissues had been reported many years earlier in humans who were suffering from 
variegate porphyria, an autosomal dominant disorder which is caused by deficiency in 
PPO activity resulting from defective PPO proteins (Brenner and Bloomer, 1980a, 
Deybach et aI, 1981). 
An important feature of PPO inhibitors is the structural similarity of these compounds 
to the substrate molecule, protoporphyrinogen-IX, Whilst studies on the herbicidal 
PPO inhibitors showed that a bicyclic structure was the minimum structural 
requirement for recognition of many molecules by these enzymes it was subsequently 
shown that some, but not aU, of the compounds with a tetrapyrrole structure were also 
effective inhibitors of PPOs. Other compounds such as haem and its metabolic 
products, biliverdin and bilirubin were also shown to be effective inhibitors of these 











By virtue of the fact that PPOs are flavoproteins they become potential targets of 
general inhibitors of this class of proteins. Indeed; inhibitors of flavoproteins, such as 
the diphenyleneiodonium (DPI) cation and related species, bis(aryliodonium), have 
been shown to be effective inhibitors of PPOs (Arnould et aI, 1997; Birchfield et aI, 
1998). The different categories of compounds which inhibit PPOs and the 











I. Herbicidal PPO inhibitors 
For years the mode of action of many PPO inhibiting compounds remained elusive to 
scientists despite their widespread use as commercial herbicides in the agricultural 
industry. This was partly due to the fact that this was a novel mode of action for 
herbicides in inhibiting plant growth, and the fact that, in their investigations, 
scientists tended to focus their attention on the target sites of already known 
herbicides. Much of the research done on these compounds was therefore 
concentrated on plants due to the known herbicidal effect of these compounds and the 
vested interest of the agrochemical industry in developing more potent and highly 
selective compounds for commercial use in crop control. 
The association of light with the development of symptoms in plants led to the 
implication of known photoreceptors like the carotenoids to be the targets of these 
compounds (Orr and Hess, 1981, Devlin et aI, 1983). The photosynthetic electron 
transport system was also implicated in the mode of action of these herbicides 
(Moreland et aI, 1970). Other possible modes of action included a direct involvement 
of these compounds in the photodynamic reaction (Orr and Hogan, 1985), 
mitochondrial involvement (Duke et aI, 1984), and possible light-dependent 
phosphorylation (Pritchard et aI, 1980). All these theories could not fully explain the 
physiological responses observed in tissues that were associated with the herbicidal 
treatment, and several inconsistencies in experimental findings observed by other 
researchers, dispelled these implications and pointed to different molecular targets 
(Ridley, 1983, Matringe and Scalla, 1987, Gaba et aI, 1988). The pioneering studies 
on plant PPO activity with acifluorfen (Matringe et aI, 1989a & b) and its methyl 
ester, methyl acifluorfen (Witkowski and Halling, 1988, 1989) produced a major 
breakthrough in demonstrating that the accumulation of protoporphyrin in plant 
tissues was due to inhibition ofPPO by these compounds. 
While it is implied that protoporphyrinogen-IX should accumulate as a result of PPO 
inhibition, it is generally accepted that there is an abnormal transient mitochondrial or 
chloroplast accumulation of protoporphyrinogen-IX, but that this leaks out of these 
organelles into the cytoplasm where it may be converted into protoporphyrin-IX in a 
light-dependent auto-oxidation. 
The accumulation of protoporphyrin-IX as a result of PPO inhibition was positively 
correlated to the extent of damage in plant tissues, and it was shown that 
protoporphyrin-IX was the primary photodynamic molecule which was involved in 
the mode of action ofPPO inhibiting herbicides (Duke et aI, 1991 a; 1994). Porphyrins 
ate photodynamic molecules which cause formation of toxic oxygen radicals in the 
presence of light. This photo-sensitization may lead to formation of highly reactive 
oxygen radicals which cause the peroxidative destruction of membrane lipids (Hopf 
and Whiten, 1978; Orr and Hess, 1981; Devine et aI, 1993). 
Recent studies have shown that, besides the light-dependent auto-oxidation, some 
form of enzymatic oxidation of protoporphyrinogen occurs in the cytoplasm (Jacobs 
et aI, 1991; Lee et aI, 1993; Lee and Duke, 1994, Retzlaff and Boger, 1996). Proteins 
with PPO activity were demonstrated in the plasma membrane of barley cells (Jacobs 











reticulwn of maize cells (Retzlaff and Boger, 1996), and these were shown to be 
relatively resistant to the inhibitory effect of the peroxidative diphenyl ether 
herbicides. Synthesis of haem by purified plant plasma membranes was demonstrated 
suggesting that there was an alternative haem biosynthetic pathway which did not 
involve the terminal enzymes found in the mitochondria and chloroplasts (Jacobs and 
Jacobs, 1995). Indeed, these investigators confirmed this in the same study when they 
identified ferrochelatase and iron reductase in the plasma membrane of plant cells. 
Several studies in animals have shown that these compounds produce a similar effect 
to that of plant tissues. When male mice were fed the PPO inhibiting herbicides, 
oxadiazon and oxyfluorfen (1000 ppm), they developed experimental porphyria which 
resembled the acute phase of VP (Krijt et aI, 1997). The decrease in PPO activity in 
herbicide treated animals resulted in elevated porphyrin content in their livers and 
kidneys. Approximately 80% of the total bile porphyrin content was protoporphyrin. 
Accwnulation of porphyrins was noted in the trigeminal nerve of animals treated with 
oxadiazon suggesting a contribution of porphyrins to the peripheral neuropathy 
observed during the acute attack of porphyria. In a similar study with hwnan 
progenitor cells (BFU·E/CFU·E), high concentrations of oxyfluorfen (10-2 M) 
produced a cytotoxic effect, whereas lower concentrations (10-4 M) only caused an 
inhibition of haem biosynthesis (Rio et al, 1997). Jacobs et al (1992) showed that 
PPO activity in chick and rat hepatocytes was inhibited in the presence of acifluorfen, 
methylacifluorfen, and nitro fen. The effect of porphyrins on tissues was not 
unexpected as photodynamic molecules have for long been regarded as herbicidal 
agents (Towers and Amason, 1988). 
PPO inhibiting herbicides consist of a large group of chemically diverse commercial 
compounds which can broadly be categorized according to their structural properties 
into the diphenyl ether herbicides (DPEs), phenyl heterocycles, and the heterocyclic 
phenylimides (figure 2.2) (Varsano et ai, 1990; Matringe et aI, 1992; Dayan and 
Duke, 1997a, b, c; Anderson et aI, 1994; Reddy et aI, 1997). The only reported DPE 
of natural origin inhibiting PPO is cyperin, which was isolated from several weed 
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Figure 2.2 Protoporphyrinogen oxidases are inhibited by a large group of chemically diverse 
compounds which bear structural similarity to at least half the substrate molecule, protoporphyrinogen­
IX 
An aspect which intrigued scientists about the thousands of commercially available 
PPO inhibiting herbicides was the fact that they were all apparently binding at the 
same site on the enzyme molecule. The common feature in these compounds, a 
bicyclic structure (figure 2.2) resembling one-half of the substrate molecule 
(protoporphyrinogen-IX), seems to be the basic minimum structural requirement 
which enables them to mimic portions of the substrate molecule and bind to the 
enzyme (Scalla and Matringe, 1994). Indeed, previous studies have showed that the 
best PPO inhibitors are those compounds that closely resemble one-half of the 
protoporphyrinogen-IX molecule both in terms of geometric shape and electronic 
characteristics (NandihaIli et aI, 1992). Acifluorfen, was shown to possess the full 
length and one-haIf width of the protoporphyrinogen-IX molecule (Nandihalli et ai, 
1992). This study demonstrated that the molecular electronic and nuclear energies of 
the acifluorfen bicyclic structure matched almost half those of the 
protoporphyrinogen-IX tetrapyrrole structure and the dimensions of this herbicide 
molecule were closely matched to the bicyclic substructures of protoporphyrinogen­
IX comprised of the ring AB and Be of the tetrapyrrole structure. In addition to these 
structural properties, this study also revealed that the enzyme inhibitory activity of 
PPO inhibitors was also positively related to the lipophilic nature of these 
compounds. 
These findings have led to the successful prediction of the herbicidal activities of 
various compounds by quantitative structure activity relationship (QSAR) analysis 
(Nandihalli et aI, 1992; Reddy et ai, 1995; Reddy et aI, 1997). The data from the 
QSAR studies importantly illustrated that for a compound to effectively compete with 











moeltles that satisfy the stereochemical properties of one-half of the substrate 
molecule (Nandihalli et al, 1992, 1994). 
Resistance to herbicidal PPO inhibitors 
In contrast to M xanthus PPO (Dailey and Dailey, 1996a), the prokaryotic PPOs of E. 
coli, B. japonicum (Jacobs et aI, 1990), and B. subtiUs (Dailey et aI, 1994a) appear to 
have natural resistance to inhibition by the diphenyl ethers. At 1 0 ~ methyl 
acifluorfen (AFM) the PPO activity from unextracted membranes of E. coli showed 
no significant inhibition in the presence of 1 or 5 mM DTT (Jacobs et al, 1990). 
Whilst the rat liver mitochondrial PPO activity was markedly inhibited by 10 IJ.M 
AFM, both the E. coli and B. japonicum were not inhibited by the same AFM 
concentration. These bacterial PPOs are structurally distinct from the well 
characterised FAD-containing PPOs thus these differences are not unexpected. At 100 
IJ.M acifluorfen the B. subtilis PPO was inhibited only 18% compared to the 
eukaryotic enzyme which was inhibited 100% by the same inhibitor concentration 
(Dailey et aI, 1994a). Transgenic tobacco plant cells expressing the B. subtilis hemY 
product in their cytoplasm also showed resistance to inhibition by oxyfiuorfen, a 
competitive PPO-inhibitor (Choi et aI, 1998). Subsequently, Lee et al (2000) created 
transgenic rice plants which were expressing the B. subtilis PPO gene, and these were 
also resistant to inhibition by oxyfluorfen. Herbicide resistant cell cultures have been 
identified and isolated from soybean and potato plants, but whole plants could not be 
regenerated from these cells (Pomprom et aI, 1994). 
A Chlamydomonas rheinhardtii mutant (rs-3) resistant to several PPO-inhibitors such 
as S-23142, oxadiazon, oxifluorfen and AFE has been isolated and characterised 
(Kataoka et aI, 1990, Sato et aI, 1994). Molecular characterisation of the wild-type C. 
rheinhardtii PPO showed that this protein had significant homology to the plastidial 
PPO isoforms of A. thaliana (51%) and N tabacum (53%), suggesting that it was 
likely to be located in the chloroplasts (Randolph-Anderson et aI, 1998). In this study, 
genetic analysis of the C. rheinhardtii rs-3 mutant PPO cDNA revealed identity with 
the wild-type protein, except for a G to A transition which resulted in a Val-389 to 
Met substitution. This residue is conserved in A. thaliana (Val-365), N tabacum 
(Val-376), B. subtilis (Val-31l) and mouse (Val-314) PPO sequences. It seems 
therefore that the Val to Met substitution in the rs-3 mutant causes a conformational 
change at the enzyme active site which decreases its affinity for the herbicides, but 
does not cause apparent phenotypic changes. 
Tolerance to some of the peroxidative herbicidal compounds have been observed in 
several plant species (Matsumoto et al, 1994; Komives and Gullner, 1994; Dayan and 
Duke, 1997a, b; Duke et al, 1997). Detailed investigations showed that this tolerance 
was not due to natural resistance of plant PPOs to these compounds. Generally, the 
mechanisms of plant resistance to the destructive effects of some PPO inhibitors have 
been identified and these include the following: 
- Hindrance of the uptake and translocation of herbicide to its site of action in cells 
(Matsumoto et aI, 1994; Komives and Gullner, 1994; Dayan et aI, 1996). 











- Natural resistance of the tissue or cells to the peroxidative effect of oxygen radicals. 
(Matsumoto et aI, 1994; Dayan et ai, 1997b). 
- Resistance at the molecular site of action. Some tissues apparently develop 
resistance through metabolic degradation of the excess protoporphyrinogen into non­
toxic compounds (Jacobs et ai, 1996). 
Resistance mechanisms to various PPO inhibitors are complex and are not yet fully 
understood. Prasad and Dailey (1995) reported the development of resistance to AF 
by the PPO activity ofmouse erythroleukemia cells, this followed prolonged exposure 
of these cells to this chemical. However, this resistance to inhibition was apparently 
due to detoxification of acifluorfen by a cytochrome P450 enzyme which was 
stimulated by the prolonged exposure to this chemical. 
Recent studies have revealed that resistance to herbicides in plants could also be due 
to the overproduction of the target enzyme. Ichinose et al (1995) isolated and 
characterised photomixotrophic cultured tobacco plant cells, referred to as YZI-1S, 
which were resistant to inhibition by the phenyl tetrahydrophthaIimide, S-23142, a 
competitive PPO-inhibitor. The YZI-I S cells had twice the PPO activity of wild-type 
cells. Molecular characterisation of the YZI-l S cells revealed that there was no 
difference between the plastidial and mitochondrial PPO sequences of these cells and 
that of wild-type cells (Watanabe et aI, 1998). It was found that the mitochondrial 
PPO mRNA in the YZI-IS cells was ten times that of wild type cells. This led 
Watanabe et aI (1998) to suggest that the herbicidal resistance of the YZI-IS cells was 
due to the overproduction ofthe mitochondrial PPO isoform. 
In a recent study Lermontova and Grimm (2000) introduced the A. thaliana plastidial 
PPO gene into tobacco plant genome, which resulted in the overexpression of this 
PPO isoform in these cells. The plastids from these cells had five times the PPO 
activity of control wild-type cells, and they were also less susceptible to inhibition by 
AF. It was suggested that the overexpression of the plastidial PPO isoform was 
responsible for the resistance to AF. 
II. Inhibition of PPOs by haem and some of its metabolic products 
During the reductive metabolic breakdown of the haem molecule the methyl, 
propionyl and vinyl side-chains remain unchanged. Thus the intermediate haem 
breakdown products, viz. biliverdin and bilirubin-IX, still possess the tetrapyrrole 
structure and side chains found in the protoporphyrinogen-IX molecule. Therefore 
these compounds are potential competitive inhibitors of this enzyme, based on their 
structural resemblance to the substrate molecule. 
Competitive inhibition of the purified mouse PPO by bilirubin (K j = 25 J-lM), with 
respect to protoporphyrinogen-IX as substrate, was reported (Ferreira and Dailey, 
1988). Both in free form, and bound to bovine serum albumin, bilirubin produced the 
same inhibitory effect, and 68 J-lM was reported to reduce the enzyme to 
approximately 30%. Patients with Gilbert's syndrome, which is characterised by an 
unconjugated hyperbilirubinaemia, reportedly have reduced PPO activity 











1987). These enzyme disturbances are similar to those observed in patients with VP, 
but in the Gilbert's patients the excretion of porphyrins and their precursors was 
found to be normaL Previously, Evans et al (1981), also reported the increased 
excretion of porphyrins in a patient with hyperbilirubinaemia. 
III. Inhibition of PPO by compounds that inhibit flavoproteins. 
The fact that PPOs are flavoproteins has been exploited in examining new classes of 
inhibitors against these enzymes. The diphenyleneiodonium (DPlj cation and its 
related species have been shown to be effective inhibitors of several flavoproteins 
(figure 2.3) (Gatley and Sherratt, 1976, Ragan and Bloxham, 1977, Doussiere and 
Vignais, 1992, O'Donnell et ai, 1993, Tew, 1993). 
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Figure 2.3 The diphenyleneiodonium cation and its derivatives are inhibitors ofseveral 
flavoproteins, including PPOs. The substituted diphenyleneiodoniums were shown to be even 
better inhibitors of PPOs (Amould et aI, 1997), 
These compounds act by removing electrons from the reduced flavin cofactors 
associated with flavoproteins; causing formation of phenyl radicals and covalent 
modification of the flavin (O'Donnell et ai, 1994). A recent study on the membrane­
bound yeast PPO has shown that the DPI cation is an inhibitor of this enzyme with 
irreversible slow binding kinetics, with maximum inhibition at pH 8 (Arnould et aI, 
1997). A 4-nitro derivative of DPI improved the PPO inhibitory effect of this 
compound. 
Birchfield et al (1998) recently showed that 100 pM DPI inhibited human PPO 
enzymatic activity by 48%. Furthermore, in the presence or absence of substrate (5 
/-LM), the binding of DPI to the enzyme molecule did not affect the binding of a 
photo affinity radioligand, N-(5-azido-4-chloro-2-fluorophenyl)-3,4,5,6-[3H] 










51 Chapter 2 
tetrahydrophthalimide (eH]THP) undergoes rapid, specific, saturable, and reversible 
binding to the substratelherbicide binding site on solubilized mouse mitochondrial 
PPO (Birchfield and Casida, 1996). Both acifluorfen and the more potent THP, which 
compete with protoporphyrinogen for binding at the catalytic site, were shown to be 
effective competitive inhibitors of [3H]AzTHP binding (Birchfield et aI, 1998), 
indicating that these compounds were sharing the same or overlapping binding site on 
the enzyme molecule. These findings demonstrated that DPI was not sharing the same 
binding site occupied by [3H]AzTHP, acifluorfen and THP on the enzyme molecule. 
This suggests that the FAD binding site is apparently distant from the 
substratelherbicide binding site on the human PPO molecule. 
Quinacrine (16 mM), a known inhibitor of FAD-containing enzymes such as the 
monoamine oxidases, was shown to be an effective inhibitor of the B. subtilis hem Y 
protein (Hansson et aI, 1997) and suggested that the enzyme was a FAD flavoprotein. 
PPO Immunological Studies 
Very few immunological investigations appear to have been done on PPOs. This has 
partly been due to the fact that this protein has proved very difficult to purify over the 
years. Siepker et al (1987) reported the raising of antibodies against the 
homogeneously purified bovine protein. On Western blotting, this antibody 
specifically recognized the 57 000 Da PPO protein, and another 53 000 Da protein 
which co-purified with PPO. They reported 80% cross-reactivity of the purified IgG 
fraction of this antibody with bovine ferrochelatase. The purified PPO also cross­
reacted with antibodies raised against purified bovine ferrochelatase, but the 53 000 
Da protein was not recognized. 
Subsequent to the identification, cloning and purification of the human PPO, purified 
human IgG antibodies cros -reacted with purified recombinant mouse PPO (Taketani 
et aI, 1995a). As these two proteins share 86 - 89% sequence identity (Taketani et aI, 
1995a, Dailey et aI, 1995), this is not surprising. Antibodies raised separately against 
the plastidal and mitochondrial isoforms of the tobacco plant PPO showed no cross­
reactivity (Lermontova et al, 1997). This lack of cross-reactivity is explained by the 
27% sequence homology between these PPOs, even though they are from the same 
species, and confirms the different ancestral origins of these two organelles. 
An antibody raised against yeast PPO was used as a tool in many of the studies on 
yeast PPO carried out by Camadro et al. (1994, 1996). 
The Cloning and Identification of PPO Genes 
In their study of the genes involved in haem biosynthesis in the aerobic bacterium, B. 
subtilis, Hansson and Hederstedt (1992) reported the identification of an open reading 
frame (hernY) which was suggested to be involved in the oxidation of 
protoporphyrinogen-IX. Initially the protein encoded by this gene was thought to 
possess either protoporphyrinogen-IX or both protoporphyrinogen-IX and 
coproporphyrinogen-III oxidising activities. Interestingly, Dailey et al (1994a) found 











of the mammalian PPO gene which they were cloning at that time (personal 
communication, P. Meissner). Thus Dailey et al (1994a) cloned and expressed the B. 
subtilis hemY gene in E. coli and showed that it encoded a monomeric protein with a 
predicted Mr of 51 200 Da which had PPO activity. This provided conclusive 
evidence that this protein was PPO and they suggested that the gene should be 
designated hemG. A striking feature of this protein was its ability to oxidise both 
protoporphyrinogen-IX and coproporphyrinogen-III. Subsequent characterisation 
revealed that the product from coproporphyrinogen-III oxidation was coproporphyrin­
III, and not protoporphyrinogen-IX which is formed during the oxidative 
decarboxylation of this compound by coproporphyrinogen-III oxidase (Hansson and 
Hederstedt, 1994b; Hansson et aI, 1997). 
Shortly after the identification of the B. subtilis enzyme by Hansson et al (1992), 
another prokaryotic PPO was isolated from the facultative anaerobic Gram negative, 
E. coli K12 strain (Sasannan et al, 1993). The E. coli hemG gene was sequenced and 
shown to be encoding a 21 200 Da (181 amino acid residues) protein which 
complemented a PPO-deficient mutant ofE. coli. Later the hemG gene from a similar 
E. coli strain was cloned and sequenced by Nishimura et al (1995a) and shown to be 
encoding the same PPO protein identified previously by Sasannan et al (1993). 
Nakayashiki et al (1995) cloned and sequenced a different E. coli gene, termed hemK, 
which they thought was involved in oxidation of protoporphyrinogen-IX, but its 
function was not fully elucidated. They found that this gene and its protein product 
(225 amino acid residues) had no significant sequence homology to any reported PPO 
gene or protein sequence, but was rather more similar to the N-terminal region of a 
Salmonella typhimurium gene, previously sequenced (Elliot, 1989). Phenotypic 
analysis and activity assay of a yeast hemK analog protein which was identified by Le 
Guen et al (1999) revealed that the isolated protein was not involved in 
protoporphyrinogen-IX oxidation. Sequence analysis with related proteins showed a 
consensus motif for S-adenosyl-methionine-dependent methyltransferase. 
Complementation experiments with PPO-deficient yeast strains in which this protein 
was overproduced showed no restoration of wild-type phenotypes. The putative hemK 
is probably a subunit of another protein that has nothing to do with PPO activity. 
A PPO gene from the aerobic Gram negative bacterium, M xanthus, was cloned and 
sequenced by Dailey and Dailey (1996a). The expressed protein was purified and 
partially characterised. It has a predicted subunit Mr of 49 387 Da, (471 amino acid 
residues). Despite the fact that M xanthus and B. subtilis are both aerobic bacteria 
comparison of the amino acid sequences of their PPO sequences revealed only 23% 
identity between them. Most of the sequence homology was found in the N-terrninal 
sequence of these proteins containing the dinucleotide binding motif (Dailey et aI, 
1994a; Dailey and Dailey, 1996a). As more prokaryotic PPOs are identified and 
sequenced it appears that they share very little homology between themselves 
suggesting that the mechanisms by which they oxidise protoporphyrinogen-IX may 
differ. Indeed, this is so as it has been shown that these prokaryotes can live' under 












Hem14, the structural gene for yeast PPO was isolated and identified by Camadro and 
Labbe (1996) by means of functional complementation of a hem14-1 PPO-deficient 
yeast mutant. This gene encodes a 59 665 Da protein (539 amino acid residues), with 
an N-terminal sequence which these authors claimed to be consistent with leader 
peptides of proteins targeted to the mitochondria. Indeed, in previous work they had 
shown purified yeast PPO to be synthesized as a high molecular weight precursor 
protein (58 000 Da) that was apparently converted in vivo through the cleavage of the 
leader sequence into the mature smaller (55 000 Da) membrane bound protein 
(Camadro et al, 1994). More recently, however, the apparent difference in molecular 
sizes has been ascribed to acylation of the protein, which is known to affect 
electrophoretic mobility rather than cleavage of a mitochondria-targeting leader 
sequence (Arnould et aI1999). 
In a separate investigation, Glerum et al (1996) also cloned and identifed the yeast 
hem14 gene encoding a 59 700 Da PPO protein with similar properties to the apparent 
precursor form of this enzyme reported by Camadro et al (1994). These workers 
reported 27% identity and 51 % similarity of this protein to the human PPO protein 
sequence. 
There is some information on PPO genes and proteins from plants. Narita et al (1996) 
reported the first identification of a plant cDNA gene encoding PPO from A. thaliana. 
The gene was identified by functional complementation of a hemG mutant E. coli 
strain. Molecular cloning and characterisation of this gene revealed that it encoded a 
protein of 537 amino acid residues with a calculated molecular mass of 57 700 Da. 
The amino acid sequence of this PPO shared approximately 27% homology with B. 
subtilis, mouse, and human PPOs, and this was mainly in the region of the 
dinucleotide binding domain. The deduced PPO protein sequence appeared to have an 
N-terminalleader sequence characteristic of mitochondrial targeting peptides. 
Lermontova et al (1997) reported the cloning of two different full length cDNA gene 
sequences from tobacco plant which encoded plastidal and mitochondrial isoforms of 
PPO. These two PPO isoforms from the same plant shared 27% amino acid sequence 
identity. The plastidal isoform was synthesized as a 59 138 Da protein (548 amino 
acid residues) with a putative 50 amino acid residues leader sequence, and was shown 
to be processed into a 53 000 Da mature protein when translocated into chloroplasts. 
Interestingly, this PPO isoform was similar in size to the yeast and A. thaliana 
proteins described above, and it also has a membrane targeting leader sequence like 
these other PPOs. Sequence analysis showed that this protein has 71 % identity to the 
A. thaliana protein sequence. The mitochondrial PPO isoform had a calculated 
molecular mass of 55407 Da (504 amino acid residues) and was shown to be targeted 
and imported into the mitochodria without any detectable size reduction. 
Other plastidal and mitochondrial PPO isoforms have been cloned and characterised 
from the potato plant (Johnston et aI, 1998). These PPOs were cloned from a cDNA 
library obtained from four week old potato leaf tissue. Primers used in isolating the 
clones were designed from homologous regions ofA.thaliana (Narita et ai, 1996) and 
maize (Ward patent number WO 95/34659, 1995) PPO sequences. The full-length 
cDNA of the plastidal PPO isoform encodes a 60 426 Da (557 amino acid residues) 












plastidal PPO isofonns, respectively. The mitochondrial partial sequence had 
similarities of 62, 92 and 55% to A. thaliana, tobacco and maize mitochondrial 
isofonns, respectively. The translocatation of these PPO isofonns to their respective 
organelle destinations was identified by sequence homology to previously known 
proteins destined for the same locations. It seems that different plant PPO isofonns 
destined for a particular organelle apparently share a common ancestry as suggested 
by the high sequence homology or the sharing of common epitopes which can be 
demonstrated by immunological cross-reactivity. The lack of homology between 
plastidal and mitochondrial protein isofonns from the same species further illustrates 
the point that these two organelles have different evolutionary origins. 
The cloning, sequencing and expression of the prokaryotic PPOs from B. subtilis 
(Hansson and Hederstedt, 1992, 1994b; Dailey et aI, 1994a) and E. coli (Sasannan et 
aI, 1993) facilitated the discovery and identification of the mammalian genes 
encoding mouse (Dailey et aI, 1995; Taketani et al, 1995a) and human PPOs 
(Nishimura et aI, 1995b; Dailey and Dailey, 1996b, 1997a, b; Taketani et aI, 1995b; 
Roberts et aI, 1995b). Genomic DNA fragments containing the whole coding 
sequence for human PPO (1431 base pairs) have been cloned (Roberts et al, 1995b). 
This gene encodes a 51 000 Da (477 amino acid residues) protein which exists as an 
approximately 100 000 Da homodimer (Dailey and Dailey, 1996b). 
The human PPO gene was mapped by fluorescence in situ hybridisation to 
. chromosome Iq22-q23 of the human genome (Taketani et aI, 1995b; Roberts et aI, 
1995b). This was in contrast to the previous localisation of the VP locus by linkage 
and haplotype analysis to chromosome 14q32 (Bissbort et aI, 1988). Further evidence 
against the linkage between the VP locus and microsatellite markers at chromosome 
I4q32 came from microsatellite DNA marker studies of this region (Warnich et aI, 
1996b). The human PPO gene has 13 exons spanning "approximately 5 kb, and the 
intronlexons boundaries have been defined (Roberts et aI, 1995b; Taketani et aI, 
1995b). Some disagreements exists on the lengths of introns 4, 7, and 9 (Puy et aI, 
1996). Northern blot analysis from a variety of tissues suggest a single mRNA 
transcript for human PPO of approximately 1.8 kb in length (Nishimura et aI, 1995b; 
Dailey and Dailey, 1996b). These transcripts contain an approximately 300 bp long 5' 
untranslated region (UTR) and a short 3' -UTR. Researchers have identified the start 
and tennination codons, as well as a consensus polyadeny1ation signal and 
polyadenylation site downstream from the tennination site (Taketani et aI, 1995b; 
Dailey and Dailey, 1996b; Puy et aI, 1996). The mouse PPO was shown to be similar 
to the human enzyme in tenns of its size, 51 000 Da (477 amino acid residues), and 
homology - the two proteins share 89% amino acid sequence identity and both lack 
typical membrane targeting signals despite their localisation to the mitochondrial 
inner membrane (Dailey et aI, 1995; Taketani et aI, 1995b). 
General Comments 
Whilst auto-oxidation of protoporphyrinogen to protoporphyrin can occur in the 
presence of oxygen; the reducing environment inside cells where this reaction takes 
place (mitochondria and chloroplasts) requires catalysis by PPO. During the aerobic 











several alternative compounds such as nitrate, and fumarate are utilised as the 
terminal electron acceptors in this reaction. It would be interesting to see if different 
PPO isoforms based on their oxygen requirements exist in these organisms, but thus 
far such isoenzymes have not been unequivocally identified. Oxygen-dependent 
(hemF) and oxygen-independent (hemN) isoforms of coproporphyrinogen oxidase 
have been identified in some facultative prokaryotes such as E. coli (Troup et aI, 
1994, 1995). 
An interesting feature of PPOs is their inhibition by thousands of chemically diverse 
compounds. Whilst eukaryotic PPOs are strongly inhibited by bicyclic compounds, 
these appear to have very little effect on the activity of prokaryotic enzymes such as 
those of E. coli, B. japonicum (Jacobs et aI, 1990) and B. subtilis (Dailey et aI, 
1994a). However, the behaviour of the M xanthus PPO rules this out as a general 
prokaryotic property, because it was shown to be strongly inhibited by the diphenyl 
ethers (Dailey and Dailey, 1996a). 
Investigation of several PPO genes by molecular biology methods has revealed that 
many of these proteins lack any identifiable membrane targeting signals despite the 
fact that it has been established that these are intrinsic inner mitochondrial membrane 
proteins. However, the N-terminalleader sequence required for membrane targeting 
and translocation has been suggested in few of these proteins (Camadro et aI, 1994; 
Narita et al, 1996; Lermontova et aI, 1997). It appears therefore that many of these 
proteins possess internal targeting signals that have not yet been definitively 
identified. 
Very interesting information is beginning to emerge as more PPO genes are identified 
and characterised. Certainly, the application of molecular biology approaches in the 












Development of this Thesis 

Context in Which this Work was Performed 
Protoporphyrinogen oxidase (PPO) catalyses the penultimate step in haem 
biosynthesis that is, the six electron oxidation of protoporphyrinogen-IX into 
protoporphyrin-IX (Kappas et al, 1989, Dailey, 1990). A genetic defect in human PPO 
is responsible for VP, an autosomal dominant disorder characterised by skin 
photosensitivity and propensity towards acute neurovisceral crises (Kappas et aI, 
1989). In South Africa this disease has an exceptionally high frequency which is due 
to a founder gene effect (Dean, 1971, Eales et ai, 1980, Day, 1986, Meissner et aI, 
1986, 1996, Warnich et aI, 1996a). Thus it is natural that VP and the defective 
enzyme responsible for this condition is of great interest to the Lennox Eales 
Porphyria Laboratories of the University of Cape Town from both an academic and 
pragmatic point of view. 
Previous Studies 
Previous studies, based on investigations carried out on crude unpurified and 
sometimes partially purified PPOs using standard chromatographic procedures, 
revealed differences among these proteins from different species (Poulson and 
Polglase, 1975, Poulson, 1976, Jacobs and Jacobs, 1981, 1987, Klemm and Barton, 
1987, Dailey and Karr, 1987, Siepker et aI, 1987, Ferreira and Dailey, 1988, Jacobs et 
aI, 1989, Proulx and Dailey, 1992). These studies indicated that PPOs may be 
different in terms of their molecular weights, subunit composition, cofactors, kinetic 
properties and terminal electron acceptors involved in the oxidation of 
protoporphyrinogen-IX to protoporphyrin-IX. The fact that these PPOs were 
characterised in the presence of other proteins which may influence their behaviour in 
one way or the other resulted in lack of information on the biochemical behaviour and 
molecular nature of these proteins. Hence, the need for protein purity in order to carry 
out reliable characterisation. 
The Project 
Thus, at the beginning of this project little information was available on the kinetic 
and biophysical properties of isolated PPOs due to difficulties associated with 
purification of these proteins from natural sources, using standard chromatographic 
techniques. This contributed in part to PPO being the last of the haem biosynthetic 
enzymes to be characterised both at the protein and gene levels. Detailed 
characterisation ofPPO therefore still remained a relevant challenge. Hence this study 
(and others conducted elsewhere). 
The application of molecular biology techniques in the study of proteins has 











recombinant proteins. In this work we demonstrate a greatly facilitated 
characterisation of various forms of PPO based on the availability of recombinant 
PPO expression systems. 
Consequently, this thesis describes work undertaken towards the optimisation of 
expression and purification of recombinant PPOs from three species (E. subtilis, M 
xanthus and human) to apparent homogeneity, using the 6X His tag system which is 
based on metal chelate affinity chromatography (Chapter 4). This allowed the 
description of the kinetic behaviour of the purified PPOs and determination of their 
inhibitor profiles (Chapters 5 and 6). Sequence information (nucleotide and amino 
acid) available from publicly accessible databases has also proved very useful in 
analysing the relationship amongst PPOs from several diverse species. Hence a 
chapter describing a phylogenetic analysis of these proteins from different species as 
obtained from the Genbank™ and TIGR databases is thus included (Chapter 7). 
A further focus of this project is based on our ability to produce a mono specific 
antibody to human PPO. This has enabled the immunocharacterisation of the human 
enzyme in tissue sections by light microscopy. Finally, using a modification of 
standard immunogold labelling techniques we have succeeded in viewing PPO at an 
intracellular level using electron microscopy. This led to the demonstration of PPO 
expression in different human tissues/organs, and its subcellular localisation in human 
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Chapter Four 
Expression and Purification of the 
Recombinant Protoporphyrinogen 
Oxidases of Bacillus subtilis, Myxococcus 
xanthus and Human 
Introduction 
In the study of PPO, a difficulty that workers encountered initially was the apparent 
low expression of PPO in readily available tissue or culture material. Thus large 
amounts of fresh tissue/culture were desirable. Secondly, in many cases there 
appeared to be a rapid loss of PPO activity, making monitoring of PPO purification 
procedures arduous. Finally, some inherent properties of PPO (intrinsic membrane 
localisation, cofactor requirement) rendered isolation of the protein biotechnically 
difficult. 
The publication of the B. subtilis hernY gene sequence was seminal in that it provided 
information on a putative PPO gene (Hansson and Hederstedt, 1992). The definitive 
identification of this as the B. subtilis PPO (hernG) gene and the development of a 
viable expression system of the soluble form of the B. subtilis PPO from the pBTac1 
expression vector in E. coli (Dailey et aI, 1994a) was a major breakthrough. Because 
of our group's focus on VP and PPO, this also resulted in a collaborative (ongoing) 
study between Professor Harry Dailey (University of Georgia, USA) and our 
laboratory. 
This chapter describes the optimisation of the expression of the recombinant B. 
subtilis PPO with a 6 histidine (6His) tag at it's N-terminus using an isopropyl-l-thio­
p-D-galactoside (IPTG) inducible pTrcHis vector. The 6His tag renders the protein 
susceptible to immobilised metal chelate affinity chromatography by virtue of the 
binding ability of histidine to divalent metal ions such as nickel. This system enabled 
establishment of a single step purification of homogeneous recombinant PPO and was 
adapted for the purification of the M xanthus and human PPOs. 
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Objectives 
• 	 To express the previously cloned PPO genes of B. subtilis, M xanthus and human 
in E. coli cells. 
• 	 To purify these recombinant PPOs to apparent homogeneity using metal chelate 
affinity chromatography. 
Methods and Materials 
Cloning of the B. subtilis PPO gene 
The cloning of the B. subtilis hemY gene, was carried out in Professor Dailey'S 
laboratory at the University of Georgia, Athens (USA) and was provided as a gift to 
our laboratory. The methodology used is described below: 
A fragment containing the full-length coding region of the B. subtilis PPO gene was 
generated by polymerase chain reaction (PCR), using the B. subtilis hemY gene 
sequence previously cloned into the pBtac 1 vector (Dailey et aI, 1994a) as a template. 
This fragment was cloned into a pTrcHis B expression vector (lnv~trogen, Carlsbad, 
California, USA). A 5' BamHI site and a 3' HindIII site were included in the primers 
for cloning purposes. Specifically, the sense primer was 5'-CGC GGA TCC ATG 
AGT GAC GGC AAA AAA-3'. The BamHI site is in bold, and the starting codon of 
the B. subtilis PPO sequence is underlined. The antisense primer used was 5' ­
TAACCGGCAAGCT TCA GCT GAA TAA ATA GGT AAG-3' (Dailey et aI, 
1994a). The PCR contained 1 IlM final concentration of each primer, 50 ng template, 
2 mM MgCh, 200 IlM dNTPs and 5 U Taq polymerase (Promega, Madison, 
Wisconsin, USA). The PCR program was as follows: 3 min at 950C, [1 min at 95°C, 1 
min at 56°C, 2 min at 72°C] X 30 cycles, and a final extension time of7 min at 72°C. 
A single PCR product ofabout 1400 bp was obtained. The product was purified on an 
agarose gel, excised and extracted from the gel by the Magic PCR preparative 
procedure (Promega). The resulting cDNA fragment was digested with BamHI and 
HindIII and cloned into pTrcHis B, which had also been digested with BamHI and 
HindIII. The resulting recombinant plasmid was named pBsubtPPO-X. 
Transformation, Expression and Purification of the Recombinant B. 
subtilis PPO 
Transformation of the PPO-containing plasmid into E. coli 
Work in our laboratories commenced with the transformation of the recombinant B. 
subtilis PPO into competent E. coli JM109 cells for expression purposes. 
Competent E. coli JMI09 cells (Promega) were transformed with the pBsubtPPO-X 
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broth (1 % Tryptone, 0.5% Yeast extract, 0.5% NaCl) was transferred into 50 ml of 
sterile LB broth in a 500 ml flask and incubated at 37°C with shaking until an OD600 
of 0.5-0.6 was reached (mid log phase). The cells were then harvested by 
centrifugation at 2000 G for 10 min at 4°C. After draining off the supernatant the cell 
pellet was gently resuspended in 300 III of ice cold transformation buffer (1 % 
Tryptone, 0.5% yeast extract, 0.5% NaCl, 20 mM MgCI2, 10% polyethylene glycol, 
5% dimethyl sulfoxide) and left on ice for 30 min. 100 III of the suspension was 
gently mixed with 1111 (-30 ng) ofpBsubtPPO-X DNA in an Eppendorftube and left 
on ice for 45 min. This mixture was then put on a uniform heating block pre warmed 
to 42°C and left for 2 min, and then transferred immediately to an ice bath for 1.5 
min. 900 III of sterile LB broth was added and this transformation mixture was 
incubated for 1 h at 37°C with shaking. Different volumes (100 Ill, 200 III and 500 Ill) 
of the transformed culture were plated onto LB plates containing 100 mg/ml 
ampicillin and incubated overnight at 37°C. Single colonies of the transformed cells 
were isolated from the plates and inoculated into 100 ml of LB broth containing 100 
mg/ml ampicillin and grown overnight at 37°C, and the best PPO-expressing colony 
(based on PPO activity assays) was used to prepare 1 ml aliquot stocks (70% culture + 
30% sterile glycerol) were stored at -80°C for future use. 
Control E. coli JMI09 cells (lacking ampicillin resistance) from an overnight culture 
were also plated onto ampicillin (100 mg/ml) containing LB plates to test the ability 
of the antibiotic concentration to suppress growth ofnon-resistant cells. 
Expression of the recombinant PPO 
For the expression of the recombinant B. subtilis PPO, 100 III of transformed E. coli 
JM 1 09 cells containing pBsubtPPO-X were inoculated into 10 ml LB broth 
containing 100 Ilg/ml ampicillin and incubated overnight at 37°C with shaking in an 
orbital shaker incubator. 100 III of the overnight culture was inoculated into 1 L of LB 
broth containing 100 Ilg/ml ampicillin and the cells were grown to mid-log phase 
(OD600 of 0.5-0.7) at 37°C. 1 mM IPTG was added to the culture for the induction of 
.. recombinant B. subtilis PPO expression, and growth was continued for 4 h. A similar 
control culture was prepared in 1 L of LB broth without ampicillin using E. coli 
JM 1 09 cells that were not transformed. Cells from the cultures were harvested by 
centrifugation at 12000 G for 30 min at 4°C, and resuspended in 3 ml of cold assay 
buffer (100 mM Tris, 3 mM DTT, 1 mM EDTA, 0.1% Tween-20, pH 8.1) and kept 
on ice. The cells were sonicated for 3X 30 sec cycles on ice. Samples from both the 
transformed (pBsubtPPO-X) and non-transformed (control) lysates were assayed for 
PPO activity according to the method of Meissner et al (1986). Essentially, the 
method is based on the measurement of the constant velocity formation of 
protoporphyrin-IX from protoporphyrinogen-IX under saturating substrate conditions 
using fluorimetry. 
Purification 
Numerous initial attempts to purify PPO to homogeneity under native (non­
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problem by developing a purification procedure using denaturing conditions, followed 
by renaturation. This approach was validated in that the kinetic parameters obtained 
using this material were not significantly different from those exhibited by semi­
purified (non-denatured) material. 
Purification of recombinant B. subtilis PPO using denaturing conditions 
Cells were harvested by centrifugation at 4000 G for 30 min at 4°C. The pellet was 
resuspended in a denaturing solubilisation buffer (6 M GuHCl, 0.1 M Na-phosphate, 
0.01 M Tris, pH 8.0) at 5 ml per g wet weight, and stirred at room temperature for 1 h. 
The lysate was centrifuged at 105000 G for 30 min, and the PPO-containing 
supernatant collected. 
The clear supernatant containing recombinant B. subtilis PPO was loaded onto a Ni­
NT A agarose column pre-equilibrated with the solubilisation buffer. After an initial 
wash with 20 ml of solubilisation buffer (6 M GuHCI, 0.1 M Na-phosphate, 0.01 M 
Tris, pH 8.0), the column was washed with 20 ml of a second denaturing buffer (8 M 
urea, 0.1 M Na-phosphate, 0.01 M Tris, pH 8.0), which was followed by another wash 
with 20 ml of the same buffer with pH adusted to 6.3. PPO was eluted with 0.25 M 
imidazole in the pH 6.3 buffer and collected in 1 ml fractions. PMSF (1 Jlg/ml) was 
added in all buffers immediately before use, to prevent protease degradation. The 
entire procedure was performed at room temperature and PPO activity monitored 
throughout. 
Renaturation of the protein was achieved by dilution of at least 50 times with the 
assay buffer (100 mM Tris, 1 mM EDTA, 3 mM DTT, 0.1% Tween-20, pH 8.7), in 
the presence of 5 11M FAD, and incubation for at least 30 min at 37°C prior to activity 
measurements. (Reactivation whilst the protein was immobilised on the Ni-NTA 
column prior to elution proved unsuccessful when renaturation was initially tried by 
using a 6 - 1 M urea gradient in 0.5 M NaCl, 20% glycerol, 0.01 M TrisHCI, pH 7.4.) 
The purity of the PPO was assessed using SDS-PAGE. 
Partial purification of recombinant B. subtilis PPO using non·denaturing 
(native) conditions 
Cells from 1 L of transformed E. coli JM109 culture (with pBsubtPPO-X) were 
resuspended in 30 ml of sonication buffer (0.05 M Na-phosphate, 0.3 M NaCl, 1 % 
Tween-20, pH 8.0). PPO was released from the cells by sonication for 4X 30 sec, on 
ice. The PPO-containing supernatant was collected after centrifugation of the lysate at 
105000 G for 30 min at 4°C. The supernatant was loaded onto a Ni-NTA agarose 
column pre-equilibrated with sonication buffer as above except that there was 0.2% 
Tween-20. After loading, the column was washed with equilibration buffer (20 ml). 
After a wash with 0.05 M Na-phosphate, 0.01 M TrisHCI, 0.3 M NaCl, 10% glycerol, 
0.2% Tween-20, pH 6.3, bound protein was eluted from the column with a 0-0.1 M 
imidazole gradient in this buffer. PMSF (1 Jlglml) was added to all buffers. 
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Cloning, Transformation and Expression of the M. xanthus and 
Human PPO genes 
M. xanthus PPO 
The construction of the recombinant plasmid containing the M xanthus PPO gene 
was perfonned in Prof. Dailey's laboratories using the plasmid pLJS43. Details are 
published (Dailey and Dailey, 1996a) and the protocol resulted in an engineered 
expression vector (PMx-PPO) essentially similar to the pBsubtPPO-X described 
above which encoded a protein that contained a 6X His tag. However, rather than 
cloning into the pBTacl vector, the pTF20E derivative of this vector was used in 
which there was an optimally spaced ribosomal binding site T7 enhancer and an A TG 
start site placed immediately downstream from the promoter. This enhanced protein 
expression and thus greatly facilitated purification. The pMx-PPO was also a gift to 
our laboratory. 
We transfonned E. coli JM109 cells with this recombinant plasmid essentially as 
described for the B. subtilis gene. The JMI09 cells were, however, rendered 
competent using the CaCl2 method (see Appendix 1 for details). 
The expression system as described for the B. subtilis protein proved entirely suitable 
for the expression of the M xanthus PPO except that no IPTG induction was 
necessary and no initial 10 ml overnight culture appeared necessary. Thus we 
inoculated 1 L LB broth with 100 III of glycerol stock of the plasmid and cultured for 
24 h prior to using for purification. 
HumanPPO 
The construction of the recombinant plasmid containing the human PPO gene was 
perfonned in Prof. Dailey's laboratories (Dailey and Dailey, 1996b). The 6X His tag 
was placed upstream from the ATG start site as insertion of this tag immediately 
adjacent to the ATG start codon resulted in poor binding to the metal affinity column. 
A nine amino acid spacer was added to the front of the protein. The engineered cDNA 
was inserted into the unique NheI site of the pTrcHis B vector and was named 
pHPPO-X. Like the other two PPO's this was also a gift to our laboratory. 
Transfonnation and expression of E. coli cells with the HPPO-X plasmid was as 
described for the M xanthus gene. 
Purification of M. xanthus PPO 
The cultured, PPO-expressing cells were harvested by centrifugation at 4000 G for 30 
min at 4°C. The pellet was resuspended in 30 ml of sonication buffer (0.02 M Tris­
HCI, 0.1 M NaCI, 1 % Tween-20, pH 8.0) and sonicated as above and centrifuged at 
105000 G for 30 min. The subsequent purification, although similar in principle to 
that of the B. subtilis purification, differed and is described here. We used "Talon", 
which is a Co-based irnrnobilised metal-affinity chromatography resin rather than the 
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from the above spin, loaded. The column was washed with 10 ml of 0.02 M Tris-HCl, 
0.1 M NaCI, 0.5% Tween-20, 10% glycerol, pH 6.3, followed by 10 ml of this buffer 
but with 0.05 M phosphate replacing the Tris-HCl. At this stage the column was 
washed with 10 ml of this phosphate buffer containing 25 mM imidazole in order to 
remove non-specifically bound proteins. Elution of PPO was in 100 mM imidazole in 
the phosphate buffer. 1 ~g/ml PMSF was added to all buffers as a protease inhibitor. 
Purification of Human PPO 
n-octyl-,B-D-glucopyranoside was the detergent of choice for the solubilisation of the 
human PPO and replaced Tween-20 in all buffers. Tween-20 proved unsuitable in 
initial purification attempts. The subsequent purification of the recombinant human 
PPO was onTalon resin equilibrated in 0.02 M Tris-HCI, 0.1 M NaCI, 1% n-octyl-,B­
D-glucopyranoside, pH 8.0. After loading under gravity the column was washed with 
20 ml of equilibration buffer prior to a 10ml wash in the same buffer containing 
0.025M imidazole followed by elution of bound PPO with 0.15 M imidazole in the 
same buffer. 
All the purification schemes were carried out at room temperature. The M xanthus 
and human PPO protein fractions were immediately stored at 4°C after elution, and 
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Results and Discussion 
B. subtilis PPO 
Expression 
The sonicate from transformed cells containing the recombinant plasmid which 
expresses B. subtilis PPO showed a significantly higher rate of protoporphyrinogen­
IX oxidation. There was an approximate 17-fold increase in PPO activity in the 
transformed cells when expressed as nmol of protoporphyrinogen oxidised/h/mg 
protein (figure 4.1). This indicated successful transformation of the cells and retention 
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Figure 4.1: .a. ~ PPO activity per mg protein from transformed E....QfJJi cells was 
approximately 17 times that of control cells. 
Purification 
Purification of the B. subtilis PPO using non-denaturing (native) conditions yielded 
partially purified PPO with Mr of approximately 56000 Da, which co-eluted with low 
concentrations of some low molecular weight contaminants (figure 4.5). As 
mentioned in the "Methodology", these contaminants were not removed in spite of 
numerous attempts of varying purification conditions. A few of these bands may have 











Table 4.1 shows that the purification of the protein under these non-denaturing 
(native) conditions from I L of E. coli culture, gave a 68% yield and an 
approximately 10-fold increase in activity per mg ofprotein. 
In contrast, the purification scheme using denaturing conditions yielded a single 
protein of 56 000 Da (figure 4.2) and a 78.5% purification of PPO from the E. coli 
lysate with a 3 I-fold increase in specific activity (activity per mg of protein) for the 
renatured protein (table 4.2). Approximately 4 mg of PPO were obtained from I L of 
culture. 
Table 4.1: Partial purification ofll. ~ PPO by Ni-NTA metal chelate affinity chromatography using 
non-denaturing conditions. 
Fractn Vol. Total Prot. PPOAct. Total Act. Act. I mg % Yield 
(apparent) (apparent) 
(ml) (mg) (nmol/h/ml) (nmol/h/ml) (nmollh/mg) 
Load 28 114.5 195.8 5482.4 47.8 100 

Eluate 10 7.6 374.6 3746.0 492.9 68.3 

Table 4.2: Purification ofa ~ PPO by Ni-NTA metal chelate affinity chromatography using 
denaturing conditions. 
Fractn Vol. Total Prot. PPO Act. Total Act. Act. I mg % Yield 
(ml) (mg) (nmol/h/ml) (nmol/h/ml) (nmol/h/mg) 
Load 15 150 56 840 5.6 100 
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Lane 1 - supernatant from E,. coli cells, expressing B. subfilis PPO, which were lysed with 6 M 

GuHCI buffer showing a wide spectrum ofproteins. 

Lane 2 - purified B. subtilis PPO. 

Lane 3 - RainbowTM molecular weight markers. 

An interesting feature of the denatured B. subtilis PPO was it's ability to refold and 
regain activity on dilution (at least 50-fold) of the denaturing agents (6 M GuHCl, 8 
M urea). During purification we observed apparent loss of flavin cofactor as the 
distinctive yellow colour associated with the flavins eluted in the void and some came 
off in the washes. Thus, this renaturation process also depended on apparent 
reassociation with the flavin cofactor which was present in the assay buffer and was 
essential for activity. 
M. xanthus and Human PPOs: Transformation, Expression and 
Purification 
For purification of M. xanthus (figure 4.3) and human PPOs (figure 4.4), IPTG 
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was followed as growth into stationary phase was sufficient for optimal induction. It 
would have been a fair assumption that the same purification procedure could be used 
for all three PPO's. However - all three purifications required modification (see 
Appendix 1) to obtain apparently pure PPO. Furthermore, the M xanthus and human 
PPOs were easily purified on metal-affinity chromatography using non-denaturing 
conditions, whereas, in our hands, purification of B. subtilis PPO appeared 
unachievable using non-denaturing conditions. 
1 2 3 4 .. 







~ 21.5 K 
Figure 4.3: SDS-PAGE of the purification of M. xanthus PPO. 
Lane 1 - supernatant from sonicated E. coli cells expressing M. xanthus PPO 
Lane 2 - unbound proteins which fell through in the void volume 
Lane 3 - purified M. xanthus PPO 
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2 3 
+--- 220 K 
+--- 97.4 K 
+--- 66 K 
+--- 46 K 
+--- 30 K 
+--- 21.5 K 
+--- 14.3 K 
Figure 4.4: SDS-PAGE of the purification of human PPO. 
Lane 1 - supernatant from sonicated E. coli cells expressing human PPO 
Lane 2 - purified human PPO 
Lane 3 - molecular weight markers. 
In initial attempts to purify human PPO we utilised Ni-NTA agarose. The human PPO 
appeared to bind strongly to the Ni-NTA agarose column requiring a high imidazole 
(800 mM) concentration and 1 M NaCl in the elution buffer for elution. Even under 
these conditions a significant quantity appeared to remain bound to the column as 
judged by the presence of the (yellow) FAD. Thus we utilised Talon metal-affinity 
resin which gave a greater yield (5-6 mg) and better purity. Ni-based resins may bind 
non-6X His tagged proteins (QIA Expressionist, 1992). Although Talon binds 6X His 



















Figure 4.5: SDS-PAGE (7.5-17.5%) showing purification ofthe human, M. xanthus and B. 
subtilis PPOs in lanes 1, 2 and 3 respectively, using non-denaturing (native) conditions. The 
low molecular weight band at the bottom of lane 3 shows the partial purification of the B. 
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Concluding Remarks 
A viable expression system was established for cloned B. subtilis, M. xanthus and 
human PPOs in our laboratory. The use of a pTrcHis expression system for the 
cloning of these proteins enabled purification of these proteins by a single-step 
procedure based on metal chelate affinity chromatography. This appears to be a great 
improvement to the purification of these proteins as previous methods involved the 
use of mUltiple chromatographic steps which contributed significantly to low protein 
yield at the end of a purification scheme (Klemm and Barton, 1987; Jacobs and 
Jacobs, 1987; Dailey and Karr, 1987; Siepker et al, 1987; Proulx and Dailey, 1992; 
Camadro et al, 1994). 
These purifications allowed production of substantial amounts of apparently 
homogeneously pure PPOs with enzyme activity, which were suitable for further, 
selected, characterisation. The ability to produce and work with purified active PPOs 
facilitated the detailed characterisation of the B. subtilis PPO, and some aspects of the 
characteristics of PPO' s from the other species purified could therefore be compared. 












Characterisation of Protoporphyrinogen 
Oxidases of Bacillus subtilis, Myxococcus 
xanthus and Human 
Introduction 
Early studies of the enzymatic oxidation of protoporphyrinogen-IX to protoporphyrin­
IX utilised crude unpurified or partially purified PPO samples derived from 
membrane fractions of isolated mitochondria and chloroplasts, or the plasma 
membranes of prokaryotic cells (Jacobs and Jacobs, 1981; 1984a, b; Klemm and 
Barton, 1985; Camadro et aI, 1985). The findings from these studies indicated that 
PPOs from different sources were rather different in terms of their molecular weights, 
subunit composition, associated cofactors, kinetic properties and terminal electron 
acceptors (Poulson and Polglase, 1975; Poulson, 1976; Jacobs and Jacobs, 1976, 
1977a, b; Camadro et al, 1985; Klemm and Barton, 1987; Jacobs and Jacobs, 1987; 
Siepker et aI, 1987; Dailey and Karr, 1987; Ferreira and Dailey, 1988; Proulx and 
Dailey, 1992). Importantly, these studies were crucial in demonstrating that the 
penultimate step of haem biosynthesis is catalysed by an intrinsic mitochondrial 
membrane protein (Deybach et al., 1985; Ferreira and Dailey, 1988). However, 
detailed kinetic analysis of these pr teins was limited to a large extent by difficulties 
associated with their purification. 
In the previous chapter we described the establishment of a viable expression system 
which facilitated the purification of the B. subtilis, M xanthus and human 
recombinant PPOs to homogeneity using metal chelate affinity chromatography. This 
enabled us, to further characterise these proteins. The broad aim was thus to 
determine biophysical and kinetic properties of the B. subtilis PPO. For comparative 




• 	 the Mr of recombinant B. subtilis, M xanthus and human PPO and the subunit 
composition ofB. subtilis PPO. 
• 	 the pH optima and kinetic rate constants of these PPOs with respect to the 
oxidation of protoporphyrinogen-IX to protoporphyrin-IX. 











• 	 the N-terminal amino acid composition ofB. subtilis PPO. 
• 	 the substrate specificity ofB. subtilis PPO. 
• 	 the flavin cofactors associated with the prokaryotic PPOs and the nature of their 
binding. 
• 	 the effects of various lipids on activity of the prokaryotic PPOs. 
Methods and Materials 
Determination of the relative Mr of the isolated B. subtilis PPO 
The Mr of the B. subtilis, M xanthus, and human PPOs were determined by 
polyacrylamide gel electrophoresis (SDS-PAGE) of the purified proteins and 
comparison with standard proteins of known molecular weight. Details are given in 
Appendices 2 and 3. 
Briefly, gradient SDS-PAGE (7.5-17,5%) was performed under reducing conditions 
in 0.15% SDS on vertical slab gels. Approximately 4 ~g of PPO protein mixed in 1: 1 
ratio with sample loading buffer was loaded in each lane. The purified proteins and 
standard molecular weight markers were boiled for 5 min prior to loading, except for 
the denatured B. subtilis proteins which were incubated in a water bath at 37°C for 15 
min before loading. The Mr's of the purified PPO proteins were determined 
graphically by interpolation from plots of the molecular weights of the standard 
proteins against their relative migration distances through the gel. 
Analysis of the subunit composition of the B. subtilis PPO 
Gel filtration on a Sephadex G-200 column (1.6X 100 cm) in phosphate buffer (10 
mM Na-phosphate, 100 mM NaCl, 0.2% n-octyl-,B-D-glucopyranoside, pH 7.4) was 
done for mono-/multimeric analysis of non-denatured semi-purified B. subtilis PPO. 
SDS-PAGE was performed to determine the nature of the eluted protein. PPO flow 
through the column was compared to molecular weight markers from Pharmacia 
Biotech (Uppsala, Sweden). 
Determination of the pH optima of B.subtilis, M. xanthus and human 
PPOs 
The pH optima for the oxidation of protoporphyrinogen-IX by B. subtilis, M xanthus 
and human PPOs were examined over the pH range 6 to 10, using the following 
buffer systems: 











.;. 0.1 M Tris (PH range: 7.2· 9) 
·0.1 M carbonate (PH range: 9.0 - 10.7) 
PPO activity was assayed in these buffer systems by measuring the constant velocity 
formation ofprotoporphyrin-IX from protoporphyrinogen-IX according to Meissner et 
al (1986), using the purified enzyme preparations. The enzyme activity was measured 
in the presence of the cofactor, FAD (5 IlM), to compensate for its potential loss 
during the purification of these proteins. 
Determination of the rate constants, Km and V max, for the oxidation 
of protoporphyrinogen-IX by the different PPOs 
The Michaelis-Menten constants (Km) and maximal velocities (Vmax), for the purified 
PPOs of B. subtilis, M xanthus and human were determined by measuring the 
constant velocity formation of protoporphyrin-IX from protoporphyrinogen-IX in the 
substrate concentration range 0.1-30 1lM, during an incubation period of not more 
than 60 min. Approximately 4 Ilg of enzyme were used in each 1 ml reaction mixture. 
The Km and V max values were determined from substrate-velocity plots created from 
sufficient representative points to give reasonable readings. Calculated values were 
determined with the computerised Gauss-Newton, iterative, non-linear curve fitting 
procedure. 
B. subtilis PPO preparations from both denaturing and non-denaturing purification 
procedures were used in order to determine if the denaturation-renaturation process 
had any effects on the kinetics of the enzyme. 
Determination of the isoelectric point (pi) of the purified B. subtilis 
PPO 
B. subtilis PPO protein sample was desalted on a PD-1O column prepacked with 
Sephadex G-25 immediately before isoelectric focusing. Flat bed isoelectric focusing 
(PH 3.5-9.5) was performed on a 5% polyacrylamide gel. The isoelectric point was 
determined with the Pharmacia Broad pI Calibration Kit (PH range 3.0-10) using 
standard protein markers of known molecular weight as per manufacturer's 
instructions. Details are given in Appendix 6. 
Amino acid composition of B. subtilis PPO 
. The amino acid composition of the N-terminal sequence of the purified B. subtiUs 
PPO was determined by the DepartIrient of Biochemistry, University of Cape Town. 
Approximately 100 Ilg of protein was subjected to 6N HCl hydrolysis, in vacuo, for 
24 h. Amino acids were separated using the Waters HPLC amino acid analysis 
protocol employing a CX pak strong cation exchange column, and detected by 0­
phthaldialdehyde (OPA) derivertisation. When proline was determined, the OPA­











Determination of substrate specificity of the recombinant B. subtilis 
PPO 
The substrate specificity of the B. subtilis PPO was determined by examining the 
oxidation of protoporphyrinogen-IX, coproporphyrinogen-III, mesoporphyrinogen-IX, 
and uroporphyrinogen-III by this enzyme. For determination of porphyrin 
concentrations, HCl was used as a solvent at concentrations suitable for dissolving the 
various porphyrin compounds (table 5.1). The extinction coefficients (emM) of the 
different porphyrins were used to calculate their concentrations in these solutions after 
measurement of their maximum absorbances. 
Table 5.1: Porphyrin compounds tested with the B. ~ PPO. 
[Porphyrin] pM =O.D.:ima/emM X Dilution factor 
Porphyrin Substrate [Solvent] A. max (nm) EmM 
Protoporphyrinogen-IX 2.7N HCI 405 262 
Mesoporphyrinogen-IX 0.1N HCI 399 445 
Coproporphyrinogen-III 0.1N HCI 399.5 489 
Uroporphyrinogen-III 0.5N HCI 405.5 541 
The assays for the different porphyrin substrates were performed at pH 8.7 in assay 
buffer. Approximately 4 J-lg of purified PPO were added in each reaction. Reduction 
of the porphyrins to corresponding porphyrinogens with 4% sodium amalgam was 
done immediately prior to the beginning of the assay. Kinetic constants for each of the 
porphyrin compounds were determined as outlined above. The data for each of the 
substrates tested represents the mean of at least three independent sets of results 
obtained from assays carried out on different enzyme preparations on different days. 
Analysis of the flavin cofactors associated with B. subtilis and M. 
xanthus PPOs 
Putative flavins were extracted from the relevant PPO preparations and analysed by 
spectrophotometry. Details are given in Appendix 7. Briefly, a TCA protein 
precipitate was removed by centrifugation and the flavin-containing acidic 
supernatant was immediately adjusted to pH 7.4 with 3 M Tris and kept at 4°C in the 
dark to avoid hydrolysis and photo degradation of flavin. An emission fluorescence 
spectrum for this supernatant was then determined. The spectra were compared to 











Effects of various lipids on activity of B. subtilis and M. xanthus 
PPOs 
The activities of B. subtilis, and M xanthus PPOs were assayed in the presence of 
palmitic (Sigma Products) and oleic acid (UniLAB) using sufficient representative 
points (9-15) over a range of lipid concentrations from 0-280 ~M. Ethanol was used 
to dissolve the lipids giving a final solvent concentration of 2.5% in the reaction 
mixture for both samples and blanks. The experiments were repeated on three 
separate enzyme preparations and the results averaged. 
Results and Discussion 
Molecular weight determinations and subunit composition of 
purified B. subtilis PPO 
SDS-PAGE of human, B. subtilis, and M xanthus PPOs yielded apparent M/s of -53 
000, 56 000 and 52 400 Da, respectively (Figure 5.1 a, b, c). This was in agreement 
with other cloned, purified and characterised PPOs with molecular weights reported 
in the 52 000 - 56 000 Da range, such as the mouse (Dailey et aI, 1995; Taketani et at, 
1995a); A. thaliana (Narita et ai, 1996); yeast (S. cerevisiae) (Camadro et aI, 1994); 
tobacco plant (Lennontova et at, 1997); spinach (Matringe et ai, 1992a) and potato 
plant (Johston et aI, 1998). 
The slightly higher Mr' s of our recombinant proteins than those predicted from their 
derived amino acid sequences may be attributed to the presence of the 6His tag at 
their N-tennini. It has been reported that proteins with the 6His tag may run slower, 
during gel electrophoresis, than the equivalent untagged proteins (The QIA 
Expressionist, 1992). 
Gel filtration chromatography of the nondenatured partially purified B. subtilis PPO 
perfonned on a Sephadex G-:-200 column yielded a monomer of - 54 000 Da (figure 
5.2) confinning previous findings based on HPLC filtration of the recombinant 
protein expressed from a pBTac 1 plasmid which also showed that the active B. 
subtilis PPO existed as a 53 000 Da monomer (Dailey et aI, 1994a). B. subtilis PPO 
appears to be different to both the human and M xanthus recombinant PPOs which 
were previously shown to be homodimers of 100 000 Da comprised of subunits of 
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Figure 5.1a: Calibration CUNe for determination of molecular weight of the purified human 
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Figure 5.1b: Calibration CUNe for determination of molecular weight of the purified B. ~ 
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Figure 5.1c: Calibration curve for determination of molecular weight of the purified M. xanthus PPO. A 
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Elution fraction 
Figure 5.2: Determination ofmolecular weight of native..,B. ~ PPO using Sephadex G200 
gel flitration. This protein eluted as a 54 000 Da monomer. The molecular weight markers 
used were Aldolase (158 000 Da), Bovine serum albumin (67 000 Da), Ovalbumin (43 000 











pH optima of B.subtilis, M. xanthus and human PPOs 
The pH optima for the oxidation ofprotoporphyrinogen-IX by the PPOs ofB. subtilis, 
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Figure 5.3: Effect ofpH on activity ofa. subtiUs PPO. Optimum oxidation of 
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Figure 5.4: Effect ofpH on activity ofM. xanthus PPO. Optimum oxidation of 
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Figure 5.5: Effect ofpH on activity of Human PPO. Optimum oxidation ofprotoporphyrinogen­
IX by the human PPO occured at pH 8.1 (n = 3). 
The pH optima of other characterised PPOs such as the rat (8.7) (Poulson, 1976); 
mouse (8.0) (Ferreira and Dailey, 1988), and bovine (8.7) (Siepker etal, 1987) were 
also within this basic range. This is in contrast to the multi-subunit, acidic PPO of the 
anaerobic bacterium, D. gigas which appears to tolerate changes in pH (Klemm and 
Barton, 1987). Optimum activity of barley etioplastic PPO was reported to occur at 
pH 7.3 and that of the spinach enzyme at pH 7.0 (Jacobs and Jacobs, 1984a). 
Similarly, the yeast PPO oxidises protoporphyrinogen-IX optimally at pH 7.2 to 7.4 
(Poulson and Polglase, 1975; Camadro et aI, 1994). A further report on barley PPO 
suggests an acidic pH optimum of 6.0 (Jacobs and Jacobs, 1987) although this may 
not reflect its operational pH in vivo as there would be significant auto-oxidation at 
this pH. 
Rate constants for the oxidation of protoporphyrinogenMIX by the 
different PPOs 
The oxidation of protoporphyrinogen-IX to protoporphyrin-IX by the purified B. 
subtilis PPO obeyed Michaelis-Menten kinetics as indicated by the typical saturation 
of enzyme by high concentrations of substrate (figure 5.6a) which yields a straight 
line when the double-reciprocal is plotted (Lineweaver-Burke plot) (figure 5.6b»). 
Similar curves were obtained for both the purified M xanthus and human PPOs with 
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Figure 5.6 (a): Substrate-velocity plot for the enzymatic oxidation ofprotoporphyrinogen-IX by 
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Figure 5.6 (b). Lineweaver-Burke plot of the oxidation ofprotoporphyrinogen-IX by the13.. 
subtjlis PPO (data from figure 5.6a). 
Vmax and Km values for B. subtilis (denatured and partially pure non-denatured), M 
xanthus and human PPO are given in Table 5.2. The Km for protoporphyrinogen-IX 
oxidation by B. subtilis PPO was similar to that reported by Hansson and Hederstedt 











Table 5.2. Michae/is-Menten constants (KmJ and maximal velocities (VmaJ for the oxidation of 
protoporphyrinogen-IX by the different PPO species. In all cases n=4. 
ppo Km(JlM) Vmax (nmol/min/mg) 
B. subtilis (renatured) 1.00 ±0.1S 3.70 ±0.12 
B. subtilis (nondenatured) 1.14±0.1S 3.87 ±0.21 
M. xanthus 0.40 ±0.03 8.80 ±0.20 
Human 0.67 ±0.29 734.00 ±39 
The denaturing conditions used in the purification of the B. subtilis PPO did not affect 
the ability of the enzyme to oxidise protoporphyrinogen-IX as indicated by the similar 
Km and approximate V max values for the nondenatured (native) and renatured proteins. 
It would appear therefore, that the renatured PPO refolds correctly. 
While it was of concern that kinetic studies on the B. subtilis PPO were to be carried 
out on a protein purified under denaturing conditions, the Km's and Vmax's for the 
oxidation of protoporphyrinogen-IX by PPO under these conditions were in good 
agreement with those of the non-denatured semipurified enzyme. 
Isoelectric point (pi) of the purified B. subtilis PPO 
Analytical isoelectric focusing yielded an experimental pI of 7.5 (figure 5.7). This was 
in reasonable agreement with that of 8.3 predicted from the amino acid sequence 
derived from the hemY gene (Dailey et aI, 1994a), and with those of 8.0, 8.5 and 8.82 
calculated for the purified human (Dailey and Dailey, 1996b), yeast (Camadro et aI, 
1994) and mouse (Dailey and Karr, 1987) PPOs, respectively. Thus, it appears that 
most PPOs have similar pI values in the neutral to weakly basic range, pH 7.5-8.8. 
However, the D. gigas enzyme is an exception in that it has a reported pI of 5.71 
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Figure 5.7. Flatbed isoelectric focusing of the 8. ~ PPO was performed on a 5% 
polyacrylamide gel (a), showing in lane 1 - 8. ~ PPO, and lane 2 - the Pharmacia 
aroad pI standard protein markers. The experimental isoelectric point of the purified PPO was 
calculated from the plot ofpH vs relative migration distance (AJ. 
The amino acid composition of B. subtilis PPO 
The experimentally determined amino acid composition of the purified B. subtilis 
PPO (Table 5.3) was in reasonable agreement with the published amino acid sequence 
derived from the hemY (PPO) gene sequence (Hansson and Hederstedt, 1992; Dailey 











Table 5.3: Chromatogram profile of the amino acid analysis ofpure 11. ~ ppo. N.d. - not 
determined. Predicted amino acid composition from tJf21l1Y. gene sequence (Hansson and Hederstedt, 
1992). 
Amino Acid Mol % Predicted Mol % 
Asp 6.37 4.70 
Glu 8.54 10.43 
Ser 6.78 7.45 
Thr 6.35 6.38 
Gly 10.69 8.94 
Ala 7.18 7.45 
Arg 3.38 3.19 
Pro 5.40 4.47 
Val 7.35 7.02 
Met 3.57 2.98 
lie 5.88 5.74 
Leu 11.29 10.00 
Phe 3.58 3.19 
Cys N.d. 0.85 
Lys 8.64 8.30 
His 3.14 2.77 
Tyr 1.86 2.55 
Substrate specificity of the purified B. subtilis PPO 
In addition to the natural PPO substrate (protoporphyrinogen-IX) both 
coproporphyrinogen-III, and the non-physiologic mesoporphyrinogen-IX were utilized 
as substrates by the B. subtilis PPO. Uroporphyrinogen-III was not oxidised by this 
PPO. The oxidation of all the substrates by this enzyme followed classical Michaelis­
Menten kinetics. The Km, V max, kcat and kcatlKm values for the oxidation of the various 
substrates are summarised in table 5.4. kcat. sometimes referred to as the turnover 
number, represents the maximum number of substrate molecules converted to product 











Table 5.4. Michae/is-Menten (Km), maximum velocity (VmsJ and catalytic constants (kcst., kcst/ KmJ for 
the various substrates oxidised by the Ii~ PPO. 


















The efficiency for the oxidation of the different substrates by the B. subtilis PPO was 
in the order, Kcat(mesoporphyrinogen) > Kcat(protoporphyrinogen) > Kcat(coproporphyrinogen)' It is of 
interest to compare the apparent specificity constants KcattKm as this relates the 
reaction rate to the concentrations of free rather than total enzyme. This preference of 
the B. subtilis PPO for mesoporphyrinogen is in contrast to mammalian PPO. Human 
liver mitochondrial PPO has preference for protoporphyrinogen (apparent Km 0.16 
flM, V max 8.5 nmollhlmg) over mesoporphyrinogen which has two different apparent 
Kms of 0.5 flM (V max 2.4 nmollhlmg) and 4 flM (V max 5.7 nmollhlmg) (Camadro et 
aI, 1985). Similarly mouse liver PPO has tenfold higher activity with 
protoporphyrinogen compared to mesoporphyrinogen (Dailey and Karr, 1987). 
Coproporphyrinogen-III, the least preferred of the B. subtilis substrates, is not utilised 
by the purified human enzyme (Dailey and Dailey, 1996b). 
This is in contrast to the findings by Hansson and Hederstedt (1994) who reported 
preference by the B. subtilis hemY protein for coproporphyrinogen-III over 
protoporphyrinogen-IX. The Km(app)s for protoporphyrinogen and coproporphyrinogen 
were 1.00 flM and 5.3 IlM respectively in contrast to 0.95 IlM and 0.56 IlM reported 
by these workers. In addition we obtained a higher V max for protoporphyrinogen than 
for coproporphyrinogen in contrast to these workers (Vmax(coproporphyrinogen) 7.0 
nmol/minlmg; Vmax(protoporphyrinogen) 0.85 nmollminlmg). Some of the differences 
in calculated kinetic parameters may be attributed to the problematic nature of 
substrate preparation and quantitation, differences in the assay medium (in particular 
our pH of 7.2 vs. 8.7 of Hansson and Hederstedt (1994)) as well as rates of 
endogenous (non-enzymatic) porphyrinogen oxidation. However, it is surprising that 
there are qualitative differences in the comparative kinetic values reported for copro­
versus protoporphyrinogen. 
This enzyme was different to both human (Dailey and Dailey, 1996b) and M xanthus 
(Dailey and Dailey, 1996a) PPOs which could not oxidise coproporphyrinogen-III. 
However, the fact that the B. subtilis PPO could not oxidise uroporphyrinogen-II1 
showed that it is not a general porphyrinogen oxidase. 
The reported inability to oxidise coproporphyrinogen-III by the M xanthus PPO 
(Dailey and Dailey, 1996a and M. Maneli- personal communication, our laboratory) 












Both protoporphyrinogen-IX and mesoporphyrinogen-IX are dicarboxylic porphyrins, 
whilst coproporphyrinogen-III is a tetracarboxylic porphyrin. Mesoporphyrinogen-IX 
differs from protoporphyrinogen-IX by the substitution of the vinyl groups at 
positions 2 and 4 of the tetrapyrrole macrocycle with ethyl groups. This structural 
resemblance between these compounds explains their recognition and high affinity for 
the B. subtilis PPO. Uroporphyrinogen-III on the other hand i:s an octacarboxylic 
porphyrin, and sterically larger than the other porphyrinogens and this may limit its 
interaction with the active site of this enzyme. 
The preference by the B. subtilis PPO for its natural substrate, protoporphyrinogen-IX 
over coproporphyrinogen-ITI suggests that this organism probably contains a non-PPO 
enzyme which catalyses the conversion of coproporphyrinogen-III to 
protoporphyrinogen-IX for the nonnal biosynthesis of haem. In several organisms this 
reaction was shown to be catalysed by two enzymatic systems that is, an oxygen 
requiring coproporphyrinogen oxidase (hemF) and an oxygen-independent 
coproporphyrinogen oxidase (hemN) (Tait, 1969, 1972; Seehra et aI., 1982). 
Following recent studies which showed that B.. subtilis could exist anaerobically via 
nitrate ammonification (Hoffmann et aI, 1995), in contrast to previous beliefs that it 
was a strict aerobe, an open reading frame which had amino acid homology to the 
. oxygen-independent coproporphyrinogen oxidase (hemN) was discovered in this 
organism (Homuth et al, 1995). This protein was subsequently shown to be involved 
in oxygen-independent decarboxylation of coproporphyrinogen-III to 
protoporphyrinogen-IX (Hippler et I, 1997). The oxygen-dependent 
coproporphyrinogen oxidase (hemF) ofB. subtilis has not yet been discovered. 
Determination of the flavin cofactors associated with the 
prokaryotic PPOs of B. subtilis and M. xanthus. 
A yellow substance, presumed to be flavin cofactors, associated with the B. subtilis 
and M xanthus PPOs was extracted from the purified proteins with cold 10% TeA. 
The fluorescence emission spectrum (Excitation wavelength = 465 nm) yielded three 
peaks in the region of 370,435 and 520 nm (figure 5.8); and this was indicative of an 










86 Chapter 5 
1600r-----~------~----~------~------c_----~------~----~ 
1400 
1200 ~···················· ..·i··........·.. ·.. ··,,·.... '· .... ,,1 














200~ ............·....·.. ·· .. ~·· ......·..····..·.. ·· .. ··~·.. ·..·.. ·· .. ··· .... ,··,,··..·.. ··....·....····+........··....·........·4 

O~ ........·.... ··· .. ·......~~~...... ~· .. ·.... ·.... ·.. ·..·....·+·.. ··· .. ····..·........j ......................... -t-................... -?-........................ ; ........................ .. 

-200~----~------~----~------~------~----~------~----~ 
250 300 350 400 450 500 550 600 650 
Wavelength (nm) 
Figure 5.B.: Fluorescence emission spectrum of the flavin cofactor released from the l2. 
subtilis PPO during purification, measured at an excitation wavelength of 465 nm. RFU = 
Relative Fluorescence Units. 
Moreover, loss of the yellow colour on reduction of this compound with dithiothreitol 
(DTT) and restoration of PPO activity after purification under denaturing conditions . 
and addition of exogenous FAD was further indicative of a flavin compound (figure 
5.9). A concentration-dependent increase in oxidation was observed up to a final 
assay FAD concentration of 4 IlM, and thereafter no further increase occurred 
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Figure 5.9. The effects of FAD on the oxidation ofprotoporphyrinogen-IX by the renatured l2. 
subtilis PPO (4 J19). Reactivation of the enzyme occurred on addition ofcommercial FAD to 
the assay reaction. 
The fluorescence emission spectra of the cofactors extracted from the purified B. 
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(PH 3.5) and neutral (PH 7.0) solutions, showed a characteristic FAD pH-dependent 
spectral shift, confinning previous fmdings that this was the cofactor associated with 
both the B. subtilis (Dailey et al 1994a) and M xanthus (Dailey and Dailey, 1996a) 
PPOs. 
The relative ease of extraction of the flavin cofactors from their respective PPOs 
(10% TCA) suggests that they are noncovalently associated with the protein which is 
similar to a report for human PPO (Dailey and Dailey, 1996b). In contrast, the FAD 
and FMN cofactors reportedly associated with the bovine (Siepker et al., 1987) and 
mouse (Proulx and Dailey, 1992) enzymes, respectively, were suggested to be 
covalently bound to these proteins, as they needed trypsin digestion or hot mineral 
acids for extraction. 
Interestingly, detailed fluorometric analysis of the reportedly purified plant (barley) 
PPO could not reveal presence of chromophoric compounds (Jacobs and Jacobs, 
1987; Jacobs et al., 1989). However, evidence at the primary structural level has 
revealed presence of the dinucleotide binding (~a~) motif in A. thaliana (Narita et al., 
1996) and tobacco plant (Lennontova et al., 1997) PPOs, suggesting that these are 
also flavoproteins. The PPO from S. cerevisiae was also shown to be an FAD­
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Figure 5.10: The fluorescence emission spectra of the flavin cofactors extracted from the lJ 
subtilis (A) and M. xanthus (8) PPOs, measured from 600 to 480 nm using an excitation 
wavelength of 450 nm, revealed a pH-dependent spectral shift typical of FAD. 
In the light of the above discussion we would suggest that PPO activity is critically 
dependent on the presence of a flavin cofactor to facilitate oxidation of 
protoporphyrinogen-IX for haem biosynthesis. 
Effects of lipids on PPO activity 
The addition of oleic or palmitic acid generally resulted in an inhibition of B. subtilis 
PPO activity although there appeared to be slight stimulation activity at low 
concentrations (figures 5.11 and 5.12). The presence of the fatty acids caused slight 
increase in the rate of auto-oxidation of protoporphyrinogen-IX but this was 
controlled for in the assay. The results represents means of data from three 
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Figure 5.11. Palmitic acid concentrations up to approximately 20 pM had a slight stimulatory 
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Figure 5.12. Oleic acid concentrations up to approximately 20 JiM had a slight stimulatory 
effect on the B.. ~ PPO activity. Concentrations above this had an inhibitory effect on the 
enzyme activity. 
In contrast to the B. subtilis PPO, oleic and palmitic acid had stimulatory effects on 
the M xanthus PPO activity up to approximately 100 flM and 80 flM, respectively 
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Figure 5.14. Effect ofpalmitic acid on M. xanthus PPO activity was also stimulatory up to 
approximately 80 pM. 
The stimulation of the M xanthus PPO by enhancement of the hydrophobic 
environment is in keeping with the concept that PPO is primarily membrane bound. 
The lack of stimulation of the B. subtilis PPO by the addition of fatty acids lends 
support to the findings that B. subtilis PPO exists partially in the soluble cytoplasmic 












This data illustrates differences and similarities in the characteristics of B. subtilis, M 
xanthus and human PPOs. A striking difference is the ability of the B. subtilis enzyme 
to utilise not only the common substrate for all PPOs, protoporphyrinogen, but also 
coproporphyrinogen and mesoporphyrinogen. Furthermore, the behaviour of B. 
subtilis PPO in the presence of lipids is unlike that of another prokaryote studied, M 
xanthus. 
These differences led us to further investigate the kinetic behaviour of B. subtilis PPO 












Inhibition Studies on Bacillus subtilis, 
Myxococcus xanthus and Human 
Protoporphyrinogen Oxidases 
Introduction 
This work provides detailed kinetic data on the inhibition of human, B. subtiUs and 
M xanthus PPOs by several chemical compounds, acifluorfen (AF), 
methylacifluorfen (MeAF), hemin (HMN) and the haem breakdown products 
bilirubin-IX (BR) and biliverdin-IX (BV), some of which have previously been 
implicated in the inhibition of various forms of PPO and have been reviewed in 
Chapter 2. 
The finding that B. subtiUs PPO (Dailey et aI, 1994a) has different inhibition 
characteristics from most other PPOs studied, led us to undertake these inhibitor 
investigations in an attempt to gain further information on the physicochemical nature 
of the enzyme active site and to characterise differences amongst the three forms of 
recombinant PPO. 
Objectives 
• 	 To examine the potential inhibitory effects of various compounds such as AF, 
MeAF, BR, BV and HMN on the oxidation of protoporphyrinogen-IX by the 
human, B. subtilis and M xanthus PPOs. 
• 	 To determine the kinetic constants, K j , Ks, a; and the mode of inhibition by these 
inhibitors. 
Methods and Materials 
Inhibitor assay preparation 
Denatured B. subtilis, native human and M xanthus recombinant PPOs were purified 
to apparent homogeneity as described in the previous chapters. 
Renatured purified PPO was used for all the B. subtilis kinetic studies apart from a 
. small pilot study in which semi-purified non-denatured enzyme was utilised for a 
comparison to show that Km and V max were unaffected by use of renatured enzyme. 
The standard reaction mixture comprised an assay buffer (100 mM TrisHCI, 3 mM 











subtilis), enzyme preparation, substrate and inhibitor. To ensure accurate 
determination of substrate oxidation, a corresponding blank was prepared for each 
and every assay reaction tube. This is described in detail in Appendices 8 and 9. 
All inhibitors were dissolved in dimethylsulfoxide (DMSO) to a fmal solvent 
concentration of 2.5% in the reaction mixture. The blanks had the same 
concentrations of inhibitor or DMSO. 
PPO assay in the presence of inhibitors 
PPO activity was assayed in the presence of the various inhibitors by measuring the 
constant velocity formation of protoporphyrin-IX from protoporphyrinogen-IX. The 
reaction was measured at four regular time intervals over a period not exceeding 60 
min. Return of fluorescence was directly proportional to time over the interval 10 ­
40 min. and the slope of this line was used to calculate the reaction rate, nmol 
porphyrinogen-1X converted/ml of enzyme/h. 
1Cso values were determined for the inhibitors by measuring PPO activity at a range of 
inhibitor concentrations from 0 to 100 J..1M, using a substrate concentration of 10 J..1M. 
A double exponential curve of inhibitor concentrations vs PPO activity was fitted 
using a computerised software package (Enzfitter). 
For determination of kinetic constants Kj, Ks and a, the substrate was added at 8 
different concentrations in the range 0.5 to 15 J..1M. Four different inhibitor 
concentrations [I], within the range 0 to 10 J..1M (final concentration) were used for 
each substrate concentration. The velocity curves followed classic Michaelis-Menten 
kinetics. Both substrate and inhibitor concentrations were selected from pilot 
experiments to provide sufficient representative points on substrate-velocity plots to 
enable the accurate determination of the apparent Michaelis-Menten constants (Kmapp) 
and maximal velocities (V maxapp), using the computerised Gauss-Newton iterative 
non-linear curve fitting procedure. The data represents the mean of at least three 
independent sets of results obtained from assays performed on different days with 
different enzyme preparations. 
Derivation of constants 
Kmapp and V maxapp were determined from substrate-velocity plots, and the kinetic 
constants Kj, Ks and a; and the model discriminations were determined from 
secondary replots of; 
Kmapp I V maxapp vs [I], and 11 V maxapp vs [I] 
where Kmapp and V maxapp are the apparent or observed values in the presence· of 
inhibitor and [I] = inhibitor concentration. 
Definitions 
• 	 ICso:- is the inhibitor concentration which at any fixed saturating substrate 











• 	 K j :- is equivalent to the inhibitor concentration required to double the slope of the 
double reciprocal enzyme velocity vs substrate concentration plot. Thus the lower 
the Ki the more effective the inhibitor. 
• 	 1(,:- refers to the dissociation constant of the enzyme-inhibitor complex. 
• 	 a:- is the factor by which Ks changes when the inhibitor occupies the active site of 
the enzyme. 
Results 
Inhibition of B. subfi/is PPO 
Bilirubin 
The renatured B. subtilis PPO was inhibited by bilirubin (BR) (figure 6.1), yielding an 
ICso of 10.8 ±1.8 JlM (n :::::: 3) with respect to protoporphyrinogen-IX as substrate. We 
have chosen to show this ICso plot as an example. In further cases the data is 
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Figure 6.1: BR was an effective inhibitor of the B subtilis PPO activity and· a competitive 
mode of inhibition was obtained with respect to the oxidation of protoporphyrinogen-IX. 
ICso =10.8 ±1.8 pM (n =3). 
Table 6.1 is an example of one of the 4 independently determined sets of inhibition 
data for the B. subtilis PPO in the presence of increasing [BR] showing increasing 












Table 6.1: Effect of {BR] on B. subtU;s PPO activity. The increasing Kmapp relative to invariant Vmaxapp at 
increasing {BR] indicated a competitive mode of inhibition. 












Analysis of the secondary replot of KmappIVmaxapp vs [BR] for the inhibition of the B. 
subtiUs PPO yielded a Kj of 5.1 ±O.29 J..LM (n = 3). Secondary replot of INmaxapp vs 
[BR] yielded a Ks of 4.16 ±O.4 J..LM (n = 3). An ex value of infinity was obtained from 
this data confirming the competitive mode of inhibition of this enzyme by BR. 
Table 6.2: The following values for Kmap,!Vmaxapp and 1Nmaxapp were used in calculating KJ and Ks for the 
inhibition of the renatured fJ subti/is PPO by BR from secondary replots (figures 6.2 and 6.3). 
{DR] (~M) KmappI'Vmaxapp INmaxapp 
0 0.0463 0.039 
2.5 0.0683 0.038 
5.0 0.0853 0.040 
7.5 0.114 0.040 
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Figure 6.2: A secondary replot of KmappNmaxapp vs [BR] for the inhibition of the a. ~ PPO 
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Figure 6.3: A secondary replot of 1N maxapp vs [BR] yielded a Ks of4. 16 ::to. 4 JiM (n =3) for the 
inhibition of the renatured S. ~ PPO. 
The effect of BR on the enzyme was examined with both the renatured and non­
denatured (native) enzyme preparations, and similar kinetic values and same mode of 
inhibition were obtained. Inhibition of the native enzyme by BR yielded ICso of 11 
±0.2 JJM (n 3) and Kj of 5.08 ±0.4 JJM (n = 4). 
Biliverdin 
BV was also an inhibitor of B. subtilis PPO and yielded an ICso of 5.40 ±0.9 f.lM (n = 











Vmaxapp remained invariant in the presence of increasing [BV] whereas the Kmapp 
values increased, suggesting competitive inhibition. 
A Ki of 4.03 ±0.66 JlM and a Ks of 2.40 ±0.25 JlM (n = 4) were obtained graphically 
from the secondary replots. An a value of infinity confinned the competitive 
inhibition of B. subtilis PPO by BV. 
Haemin 
The inhibition of B. subtilis PPO by HMN was tested over a concentration range not 
exceeding, 50 JlM due to the difficulties in maintaining this inhibitor in solution at 
high concentrations. HMN yielded an ICso of 10.2 ±1.4 JlM (n =4). Once again there 
was an increase in Kmapp, an invariant Vmaxapp and an a value of infinity suggested a 
competitive mode of inhibition. A Ki of 2.31 ±0.2 J..LM and a Ks of 1.63 ±0.21 was 
obtained with respect to the substrate, protoporphyrinogen-IX. 
Acifluorfen andMethylaciflourfen 
The B. subtilis PPO was not inhibited by 100 J..LM AF. At the same concentration 
MeAF reduced the enzyme activity minimally, by only 35%. Thus no further kinetic 
parameters for these two potential inhibitors were detennined. 
Summary 
Table 6.3 summarises the kinetic inhibitory constants and model discrimination for B. 
subtilis PPO. 
Table 6.3: KinetiC constants for the inhibition of B subti/is PPO by BV, BR, and HMN, with respect to 
oxidation ofprotoporphyrinogen-IX. BR =bilirubin, BV =biliverdin, HMN =haemin, AF =acifluorfen, 
MeAF =methylacifluorfen. 
Mode of inhibition
INHIBITOR IC50 (J.1M) 
co Competitive5.10 ±0.29 4.16 ±OAOBR 10.80 ±1.80 
4.03 ±0.66 2040 ±().25 CompetitiveBV 5040 ±0.90 
2.31 ±0.20 1.63 ±0.21 co CompetitiveHMN 
AF No inhibition at 100 JJM 











Inhibition of M. xanthus PPO 
An example of the inhibition of this enzyme by the various compounds, AF, MeAF, 
BV and HMN is illustrated in figure 6.4 (AF). The diphenylethers, AF (ICso ::::; 0.26 
±0.04 ~) (n ::::; 4) and MeAF (ICso ::::; 0.01 ±0.001 ~ (n::;: 4) were highly effective 
inhibitors of this prokaryotic PPO compared to BV (ICso ::::; 6.6 ±0.76 !lM) (n::::; 4) and 
HMN (ICso ::::; 7.9 ±0.67 IlM) (n ::::; 4) which inhibited to a lesser extent. BR did not 
inhibit this enzyme (up to 50 IlM concentration and higher concentrations were not 
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Figure 6.4: Effect ofAF on M. xanthus PPO activity. AF was a strong effective inhibitor of the 
M. xanthus PPO activity_ ICoo = 0.26 ± 0.04 p.M (n =4) was obtained. 
All the effective compounds were competitive inhibitors of this enzyme as observed 
by the increase in Kmapp values with V maxapp values remaining relatively invariant in 
the presence of increasing concentrations of inhibitor (data not shown). Secondary 
replots of INmaxapp against [I] yielded a values of infinity for all the inhibitors, which 
confirmed the competitive mode of inhibition of the M xanthus PPO by these 
compounds. 
Table 6.4 summarises the ICso, Kj, Ks and a values obtained for the inhibition of the 












Table 6.4: Kinetic constants for the inhibition ofM. xanthus PPO by AF, MeAF, BV and HMN. The 
diphenylethers (AF and MeAF) were the strongest inhibitors of this enzyme. 
Inhibitor IICso (IlM) K1(IlM) Ks (IlM) a. 
AF 0.26 ±0.040 0.022 ±0.0020 0.041 :to.050 00 
MeAF 0.01 ±0.001 0.003 ±0.0002 0.003 ±0.001 00 
BV 6.60 ±0.760 0.650 ±O.OSOO 0.240 ±0.020 00 
HMN 7.S0±0.670 0.330 ±0.0400 0.530 ±0.020 . 00 
BR No inhibition at 50 IlM 
Inhibition of human PPO 
This enzyme, like the M xanthus ppo, was also more sensitive to the DPEs, AF (ICso 
= 4.8 ±0.28 JlM) (n:::: 3), and MeAF (ICso ;:;; 0.17 ±0.015 JlM) (n = 3)than to the 
tetrapyrrole compounds BV (ICso = 31 ±3 JlM) (n ;:;; 3)and HMN (ICso = 20.81 ±3.l 
JlM) (n 3). All the results were calculated from at least three independent sets of 
data from different assays, using different enzyme preparations. In all cases, and in 
particular for AF the inhibition was several fold less than for the M xanthus form. 
Because of the poor inhibition of the human PPO by BV and HMN no further kinetic 
studies were performed with these compounds. Similarily to the M xanthus form, the 
human enzyme was not inhibited by bilirubin up to 50 11M. 
Figure 6.5 gives an example of the inhibition of human PPO by the DPE's. The ICso 
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Figure 6.5: Effect ofAF on human PPO activity. AF was a strong effective inhibitor of the 











Table 6.5 summarises the ICso, Kj, Ks and a values obtained for the inhibition of 
human PPO by AF and MeAF. As BY and HMN were poor inhibitors, further kinetic 
values were not determined. . 
Table 6.5: Kinetic constants for the inhibition ofhuman PPO by AF, MeAF, BV and HMN. The 
diphenylethers (AF and MeAF) were the strongest inhibitors of this enzyme. n =3 for all the values. 
Inhibitor ICso (IlM) Ki (IlM) 
AF 4.80 ±0.28 0.240 ±0.050 0.64 ±0.10 00 
MeAF 0.17 ±0.015 0.019 ±0.001 1.73 ±0.08 00 
BV 31.00 ±3.00 
HMN 20.81 ±3.10 
Discussion 
In this study the effects of acifluorfen, methylacifluorfen, bilirubin, biliverdin and 
hemin were investigated on the activity of the purified recombinant PPOs of human, 
B. subtilis, and M xanthus. In many cases these compounds were shown to be 
inhibitory which is possibly based on their electronic and structural similarities to the 
substrate molecule. Indeed, all of the above compounds which effectively inhibited 
the enzyme activity were competitive inhibitors with respect to the substrate, 
protoporphyrinogen-IX, indicating that they were binding very close to, or 
overlapping the enzyme catalytic site. 
Indeed, inhibition by AF, ofmaize etioplasts and potato mitochondria (Camadro et aI, 
1991), as well as human placental and liver mitochondrial PPO (Corrigall et aI, 1994) 
is of the competitive type. Mixed-type inhibition for the AF has been reported for 
yeast membrane (Camadro et aI, 1991) and pig liver PPO (Corrigall et aI, 1994). 
However, in yeast PPO, this mixed-type inhibition was subsequently shown to be due 
to partial hydrolysis of the enzyme and the mode of inhibition is in fact competitive 
(Camadro et aI, 1994). Non-competitive inhibition of yeast PPO by both haemin and 
haem have been described (Poulson and Polgiase, 1975) whereas competitive 
inhibition of mouse liver PPO by bilirubin has been illustrated (Ferreira and Dailey, 
1988). Inhibition of human liver PPO by haem has been reported (Camadro et 
aI,1985). 
Our data indicates clear interspecies behavioural differences. It is interesting that, in 
contrast to PPO from the prokaryote M xanthus and other eukaryotes (Camadro et aI, 
1991, Corrigall et aI, 1994, Dailey and Dailey, 1996a, 1996b) including human, B. 
subtilis PPO is not inhibited at IOOI-lM acifluorfen and is only slightly inhibited by 
methylacifluorfen at this concentration. Methylacifluorfen is normally a more potent 
inhibitor of PPO than acifluorfen (Camadro et aI, 1991) and was demonstrated in our 
results for the M xanthus and human PPO. Furthermore a considerable range of 











The lack of inhibition by these DPE's is not limited to B. subtilis. Two other 
prokaryotic PPOs, E. coli and B. japonicum were previously shown to be resistant to 
inhibition by the DPE's (Jacobs et aI, 1990). Our findings suggest that these are not 
simply general differences between prokaryotic and eukaryotic forms of PPO as 
indicated by the different inhibitor profiles obtained for the B. subtilis enzyme and 
that of M xanthus. Interestingly, the M. xanthus PPO behaved like the eukaryotic 
PPOs, being strongly inhibited by both AF and MeAF. It is possible that B. subtilis, E. 
coli and B. japonicum PPO exhibit conformational differences compared to the other 
PPOs making a good fit into the active site, for these DPEs, more difficult. 
The PPOs of M xanthus and E. coli, both Gram negative prokaryotes, behave 
differently towards the DPE's in that one was strongly inhibited and the other was 
resistant to inhibition. It therefore unlikely that differences in the behaviour of 
prokaryotic PPOs towards the DPE's are simply a reflection of the Gram +/- status. 
Further differences were noted. Specifically BR inhibited B. subtilis PPO but was 
ineffective in inhibiting both human and M xanthus PPO. On the other hand BV and 
HMN inhibited all three forms of PPO to varying degrees, although weakly in some 
cases. 
In B. subtilis PPO, the ICso of biliverdin is approximately half that of bilirubin but the 
Ki's are similar. The conformation of bilirubin is more convoluted due to the 
intramolecular hydrogen bonding between the hydrophilic -COOH and -NH groups 
making it more rigid compared to biliverdin. Although biliverdin has a double bond at 
the C(9)-C(10) methene bridge, rotation can still occur at C(lO)-C(ll) which may 
present the dipyrrole moiety to the active site more favourably. 
Both human and M xanthus PPOs were resistant to inhibition by bilirubin. 
Interestingly, bilirubin was previously shown to be a competitive inhibitor of the 
purified mouse PPO with a K j of 25 /-lM, with respect to protoporphyrinogen-IX as 
substrate (Ferreira and Dailey, 1988). 
A recent study by Arnould and Camadro (1998) on yeast PPO showed that, besides 
the f3af3 (dinucleotide binding) motif, two main blocks of conserved amino acid 
sequence homology were present in several PPOs, one is a C-terminal domain and the 
other an N-terminal domain. Relevant to that study was the fact that both conserved 
sequence homologies were identified in the human and M xanthus PPO sequences 
whereas in the B. subtilis PPO sequence the C-terminaI domain homology was not 
present. Based on mutagenesis studies these conserved sequence homologies 
appeared to be playing a crucial role in substrate binding and catalytic activity of these 
enzymes. In this work 28 PPO sequences were retrieved from the Genbank ™ and 
TIGR (The Institute for Genomic Research) databases (see Chapter 7 for details). 
CLUST AL-W 1.4 alignment of primary protein sequences revealed presence of these . 
domains in several different PPO species (figure 6.6). Whilst the N-terminal domain 
(figure 6.6 - domain A) appears to be conserved in all the PPO species, homology of 
the C-terminal domain (figure 6.6 - domain B) is lacking in several prokaryotic 
sequences which include the mycobacteriaceae (M leprae, M tuberculosis, and C. 











domains were not identified in the human monoamine oxidase-B (MAO-B) which 
was analysed with these PPO sequences. 
These differences at the primary structural level may shed light on our observations of 
the behaviour of PPOs towards different inhibitors used in this study. Specifically, 
PPOs containing both conserved sequence homologies appear to have greater affinity 
for the DPE inhibitors, whereas in the case of the B. subtilis PPO which contains only 
the N-terminal conserved sequence these compounds are not effective. Furthermore, 
the E. coli PPO which lacks sequence homology to any of the known PPO sequences 
(Sasarman et al, 1993) also behaved like the B. subtilis enzyme towards these 
compounds. This could also explain the broad substrate specificity of the B. subtilis 
PPO. It would be interesting to see how the other prokaryotic PPOs which lack the C­
terminal domain homology would behave like the B. subtilis PPO. 
Domajn A 
H. sapiens PR-GKEP-DE-----TVHs~QRRLGP~SL-AMDSLCRGVFAGNSRELSIR-SCFPSL 
M. musculus PR-GKEP-DE-----TVHS~QRRLGP~SL-AMDSLCRGVFAGNSRELSIR-SCFPSL 





















































Figure 6.6 (A). CLUSTAL-W 1.4 alignment of PPO protein sequences from various species showing 
the organisation of the N-terminal domain which is thought to be involved in membrane anchoring of 
these proteins through a nonpolar plateau (Arnould and Camadro, 1998). The underlined regions 












H. sapiens v-------QGFGHLvP-SSE--DpGvLGIvyDS-------vAFPEQDGSp---pGLRVTV 
M. musculus V-------QGFGHLVP-SSE--DPTVLGIVyDS-------VAF.PEQDGNP---PSLRVTV 
D. melanogaster Q-------DGFGLLVPPVEK---LPLLGVIFDS-------CCFDMG-------ENTVLTV 
M-N. tabacum N--VKYPLEGFGVLVPSKEQQHGLKTLGTLFSS-------MMF.PDR--AP---NNVyLyT 
G. max N--VKRPLEGFGVLVPSKEQKNGLKTLGTLFSS-------MMF.PDR--AP---SDLyLyT 
A. thaliana C-LIDGELKGFGQLHP-RTQ--GVETLGTIYSS-------SLF.PNR--AP---PGRILLL 

C-N. tabacum R-LVDGELKGFGQLHP-RTQ--GVETLGTlySS-------SLF.PNR--AP---KGRVLLL 

Z. mays C-LIDGELQGFGQLHP-RSQ--GVETLGTlySS-------SLF.PNR--AP---DGRVLLL 
S. tuberosum R-LVDGELKGFGQLHP-RSQ--GVETLGTIYSS-------SLF.PNR--AP---NGRVLLL 
C._intybus R-LIDGQLKGFGQLHP-RSQ--GVETLGTIYSS-------SLF.PNR--AP---PGRVLLL 
S. cerevisiae D------LQGFGYLVPKSNK-NPGKLLGVIFDSVIERNFKPLFDKLSTNPNALNKyTKVT 
S. pombe R--------GFGLLIPSCTPNNPNHVLGIVFDSE------QNNPEN--------GSKVTV 
M. leprae p-------QNSGVLVA-SGE--RLRAKAVTLSS-------RKWGLQ--GD-----TQLVR 
M. tuberculosis p-------HCSGVLVA-GDE--SPHAKAITLSS-------RKWGQR--GD-----VALLR 
P. freudenr. p-------DSQGWLEADAGP---VSGLTASS---------IK~GR--AP---DGSVLMR 
C. reinhardtii RKASDGSVPGFGQLHP-RTQ--GITTLGTlySS-------SLF.PGR--AP---EGHMLLL 
D. radiodurans M-------HLHGLQVAADEG---IEMKAITVHS-------AKLHGR--AP---EGHVLLR 
M. xanthus D--------GFGFLVPAEEQ---RRML~IHAS-------TTF.PFR--AE---GGRVLYS 
B. subtilis H-------EGTGFVIS-RNS--DFAITACTWTN-------KKWPHA--AP---EGKTLLR 
B. anthracis I-------DGTGFVVS-RNS--DyTITACTWTH-------KKWPHT--TP---EGKTLLR 
S. aureus H-------DGTGFVIA-RTS--DTDITACTWTS-------KKWPFT--TP---EGKVLIR 
A. aeolicus R-----------LLSSESGK---KRILGAMFMS-------KLF.PGR--AP---QGKELLT 
T. ferrooxidans L-------DGFGMLIPRVMG---LETLGVLFSS-------TLF.PGR--AP---AGQVLLT 
S. coelicolor p-------EGSGFLVPPVDG---HTlKASTFAS-------RKWGWIADED---PDLVVLR 
C. diphtheriae N---------SGILVATDAE---VTAKAFTFSS-------KKWPHLG--Q---RGGALVR 
C. muridarum H--------GYGMLFA--DT---PPLLGIVFNT-------EVF.PNS--QQ---PSTTLSL 
C. trachomatis H--------GYGMLFA--DT---PPLLGIVFNT-------EVF.PQP--ER---PNTIVSL 
C. pneumoniae K--------GYGMLFA--DE---LPLLGIVWNS-------QIF.PQA--TP---GKTVLSL 
H.sapiens-MAO H-----KARKLARfT~EERLKKLCELyAKVLG~------LEALEPVHyEE---KNWCEEQ 
Figure 6.6 (8) Organisation of the C-terminal domain identified in a CLUSTAL-W 1.4 alignment of 
various PPO primary sequences. This region is thought to contain important residues of the enzyme 
active site which are involved in catalysis (Arnould and Camadro, 1998). Importantly, this domain is 
less conseNed in some prokaryotic PPOs such as 8.. ~ which demonstrate poor substrate 
specificity and lack of inhibition by the diphenyl ethers which are known PPO inhibitors (This work, and 
Dailey et aI, 1994a). The Mycobacteriaceae (M iewae, M tuberculosis, and C. d(Dhtheriae J, B. anthracis 
and D. radiodurans also lacked the sequence homology which is characteristic of this domain. Regions 












Our data highlights differences in the inhibition of B. subtiUs, M xanthus and human 
PPQs in the presence of AF, MeAF, BR, BV and HMN. When present, the mode of 
inhibition was always competitive probably as a result of electronic and structural 
similarities to the substrate molecule. 
These clear behavioural differences between the different forms of this protein appear 
not to reflect simple prokaryotic and eukaryotic diversification nor Gram 
positivity/negativity in the case of prokaryotic differences. 
Primary structure variation clearly affects the ability of PPO to handle various 
substrates and it's susceptibility to various inhibitors (see chapters 5, 6). While it was 
not the aim of this thesis to investigate the effects of alterations in gene sequence 
arising from both naturally occurring mutants and/or engineered recombinant protein, 
inhibitor and substrate studies on these forms may well provide information on the 
identity of amino acid(s) involved in catalysis and/or substrate binding. This chapter 












Phylogenetic Analysis of 
Protoporphyrinogen Oxidases Using 
Protein Sequences 
Introduction 
PPOs, like many other known FAD-containing proteins, have been shown to 
contain a conserved signature sequence referred to as the dinucleotide binding 
motif (Wierenga et aI, 1986). Analysis of PPO sequences revealed that these 
proteins share conserved regions with mammalian monoamine oxidases (MAOs) 
A and B, as well as with plant and bacterial phytoene desaturases (PHDs), and a 
signature motif was identified which groups these proteins into a superfamily of 
F AD-containing enzymes (Dailey and Dailey, 1998). In that study growtree 
analysis put all PPOs in a cluster more closely linked to a cluster of bacterial 
PHDs and more distantly related to mammalian MAOs (A and B) and plant 
PHDs. 
All living organisms have a pattern of relationship based on their evolutionary 
history. At the molecular level evolutionary change over time is represented by 
the appearance of different gene and protein sequences. The vast information 
obtained from gene and p otein sequences is therefore very useful in inferring 
phylogenetic relationships among sequences and also among the organisms they 
come from (Creighton, 1993, Swofford and Olsen, 1996). Evolutionary 
divergence into different species has resulted into many variants of the same 
protein containing different amino acid sequences, which essentially perform the 
same biological function. Generally, the higher the level oforganisation, the 
greater the molecular differences among species. The importance of using gene 
and protein sequences in reconstructing evolution is based on the realisation that 
similar sequences generally imply descent from a common ancestor (Creighton, 
1993). On the whole evolution is a gradual process and thus, species that are 
genetically more similar are likely to have diverged from each other more 
recently than they did from less similar species (Ayala and Kiger, 1980). 
Biochemical studies on human, B. subtilis and M xanthus PPOs carried out in 
this work (see chapters 5 and 6) revealed interspecies differences in the behaviour 
of these proteins. Generally, M xanthus PPO was found to behave more like the 
eukaryotic enzymes than other prokaryotic PPOs. Importantly, this enzyme was 











strongly inhibit many PPOs whereas, the B. subtiUs (chapter 5 of this work), E. 
coli and B. japonicum (Jacobs et aI, 1990) PPOs were shown to be resistant to 
inhibition by these compounds. 
In view of our interest in pursuing the interspecies characterisation of these 
proteins, we performed a phylogenetic analysis of several PPOs, from both 
prokaryotes and eukaryotes. Presently, the two major sources ofdata for 
determining phylogenetic relationships between species are molecular (e. g. 
nucleic acid or protein sequences) and morphological (e. g. structure and anatomy 
of parts ofplants and animals, and fossil records). Phylogenetic analysis based on 
nucleic acid or protein sequences are generally similar to those constructed by 
classical taxonomy techniques, and these are becoming more accepted due to the 
vast amount of information provided by sequences (Creighton, 1993). This 
section of the work describes the phylogenetic analysis ofPPO sequences from 
diverse species and the relevant results are then discussed. 
Objectives 
• 	 To perform a phylogenetic analysis of several PPOs, from both prokaryotes 
and eukaryotes using the available amino acid sequences of these proteins, in 
trying to establish their evolutionary relationship. 
Methods and Materials 
Identification and Retrieval of PPO Sequences from Genbank™ 
and TIGR Databases 
Database searches of Genbank™ and TIGR (The Institute for Genomic Research) 
were performed by BLASTP method (Altschul et aI, 1997) using the human 
(Dailey and Dailey, 1996b), B. subtiUs (Hansson and Hederstedt, 1992) and M 
xanthus (Dailey and Dailey, 1996a) PPO protein sequences. Identified PPO 
sequences were retrieved and kept in one file for mUltiple sequence alignment. 
The Hem K sequences and their homologs, originally thought to be PPO proteins 
(Nakayashiki et aI, 1995), which were also hit during the blast search, were not 
included in the group as recent studies have revealed that these proteins do not 
have PPO activity (Le Guen et al, 1999). 
Putative PPO sequences, which showed significant similarity to known PPO 
sequences, such as having the dinucleotide binding motif and other conserved 
regions, were identified and included in the analysis group. These included new 
sequences which have not yet been characterised, such as the 'PPO' sequences of 
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Thermobacillus ferrooxidans which were identified in the unfinished genomes in 
the TIGR microbial genome database by TBLASTN method (Altschul et aI, 
1990), using the B. subtilis PPO sequence for the search. Nucleic acid sequences 
of these proteins showed significant similarity to PPOs and were retrieved from 
the genome sequencing projects. These were converted to protein open reading 
frames (ORFs), using the Molecular Biology Shortcuts (MBS) translator at the 
Expasy Molecular Biology server (http://www.expasy.chltools#translate 
dna.html). The sequences were read from the first nucleic acid residue in six 
phases that is, 3 phases from both orientations ofDNA. A blast search was 
performed with the putative protein sequences in Genbank ™to determine the 
level of identity and similarity to other known PPOs. Selected positive matches 
were those with significant identity and/or similarity of 45 - 80% to the known 
PPO sequences. 
Short fragments, ego less than 100 amino acids were not included in subsequent 
analysis, even though some of them showed similarity to PPOs, because these 
would disrupt the phylogenetic analysis. The entire search process in these 
databases yielded 28 PPO sequences in all which were used in the phylogenetic 
analysis. The human MAO-B sequence, retrieved from Genbank ™was used as 
an outgroup for rooting the tree during phylogenetic analysis. 
Multiple Sequence Alignment and Phylogenetic Analysis 
Performing multiple sequence alignments is a computationally intensive task. In 
essence the sequences are written down underneath one another, and then 
shuffled to-and-fro until the best possible match between one sequence and the 
next is obtained (Parkin, 1979). A comparison of the 28 PPO sequences and the 
human MAO-B sequence was done using CLUST AL-W 1.4 alignment ofprotein 
sequences and applying its default values for gap creation and extension 
penalties. Since mutations occur during evolution of proteins it is necessary to 
allow for some insertion and deletion when comparing sequences, and this 
increases the percent identity (Parkin, 1979, Pearson and Lipman, 1988, Subbiah 
and Harrison, 1989, Altschul et aI, 1990, 1997). The gaps in the multiple 
sequence pileup are created by computer analysis in order to maintain regularity, 












Results and Discussion 

A mUltiple sequence alignment was produced in order to predict which sequence 
positions were likely to correspond. This is the simplest and most commonly 
used criterion for building phylogenetic trees and is referred to as the maximum 
parsimony method (Farris, 1983, Subbiah and Harrison, 1989). The general 
criterion of this method is to identify the alignment that minimizes the number of 
genetic mutations needed to account for the differences between the sequences. 
Figure 7.1 shows a pileup alignment of the N -terminal region of the different 
PPO and human MAO-B sequences indicating, within the boxed area, the 
dinucleotide binding motif (Wierenga et aI, 1986). This alignment also shows the 
extended N-terminal sequences in the plant PPOs thought to be presequences 
involved in membrane targeting and translocation (Narita et aI, 1996, 






A. thalian --------------------------MELSLLRPTTQSLLP-SFSKPNLRLNVYKPLRLR 

C-N. tabac MTTTPIANHPNIFTHQS--------SSSP-LAFLNRTSFIP-FSSISKRNSVNCNGWRTR 

A. aeolicu 
S. tuberos MTTTAVANHPSIFTHRSPLPSPSSSSSSPSFLFLNRTNFIP-YFSTSKRNSVNCNGWRTR 
S. cerevis ----------------------------------------------------------ML 













G. max PPO ----------------------------------------------------------MA 
M. musculu 





C. reinhar MMLTQTPGTATASSRRS--QIRSAAHVSAKVAPRPTPFSVASPATAASPATAAARRTLHR 
C. trachom-













Figure 7.1 CLUSTAL-W 1.4 pileup alignment of the N-termina/ regions of different PPOs and the 
H. sapiens MAO-8 sequences showing the dinucleotide binding motif within the selected area 





































































In order to facilitate phylogenetic analysis the gaps and widely divergent 
sequence regions were removed from the full sequences, leaving only the more 
conserved regions. Recent work has shown that the quality of a phylogenetic 
analysis improves when the input consists only of the highly conserved regions in 
a sequence alignment (Grundy and Naylor, 1999). The resultant sequence 
alignment (figure 7.2) was used for constructing the phylogenetic tree of these 












Figure 7.2 A pileup alignment ofprotoporphyrinogen oxidase amino acid sequences from different 
species showing the dinucleotide binding motif in the boxed region (gaps and divergent sequence 
regions have been removed to facilitate phylogenetic analysis). The bold region represents part of 
the signature sequence of a superfamily of FAD-containing enzymes previously identified by 
















































g~aaa~ym~~ ve asprvggk iqtvkkgyii ergp dsfIer kkspqIvkdg 
glavahhlal Ie ssarlgga vgthalgylv eqgp nsfIdr eparaIaaan 
glaasyhlvl ve sserlggw irsvrggaif elgp rgirpa gaIIIIvseg 
glciaqallv te akdrvggn iitreegflw eegp nsfqps dpmtmvvdsg 
glciaqvmlv te ardraggn ittvergylw eegp nsfqps dpmtmavdcg 
glstayrlvv ye kddriggt ihtvkegylf evga qtilad qevidfIkeg 
glciakvilv te ardraggn ittvergylw eegp nsfqps dpmtmavdcg 
glcftyflil fe sqnrtggw iyscntpiml ekgp rtIrgv sdgmdtIkdg 
glaaayklvv fe aegkaggk lrsvsqgliw dega ntmtes egdtfIidsg 
glaagwwliv Id keayaggf vrtespgfsf dlgp kgfItr gdgIkIiheg 
gltaayrlil fd pgdrlggv lrtecvgqpm dlga eafIIr rpepaIIaeg 
gltsayrlil fe padrlggv lrtehigqpm dlga eafvIr rpepaIIaeg 
glstafylil ye kgprlggw lqsvkitvlf eqgp rtIrpa gvaIdIiskg 
glctaqalvv te ararpggn ittvergylw eegp nsfqps dpvtmavdsg 
glaaayklvv fe aegraggr lrsvsqgliw dega ntmtes eiekgIidag 
glaasyhlvl ve gskrlggw irsirggaif elgp rgirpa gaIIIIvseg 
glaaawqgvv ve sddhfggk vvtdrrgflv eqgp dsfvay rpaIkIieeg 
glaaahrlvv Ie asgrvggk Ilpgeigvrv dlga esmIar rpevgIarag 
glciaqalvv te ardrvggn istvergylw eegp nsfqps damtmvvdsg 
glvtgqalfv te arervggn itsmsggyvw eegp nsfqpn dsmqiavdsg 
glsaawwlli Ie kesrsggl ivtekqgfsl nmgp kgfvIa hdgIhIiqsg . 
glaaawelyl Ie agdsfggk vqserteflv ekaa dafilg kpwIqIaqeg 
glsagyylli ye asprvggw vrsenrnfif esgp rtirpv gepIeIvedk 
glsaawwlli Ie kesrpggl vvtekqglff nmgp kgfvvs hdgIhIiqsg 
glttmyhltl ie asgklggk iqtvrkgfti ergp dsfIar kesarIvkeg 
glssayflvi fe iasnrpggk iqsyrkgymi elgp esylgr ktiteIakdg 
glatayfl11 Ie agaapggn lqsrqegylr dmgp nsImIk gripewIreq 
gltaayrlvv fe atdriggk 1htvafsgpt dmga eaylaf redtaffkeg 
gmaaakllvv Ie ardrvggr tytlrnvkyv dlgg syvgpt qnrIrIakeg 
51 100 
leIvnrtIhp mkgavrngipt kIfslsgkar aamdfilpas slgeffrrrv 
Iedpaakryv yrgrIrsvpa siIplgarIr vageIfsrra slaafgrrhl 
Idpaaqnrfl yggaIhaIpt gppfskpIfw agIreltkpr tvhsfaqrrl 
Ikdptaprfv Ingklrpvps klmsiggkir agfgalgirp sveefvrrnl 
Ikdpnaprfv Ikgklrpvps kImsipgkIr agfgaigIrp sveqfvrrnl 
iespsskryi ykgrIiplpm sllslktkIk vIteifkrgv siadfvrehf 
Ikdpdaprfv IkdkIrpvpg klmsipgklr agfgaigIrp sveqfvrrnl 
keciadkfll dsdkIvqvpn splgkglitg mmgewfrkks svesicdrrf 
Irlsqnkryi angtpvIlps nflstgskIq mIlepilwkn svsgffqrhf 
Iqdraakrfv yrgkahkist wrkgllpsli kdfrapcytq svqdfIkrhs 
Isysqqrlhs Ipdtvagips slvddatvar igaeavrpls amaelvadrf 
Isysqqrlhp Ipqtvvgips slvddatIar idaeaarpft avadIvadrf 
iespsakryi ypdrIneips spalrpmpla mmlepfrksk svgsfmrrrf 










Chapter 7 III 
G. max lqisqhkryi vngapllvpt nllsaqskih lifepfmwkr svgrfferhf 
M. musculu lepaaqnrfl yggtlhplps gppfskplfw aglrellkpr tvhsfaqrrl 
P. freuden lsllsrglrp magmgmvlpt rvlswpdkir agldlviprr aigaflrqrl 
s. coelico lappstaasl wrgalrpmpk gaaalsgvls eeglarierd avgeyvaarl-
C._intybus lkdptaprfv 199dlkpvps klmsfpgklr agfgalgfrp sveefvrrnl 
C. reinhar cedptaprfv wegklrpvps glmsipgkir aglgaiglin sveqfirrnl-
C. trachom laspeakrfi hnnktrkvsp wkqnlplsfa kdffarpykq sveaffkrhs 
D. radiodu lqraetklyf 19gelldfpq nvlspeglrr mldeqnvppk sladfiirrf 
D._melanog lehvaarrml ykgqlcmlpn sppftkplyk avlrdlftas siysfaerrf 
C. muridar lsspaakrfi hknktrkvsp wkqnlpltli kdlfarpykq sveaffkrhs-
B. anthrac 19lvnnrlhk msgsmmgipt qlfspigklr agfdllmprs slghffrhrl 
s. aureus lefaknklyp iggsimgipt dlisplgklr agfdllkkpt svgaffrarl-
T. ferroox lenplagryv Inrhrqpval gllsirgrlr llgepfqpph siadfvrrrl-
C._diphthe lespsglsll yngelhpmpm nskgleklvs aetaaridae tlgevlrerf 
H.sapiens leihhvkksy prgpfppvwn pwrtmddmgr eipsdapwka tmkelldklc 
101 150 
B. subtili gdevveliep llsgiyagdi dklslmstfp qfyqslilgm kktgqfqtls 
M. xanthus ghratqllda vqtgiyagdv eqlsvaatfp mlvkslilga iragalstfd 
H. _sapiens gpevasamds lcrgvfagns relsirscfp slfqsillgl llgwsqwslr 
A. thalian gdevfeliep fcsgvyagdp sklsmkaafg kvwksiiggt fkaqtvgsfr-
C-N. tabac ggevfeliep fcsgvyagdp sklsmkaafg kvwksiiggt fkaqtvgsfr 
A. aeolicu geeflnvvap fisgvyagdp eklslkhatp klyeslikaf ikegklisfg-
s. tuberos gaevfeliep fcsgvyagdp sklimkaafg kvwksiiggt fkaqtvgsfr 
s. cerevis gnnyismisa llrgiygddv sllsakrtfk kiyydnmrgk srsypmlgla-
M-N. tabac gkevvdlidp fvagtcggdp dslsmhhsfp elwnsvilga irsrgsfsfl 
C.yneumon sqnftsildp litairaghs silsthmafp elaksllrsy lknrylasls 
M._leprae geqavalvdp llggvyagsa atiglragap svaaaldcga tslpvfgald 
M. tubercu gdqvvasvdp llsgvyagsa atiglraaap svaaaldrga tsvpvfgald-
S.yombe gknvtdvrnsa mingiyagdl ndlsmhsmfg flaknitlgl iratsmfafk 
z. _mays gaevfeliep fcsgvyagdp sklsmkaafg kvwrsiiggt iktqtvasfr 
G. max gkevvdlidp fvggtsaadp eslsmrhsfp elwnsiiaga lqsrgsfsfq 
M. musculu gpevasamds lcrgvfagns relsirscfp slfqsillgl llgwsqwslr 
P. freuden gdgivrfadp mvggiygagi delsldavlp slrdslaggr asrspfrtlr 
s. coelico grevvdlvep llggvyagda yrislrsavp qlfetsltea vrapvfmgie-
C._intybus gdevfeliep fcsgvyagdp sklsmkaafg kvwnsivgga fkaqtvgsfr 
C. reinhar gdevffliep fcsgvyagdp sklsmkaafn riwislvgga iklqtvgsfr-
C. trachom ssklrrllnp isiairaghs hilsaqrnayp eltrsllrsy lkdpylatlr 
D. radiodu gaeamnfivp laagiyvanp felsmkaafp qflasvikgs ratpifgsfk 
D._melanog gkeiadaisp micgicagda reisvrflme glfegvlkgt liswamyglk 
C. muridar stklrtllnp inlamraghs hilsaqrnayp eltrsllrsy lrdpylatlr 
B. anthrac gnevveliep llsgiyagdi demslmstfp qrnyqsislgm rtlgifqtvk 
s. aureus gnevleliep Imggiygtdi dklslmstfp nfkeslikgm kdegqfkqfk-
T. ferroox gdealtlvdp fvsgvfagnp arlsvqatlp rlaasllrga lratrlvsfr-
C._diphthe gddlvdvvsa lqggvyssts ddlslrdtvp qlarvtitaa vqssvfaafp 
H.sapiens wtesaklatl fvnlcvtaet hevsalflwy vkqcttnggq erkpviyidq 
151 200 
B. subtili tglqtlveei ekqlykgtkv tklshyslel dndadsvivt aphkaaagml 
M. xanthus gglqvlidal aaslarvegl aredgwrlii eesvaqvvla apahatakll 
H. _sapiens gglemlpqal ethllrgqpv cglslwkvsl rdeadhvisa ipasvlsell 
A. thalian kglrmlpeai sarlwklsgi tklesynlty etqsksvvrnt vpshvasgll-
C-N. tabac kglrmlpdai sarlwklssi tksekyhlty etqsrsivrnt vpsyvasnil 































































kglrmlpdai cerlwklssi tksekyllty etrsrsivmt vpsyvasnil 
ggletfpkiv rnalnpvtqi mkrpattigl katfdhlrlt itppkiakll 
ggmqtltdai ckdlsrvlel scsctwsiis assfdavimt aplcdvksmk 
psmgtlitti qekltsvthi dcspkacvtt psfadmviyt gplqqlpvll 
ggyqvlidel vrrswvaatv vgldrwtlvd dtsadgvila vpaprlvrll 
ggyqvlldgl vrrswvrarv vqlerwvlrd etqadavila vpaprlarlv 
egietitlsi adelmpnvki hlnkpktlvp hklvdvngqa yeyvvfanss 
kglamlpnai tsslwkltsi tksddyvley etqaksvimt ipsyvasnil 
ggmqtltdtl ckelekvltl ayghdwsits asdvdavimt aplynvkdik 
gglevlpqal hnhllsgqpv cglslwkvsl gdeadhiisa ipaselskll 
gglgqlidal vdqllvntsv dllgrvhlsd grpadavvla ggvassarll 
ggigtlppav adsvapvtel rrtaswriva gdhagavvva vpagpaaell 
kgqamlpnai strlwkltsi sklenynlty etqtktivmt vpsyvasdll 
kglkmlpdai erniwklvsl greadyglvy dtfaravalt apsyvvadlv 
sgmgmltqal hdklapvski rqlanislss pqtgdmliya gsvhdlpscl 
dgmstlanav aaklrlntpv lavhpvtltg geaasgvvlt apawvaaptl 
gglenlpktm rkylqlsnec rnltfvrmni kdpvehvvss Ipayklaplv 
sgmesliqtl hdkltpvtki rqlsnislss sqtgdiliya gsvqdlpscl 
tglesivesl elkmikgtri ekvakyaitl sneadavvva sshkvlpsmf 
hglssfieal eqdvryntsv ddiitykivy ndvydgvlvt tphqvflnwf 
eglqvlplrv antltpvdql aysgdwqvgs gnqskrlvla Ipagaaarll 
ggyaelyeal aeksafitgi qwkdgftlkg aetfdkviva vpaptaamll 
trenvlvetl nhemsaippt 19mkilpmmr nqikcivyyk epfwrkkdyc 
201 250 
elpaishlkn rnhtsvanval gfpegvqmeh fvisfaitac twkkwphakt 
ddalaalvag iaapiavvhl gfdaglpapd flvprrmlga ihttfpfrrv 
aeaaplaral satavsvavv nlqyqahlpv hlvppgvlgi vyvafpeqlr 
sesaanalsk lyppvaavsi sypkeirtec qlhpvetlgt iyslfpnrri 
svaaadalsn fyppvgavti sypqeirder qlhpvetlgt iyslfpnrrv 
sfsaseefdk idppvvvvnv gvegkfpkvr llsskrilga mfklfpgrke 
svaaadalss fyppvaavti sypqeirder qlhpvetlgt iyslfpnrrv 
qnslskllde iqntiilvny ylpnkvidad ylvpgkllgv ifplfdklyt 
iakrgnpfll nfpevdyvp1 svvitfkren vlvplktlgt lfmmfpdrvy 
ygienlskrv Ipwnlssisl gwhhafslpk mlfalpllgi vwqifpqatv 
qiaprtvaaa srvsassavv alsvpdttfp vlvalrakav tlrkwglqtq 
giaprthaaa rqvsassavv alavpgtafp vlvaphakai tlrkwgqrva 
enliscpkme tpssvyvvnv yykdpvlpir llipnhvlgi vfqnnpensk 
ssdaadalsr fyppvaavtv sypkeirkec qlhpvetlgt iyslfpnrrv 
itkrgtpfpl nfpevsyvpi svmitfkken vlvplktlgt lfmmfpdrly 
aeaaplaril stkavsvavv nlqyraclpv hlvpptvlgi vyvafpeqlr 
Ipaaaralaq ipasttivsl awpvsfdvap wleavsglta ssikfagrsv 
apaaaaelsa veasmalvtl ayrrsaaalp flvphtikas tfrkwgwilv 
slgaadalsk fyppvaavsi sypkdiradr qlhpvetlgt iyslfpnrrv 
apaaaealgs fdppvgavtl syplsvreer qlhpittlgt iyslfpgrhm 
ipetklikqt tswdlscvsl gwhasfpiph mlfappllgi vfevfpqpti 
fpaasalvge lqngsvavil ayregfprdm lqvaiemkai tvaklhgrhv 
qqhpslsaql lspyvdvlvv nmqfpkllkq Ilvplpllgv ifccfdmgtv 
ipesalvkqt tswdlscval gwhsslplph mlfappllgi vfevfpnstt 
qykqfrffrn iptsvanvam afpksiqrdi fvvsytitac twkkwphtkt 
qdpafdyfkt mdttvatvvl afdekienth fviatditac twkkwpftkv 
datlarelda ippavgslsi gfrrpvehpl mlipletlgv lftlfpgrqv 
apeasallkn ikassavvgm kfdsaglpdn ilvavtakaf tfkkwphlga 
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llrayvgndi inivledlkk vmningpemt cvtrwhesmp qyhvghkqri 
lyscmvgdal aalareelka lagvtapsft rvfrwplgip qynlghlerv 
vtvmlggelf qqraqeaaat qlglkepshc Ivhlhkncip qytlghwqkl 
Illnyiggel veavdrdlrk mlikpnplkl gvrvwpqaip qflvghfdil 
Illnyigsql vevvdrdlrk mlikpkplvv gvrvwpqaip qflvghldtl 
lltvflgeei eniverelke ilqidcidfm hvqkwkraip qytlgydrfl 
Illnyigsql veavdrdlrk mlikpkpfvt gvrvwpqaip qflvghldtl 
kvtamigevt inavkdalnn hlgisnagqw eftiadrclp rfhvgydawq 
lyttfvgtel keivtsdlkq llgaegptyv nhlywskafp lyghnydsvl 
lslliegsea hafaiaalse ylninqpdaf alfssqdgmp qhavgflerk 
Ivrlsfgdel lawavsdlaa vfdvtvpvdv cvqrwidamp qygpghadlv 
llrlsfgdql lawaaddlvt vfgvavpvdv rvrrwieamp qygpghadvv 
vtvmmggeea vnnalkalqh tlkissptlt natlqqncip qyrvghqdnl 
lllnyigsel veavdrdlrk mlinstplvl gvrvwpqaip qflvghldll 
lyttfigdel rkivtsdlrk llgaegptfv nhfywskgfp lygrnygsvl 
vtvmlggelf qqqaqeaaat qlglkepshc Ivhlhkncip qytighwqkl 
Imrvfvpdel lsavidhvrp llgvhgpglt qitrwhkvmp kytvghlera 
vlrtsvgagl vavsrhdlae atgltapvat rvtrwqdglp qypvghharv 
Illnyiggei vdavdrdlrt rnlirrdpltl gvrvwpraip qflighydil 
Illnyigeql veqvdkdlrn rnvikpdprvv gvrvwpraip qfnlghleql 
vslilegeea yafslaaise ylqiytpqaf slfspreglp qhhvgfiqsr 
llrvffkqka laeavhevar Ifgaqgplwh ayadwrgknp ayqvghldhi 
ltvmrnggkqi vdlatshvqk rnlqirepkfs rvhtlhkcip qytvghkrrv 
lsillegeea yafslatise ylqiytpqaf slfspkeglp qhhvgfirsr 
llrcyvgeel vqlvledlrk trnditepeft vvsrwkearnp qytvghnerrn 
lirayvgnel vsivrrdlsq mrntfkgpeft ivnrlpksrnp qyhvghiqqi 
lltafigddl latvlreigp llgisgpvfs rcrvwpkaip qyeighldrrn 
Ivrasfgdll vdtalddlqt itgfdglsei yvqrwfgglp vygpghsdlv 
eeqysggrvl rqpvdriyfa gtetatymeg aveageraar eilharngkie 
301 321 
kelrealapg vymtgasfeg v 
aaidaalqpg Ihlignaykg v 
esarqfltlp Itlagasyeg v 
dtaksslteg Iflggnyvag v 
stakaamneg Iflggnyvsg v 
nlaqernekpg Ifltgnwlyg v 
gtaktalsdg Iflggnyvsg v 
eraerklqqt vsvggmgfsr p 
daidkrnekpg lfyagnhrgg 1 
erilphlpgn lkivgqniag p 
aevraglppt Ivvagshrndg i 
aelraglppt lavagsyldg i 
nslkswiegr illtgswyng v 
eaakaalddg Iflggnyvag v 
qaidkiekpg fffagnykgg 1 
dsamqfltlp Itlagasyeg v 
avvdstlapt wavagsalhg v 
arvrehvapg lavcgaaydg v 
dsakaalsqg mflggnyvsg v 
dkarkaldqg vhlggnyvsg v 
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D. radiodu ariraalppn iqvagssytg v 
D._melanog eairnyiklp lsvcgaaydg v 
C. muridar killsklppn ikivgqnfag p 
B. anthrac kklttfmepg iylagssyag s 
S. aureus rqiqahikpr lrvtgasfea v 
T. ferroox kridtlsapg Ihfranwqgg v 
C._diphthe aaikdalpvg iyatgawadg v 
H.sapiens deiwqseppa qpitttfler p 
Phylogenetic analysis of these PPO sequences (figure 7.2) was done using the 
maximum parsimony method (Farris, 1983, Subbiah and Harrison, 1989). When 
a tree is constructed it may be rooted, meaning that one of the sequences 
represents a common ancestor to all the others and this is used as the outside 
distant protein, or it may not be rooted, meaning that no common ancestor could 
be identified (Swofford and Olsen, 1996). Although the human MAO-B sequence 
was used to root the tree, phylogenetic analysis using maximum parsimony 
produces trees with no evolutionary root (Weston, 1994), and the human MAO-B 
sequence was used as an outgroup for the construction of this tree. The rooting of 
this tree with human MAO-B derives from the fact that, although MAOs share a 
region of similarity with PPOs, comprised of the signature sequence of F AD­
containing enzymes identified by Dailey and Dailey (1998), PPOs are more 
closely related to each other than they are to MAOs. 
The procedure for the PHYLIP package creates several possible trees and 
chooses the tree that minimizes the total number of mutations required 
throughout the sequences. Statistical analysis of the phylogenetic results was 
done using 'bootstrap' analysis (Felsenstein, 1988) and this showed that the 
resultant tree (figure 7.3) was stastistically significant. Basically, the technique 
involves analysis ofa sample of randomly perturbed data sets (100 in this case). 
In each perturbation the original characters (protein sequence positions) are 
randomly resampled with replacements and the new sequence alignments, of 
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Figure 7.3 Growtree analysis of the different PPO sequences (figure 7.2) showing the 
phylogenetic relationship between these proteins. 
The data showed mammalian PPOs clustered together with the insect protein 
from D. melanogaster (D. mel.) indicating a close relationship as would be 
expected. Interestingly, this cluster was more closely linked to that ofyeast, S. 
cerevisiae (S. cer.) and S. pombe, PPOs than to plants as would normally be 
expected. Importantly, all plant PPOs were clustered together although they 
branched into two groups, apparently on the basis of the organelle in which the 
PPO isoform was located. For example, the N tabacum (C-N tabacum), S. 
tuberosum and A. thaliana chloroplast isoforms, and other closely related plant 
PPO sequences were grouped together, and these proteins share the extra N­
terminal presequence. The mitochondrial (M-) isoforms and similar sequences 
formed the second group ofplant PPOs. This suggests different ancestral origins 
of the proteins from these two organelles. 
The green alga, C. rheinhardtii, was clustered with plant PPOs (figure 7.3), as 
would be expected, and it was grouped with the chloroplast isoforms. Like these 
isoforms, it also had an extra N-terminal sequence (figure 7.2). Previously, 
molecular characterisation of the wild-type C. rheinhardtii PPO showed that this 
protein had significant homology to the chloroplast PPO isoforms ofA. thaliana 
(51 %) and N tabacum (53%), suggesting that it was also located in the 











Most of the bacterial PPOs were grouped together from a common branch, 
indicating a common ancestral origin but, they branched into two distinct groups. 
Interestingly, both Gram positive and negative organisms were present in both 
groups. For example, P. jreudenreichi, a Gram negative rod was grouped with 
several Gram positive organisms, D. radiodurans, B. anthracis, B. subtilis and S. 
aureus. All the organisms belonging to the Gram positive Mycobacteriaceae 
family, M tuberculosis, M leprae, and C. diphtheriae were clustered together 
indicating a common ancestral origin. 
Interestingly, the M xanthus PPO shared a distant common branch with the 
eukaryotic (yeast and mammalian) PPOs. Biochemical studies previously showed 
that, in terms of its properties the M xanthus PPO behaved more like the 
eukaryotic than prokaryotes PPOs (this work chapters 4 and 5, Dailey and Dailey, 
1996a). These findings therefore confirmed the biochemical behaviour of this 
enzyme. The thermophilic bacteria, T.ferrooxidans (T.ferr.) andA. aeolicus also 
diverged from the general clustering ofprokaryotic PPOs as they shared a distant 
clustering with the mitochondrial isoforms ofplant PPOs. It seems therefore that 
these bacterial proteins share a common ancestral origin with these isoforms of 
plant PPOs. Generally, it seems that prokaryotic PPOs are quite distinct 
phylogenetically and this is similar to the findings on bacterial MAOs reported 
previously (Dailey and Dailey, 1998). 
Concluding Remarks 
The grouping of these proteins shows that the phylogeny based on these PPO 
sequences is similar in many respects to species phylogenies constructed by 
classical techniques using morphology and fossil records. Interesting 
observations from this study were the divergences ofM xanthus, T. ferrooxidans 
and A. aeolicus from other prokaryotes, and the close relationship of these 
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Chapter Eight 

Immunocharacterisation of Human 
Protoporphyrinogen Oxidase 
Introduction 
Chapters 4, 5 and 6 reported on the biochemical characterisation of recombinant 
human, M xanthus and B. subtilis PPOs. Their kinetic properties and inhibitor 
profiles revealed some inter-species differences. The phylogenetic analysis of PPOs 
from diverse species, based on 28 protein sequences, obtained from several protein 
. databases is described in chapter 7. 
Little is known of the tissue distribution (intra- and inter-organ) of PPO in humans. 
PPO activity has been described in human liver (Camadro et ai, 1985, Corrigall et ai, 
1994, Li et ai, 1989), placenta (Corrigall et aI, 1994), skin fibroblasts (Brenner and 
Bloomer, 1980b), lymphocytes (Guo et aI, 1991) and Epstein-Barr virus transformed 
lymphoblasts (Meissner et aI, 1986). While all tissues are potentially able to 
synthesize haem, it is assumed that those primarily involved in haem production 
would demonstrate strong expression of various haem enzymes, including PPO. 
However, this data is lacking. 
Earlier studies using subcellular fractionation methods showed that yeast and 
mammalian PPOs were associated with mitochondrial membranes and required 
detergents for solubilisation (Poulson and Polglase, 1975, Poulson, 1976). PPO 
activity was localised to the cytoplasmic side of the inner mitochondrial membrane 
(Deybach et aI, 1985, Ferreira and Dailey, 1988). In subsequent studies, using specific 
labelled PPO ligands such as the tetrahydrophthalimide inhibitors, presence of this 
protein was demonstrated in subcellular fractions of mitochondria (Matringe et aI, 
1992b) and the in vitro translation and targeting of labelled PPOs into mitochondria 
and chloroplasts has been demonstrated in preparations of these organelles 
(Nishimura et ai, 1995b, Lermontova et aI, 1997). To date, no studies on the 
immunohistological localisation of PPO have been reported. 
In view of our interest in determining the properties of PPOs, and the ability to 
produce antibodies against these proteins, we embarked on immunocharacterisation of 
human PPO. This section of the work reports on the immunohistological localisation 
of human PPO in a variety of organs, in an attempt to shed light on the intra- and 
inter-organ expression of this protein. It also reports on the subcellular localisation of 
PPO in human hepatocytes, in which the electron microscopy techniques of 
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Objectives 
• 	 To demonstrate intra- and inter-organ expression ofPPO in a variety ofhuman 
organs using immunohistological localisation methods and light microscopy. 
• 	 To determine subcellular location of human PPO in liver tissue sections using 
immunogold labelling techniques and electron microscopy. 
Methods and materials 
Antibody production 
Human PPO was purified as previously described (see chapter 4). Purified PPO was 
blotted onto nitrocellulose paper (0.45 !llll) (Schleicher and Schuell, Dassel West, 
Germany)., dissolved with DMSO and used for the inoculation of New Zealand white 
rabbits (Kirsch et aI, 1975), using approximately 100 f.lg ofPPO per inoculation. The 
strength and specificity of the antibody were assessed by Western blotting (Towbin et 
aI, 1979). For full details of the methodology see Appendix 10. 
Light Microscopy - Determination of the expression of PPO in 
various human tissues 
Tissue specimens 
Surgically removed material was examined from liver, kidney, lung, testis, ovary, 
stomach, small and large intestine and placenta. Small intestine and colon specimens 
were used as representative tissue of small and large intestine, respectively. Only 
normal tissue was used in the study. All specimens were fixed in buffered formal­
saline, embedded in paraffin wax and sections were cut at five microns. Five 
examples of each tissue were examined. 
Immunohistochemistry 
The immunoperoxidase technique was performed essentially as previously described 
(Campbell et al, 1991) except that the swine anti-rabbit immunoglobulins utilised 
were biotinylated and streptavidin conjugated to the horseradish peroxidase. Briefly, 
the tissue sections were dewaxed and incubated in 0.3% H202 in methanol to block 
endogenous peroxidase. The sections were exposed to normal swine serum (1/20) in 
PBS for 15 min followed by incubation with a 11100 dilution of rabbit PPO antiserum 
for 60 min. The sections were exposed to biotinylated swine anti-rabbit 
immunoglobulins (11250) for 30 min. After exposure to streptavidin conjugated to 
horseradish peroxidase (1/500) the specifically bound antibody was visualised using 
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Counterstaining was with Meyers haematoxylin. The entire procedure was performed 
at room temperature. 
Non-immune rabbit serum at the same dilution as the primary antibody was used as a 
negative control for each and every specimen studied. Pi glutathione S-transferase 
(GST) specifically stains bile ducts in human liver (Campbell et al,I991) and a liver 
section thus stained was included in every run as a positive control. The 
immunostaining was evaluated by an arbitrary semiquantitative scale as being strong, 
moderate, weak or negative. See Appendix 11 for full details . 
. Electron microscopy - Determination of the sub-cellular distribution 
of PPO in human hepatocytes 
Liver tissue specimens 
Fresh human liver biopsy tissue was obtained, with informed consent, from patients 
who were undergoing routine, follow-up investigation at the Liver Clinic at Groote 
Schuur Hospital, Cape Town. Small tissue pieces (0.5-1 mm3) were used for the 
immunohistological investigations and these were cut from biopsy specimens taken 
for the routine histopathological diagnosis of these patients. The methods of 
cryoultramicrotomy and immuno-gold labelling were optimised for use with fresh 
human liver biopsy specimens. See Appendix 11 for full details. 
Specimen preservation and cryoultramicrotomy 
Considerable time was spent achieving the desired preservation of tissue 
ultrastructure and antigenicity. The best preservation was obtained when the small 
liver tissue pieces were immediately transferred into a fixative (4% paraformaldehyde, 
0.1 % glutaraldehyde, in PBS buffer pH 7.4), and fixed for at least 6h, followed by 
cryoprotection in sucrose. The fixed tissue specimens were gradually infiltrated 
overnight with sucrose up to a final concentration of 2.3M, and then rapidly frozen in 
liquid propane at -180°C. Thereafter very thin (120 nm) microtome sections were cut 
at -120°C and transferred onto formvar-covered carbon-coated nickel grids for the 
immuno labelling procedure. 
Immunogold labelling 
For immunohistological detection and electron microscope visualisation of PPO, an 
immunogold labelling protocol (Horrisberger and Rosset, 1977, Pollack and van 
Noorden, 1987), which effectively attaches 5 nm gold particles to the PPO bound 
primary antibody in the liver sections, was used. 
The tissue sections on nickel grids were blocked for non-specific antibody reactions 
with 2% gelatin and 20 mM glycine in PBS pH 7.4. The primary PPO antibody 
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antibody had been raised. After rinsing the sections the antibody bound to PPO was 
then labelled with a goat antirabbit complex containing the 5 nm gold particles for 
electron microscope visualisation. After stabilisation of the gold complex with 1 % 
glutaraldehyde, and silver enhancement for 4 min (Hainfeld and Furuya, 1995), the 
sections were stained with uranyl acetate/methyl cellulose and dried before 
examination with a Zeiss EM 109 transmission electron microscope. Several 
micrographs of the experimental and control sections were taken. Normal rabbit 
serum (1/50) dilution replaced the PPO antibody in the controls. 
An initial study using transformed E. coli cells which overexpress recombinant 
human PPO was performed as further confirmation of positive reactivity of the 
antibody and visualisation of human PPO. The cells were grown overnight and 
harvested for labelling as described above for the liver cells. The cells were also fixed 
in the same solution and then mounted onto low melting point agarose for 
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Results 
Western blotting 
The results of Western blotting are shown in figure 8.1. Specificity of the antibody to 
human PPO is demonstrated by the single band in Figure 8.1 A lanes 1 and 2. No 
bands were apparent in the non-immune control, Figure 8.1 B lanes 1 and 2. 
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~ 14.3 K 
Figure 8.1 Western blot showing specificity of the polyclonal antibody to human PPO. On the left is the 
SOS -polyacrylamide gradient gel (7.5-17.5%) showing in lane 1 =sonicate of J;.. Q;.Jj cells expressing 
recombinant human PPO with a wide spectrum of proteins, lane 2 =purified human PPO, and lane 3 = 
molecular weight markers. On the right, A and B =Western blots of identical gels on Nitrocellulose 
paper, A =incubated with the human PPO antibody and B =incubated with non-immune normal rabbit 
serum. The single positive band in A, lane 1 shows specificity of the antibody to human PPO in the 
presence of the wide spectrum ofproteins from the sonicate of £...J;.Qjj cells. 
Light Microscopy - Expression of PPO in various human tissues. 
The five livers examined showed a strong staining of the cytoplasm of the 
hepatocytes, but not the nuclei. Kupffer cells were negative but staining of the bile 
ducts was noted. No staining for PPO was apparent in all the non-immune controls 












Figure 8.2 Selected stained sections (left column) and their corresponding non-immune controls (right column): 
A strong PPO staining of the hepatocytes 
B strong staining in the proximal convoluted tubules of the kidney 










E. (Small intestine) 
--~~__r------­
X40 NOD-ipunllne control X40 
F (Large intestine) 
Figure 8.2 Continued: 
D strong PPO staining of the parietal cells in the stomach 
E PPO staining present in tips ofvilli in small intestine 














Figure 8.2 Continued: 
G strong PPO staining of the interstitial cells in the testes 
H negative PPO staining of a mature follicle in the ovary 
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All 5 kidneys exhibited strong staining of the cytoplasm in the proximal convoluted 
tubules. There was moderate to strong staining in the collecting tubules. No staining 
for PPO was observed in the distal convoluted tubules or the glomeruli. All non­
immune controls were negative (figure 8.2 B). 
The bronchial epithelium and the alveolar macrophages showed moderate staining for 
PPO. In one case, peribronchial glands were present and showed negative staining in 
the mucous cells but strong positive staining in the serous cells (figure 8.2 C). All 
non-Immune controls were negative. All the lung specimens contained carbon 
pigment. 
In the stomachs there was strong cytoplasmic staining of parietal cells. No positive 
staining was noted in any of the non-immune controls (figure 8.2 D). 
The staining in the intestine varied. PPO staining in all cases was strongest in the 
proximal small intestine and involved cells at the tips of the villi, but not cells at the 
base of the crypts which were unstained (figure 8.2 E). Mucosal epithelial staining 
became progressively weaker as more distal portions of the bowel were examined. 
Indeed, epithelial cell staining in the colon was weak to negative (figure 8.2 F). 
However, mucosal macro phages also showed moderate cytoplasmic staining for PPO. 
No staining of plasma cells anywhere in the gut was noted. 
In all 5 testes the columnar cells of the seminiferous tubules stained moderately. 
When present, the interstitial (Leydig) cells, stained strongly (figure 8.2 G). In two 
sections the epithelium of the epididymus was present and showed moderate staining. 
Staining of spermatozoa was impossible to assess at this magnification. No staining 
was seen in the non-immune con rols. 
From five ovarian sections examined, primitive follicles were observed in three and 
no staining for PPO were observed in these cells. In four out of five sections, the 
mature follicular cells showed negative staining. However, in one case the epithelium 
of one mature follicle showed strong staining. All non-immune controls were negative 
(figure 8.2 H). 
In all five placental tissue sections examined, the cytotrophoblasts showed a moderate 
staining of the cytoplasm for PPO (figure 8.2 I). All non-immune controls were 
negative. As all the placentas were from cases of full term pregnancies no 
syncytiotrophoblasts were present. 
Electron microscopy - Subcellular distribution of PPO in human 
hepatocytes 
Figure 8.3 is an electron micrograph showing transformed E. coli cells which express 
recombinant human PPO. As expected a high concentration of specifically labelled 
PPO, visualised as a mass of small black dots which represent the 5 nm gold particles 











Figure 8.3 Electron micrograph of E.coli expressing-PPO showing positive immunogold labelling 
of PPO (left) when compared to non-immune control (right) . 
Liver 
Figure 8.4 Electron micrograph (X5000, left; XlOOOO, right) of liver biopsy specimen 











Mag. X37000 I 
Mag. X37000 
Figure 8.5 Electron micrograph of liver cell showing positive inununogold labelling of PPO in the 
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to the relative absence of labelling in equivalent non-immune controls, which had 
been incubated with nonnal rabbit serum. 
The electron micrograph in figure 8.4 shows a section of a liver cell with a well 
preserved nucleus and several distinct mitochondria within the cytoplasm, thus 
demonstrating adequate preservation of tissue integrity. 
Figure 8.5 shows mitochondria labelled with gold particles, demonstrating the 
presence of PPO in these organelles. Interestingly, there was lesser but significant 
labelling in the cytoplasm. Minimal or no gold particles were observed in the nuclei. 
This labelling pattern was observed in several experiments with liver tissue sections 
from different patients. All non-immune controls showed minimal labelling. 
These observations were quantified by counting the number of gold particles per unit 
area (flm2) and the results shown in table 8.1. This is represented graphically in figure 
8.6. The number of gold particles per flill2 area in sections labelled with PPO antibody 
ranged from 91 - 139 (mitochondria) and from 15 - 39 (cytosol), whilst in sections 
labelled with non-immune rabbit serum, the range was 0 - 10 (negative controls). The 
results represent data from 5 different livers. 
Table 8.1 Immuno-gold labelling of liver tissue sections using the human PPO antibody. 
Mitochondria+PPO-Ab Cytosol+PPO-Ab Negative Controls 



































Mit+PPO-Ab Cyt+PPO-Ab Neg-Ctrl 
Figure 8.6 lmmuno-gold labelling ofhuman liver tissue sections with PPO antibody (PPO-Ab), and with 
normal rabbit serum used for negative controls (Neg-Ctrl), showing the predominant location of PPO 
within the mitochondria and its presence, to a lesser extent, in the cytosol. Mit = mitochondria, Cyt = 
cytosol. 
In an attempt to further minimise non-specific staining IgG was extracted from the 
rabbit serum in which PPO antibody had been raised (see Appendix 10) by 
ammonium sulphate precipitation (Hebert et ai, 1973). However, non-specific binding 
was not reduced. 
Discussion 
Generally, cellular activity and the demand for energy is reflected by the number of 
mitochondria in the cells. In highly active cells where there is a high haem 
requirement there will be large numbers of mitochondria, whilst in less active cells 
there will be few. As the mitochondrion is the predominant location of PPO, the 
number of mitochondria should correspond to the relative staining for PPO. 
The liver is a multifunctional organ in the body involved in several metabolic 
activities such as synthesis of proteins, lipoproteins, conversion of sugars into 
glycogen for storage, degradation of various· toxic products, and several other 
processes. To produce the energy required for these processes hepatocytes contain a 
large number of mitochondria, which are the predominant locations of PPO, hence 
these cells stain strongly for this protein. The phagocytic Kupffer cells are relatively 
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In the kidneys the proximal convoluted tubules are lined by simple cuboidal epithelial 
cells with microvilli which contain large numbers of mitochondria. These are very 
active cells involved in the reabsorption ofapproximately 75% of ions and water from 
the renal tubules into blood capillaries. In addition to the active transport ofNa+ ions, 
these cells also engulf proteins from the tubules into endocytic vesicles which link up 
with lysosomes for their degradation. The distal convoluted tubules are relatively less 
active and possess fewer mitochondria hence their lack of staining for PPO. Similarly 
the glomeruli are less active, involved in the filtration of water and dissolved 
substances down a pressure gradient, and this process requires less energy production 
by the cells. It follows therefore that these cells will have much fewer mitochondria, 
and therefore will stain less or not at all for PPO. 
The ciliated bronchial epithelium stains positively for PPO. These cells are involved 
in mucus production and the co-ordinated movement of mucus by a sweeping 
movement of the cilia along the respiratory tract, both of which are energy requiring 
processes. Similarly, the serous cells in bronchial glands which contain secretory 
granules, for the secretion of peptide compounds stain strongly. In contrast, the 
mucous cells which produce and store mucus contain fewer mitochondria hence, they 
lacked staining for PPO. 
The parietal cells of the stomach are secretory cells which produce and secrete Hel 
and other factors. These cells contain large numbers ofmitochondria which reflect the 
high energy need for production and secretion of these substances and thus a high 
haem requirement. The strong staining for PPO observed in these cells supports this. 
Similarly, in the small intestine, the cells at the tips of the villi, which are involved in 
the absorption of nutrients and the synthesis of digestive enzymes stained strongly. 
These cells contain numerous mitochondria to provide the energy requirement for 
these activities. On the other hand, the cells at the base of the crypts of Lieberkuhn, 
did not stain for PPO. The crypts are composed mainly of stable cells with a low 
turnover. 
In the testes, the stratified columnar cells lining the seminiferous tubules are a 
proliferating population involved in spermatogenesis. Between these cells are the 
secretory Leydig cells which produce and secrete the male hormone, testosterone. 
These are very active populations of cells, hence the strong staining for PPO. The 
primitive follicles in the ovary contain a population of dividing cells which are 
relatively inactive, hence they stain negatively for PPO. In mature follicles most of the 
cells are still dividing, but at a certain stage some of the cells will start producing and 
secreting female sex hormones, oestrogen and progesterone. Depending on the 
activity of the cells and therefore the energy requirement which is reflected by the 
number of mitochondria, these follicles may stain positively for PPO. This may 
explain the positive staining in one of the sections. Similarly, the cytotrophoblasts in 
the placenta, which contains relatively undifferentiated stem cells which produce 
peptide hormones, oestrogen and progesterone, will show features of energy demand. 











In initial electron microscopy experiments it was realised that the immediate transfer 
of the liver tissue into our prepared fixation solution was crucial to preservation of 
tissue ultrastructure. We had observed that tissue left in the fonnalin solution used for 
collecting samples for histopathological diagnosis at Groote Schuur hospital resulted 
in deterioration of ultrastructure. As the amount of liver tissue required for our 
purposes was very small it proved unnecessary to fix the tissue by puncture perfusion 
as is often described by others (Perroti et aI, 1987). Our methodology enabled us to 
achieve adequate preservation of both tissue integrity and antigenicity of PPO. The 
staining procedure used also produced good contrast for the electron microscope 
visualisation of different cellular organelles. 
In this study cryoultramicrotomy and immuno-gold labelling were utilised to study the 
subcellular localisation of PPO in human liver biopsies. PPO was shown to be 
predominantly located in the mitochondria of human hepatocytes as well as the 
cytoplasm though, to a lesser extent. The mitochondrial location of PPO was not 
unexpected as it has previously been reported in subcellular fractionation studies that 
PPO activity was associated with mitochondrial membranes (Poulson and Polglase, 
1975; Poulson, 1975; Jacobs and Jacobs, 1981 and 1984; Deybach et aI, 1985, 
Ferreira et aI, 1988, Camadro et aI, 1994). Previous subcellular fractionation studies 
on photosynthetic cells showed that, in addition to the mitochondria, PPOs were also 
associated with chloroplasts (Matringe et aI, 1992b; Smith et aI, 1993). Although no 
specific mitochondrial targeting signal has been identified in the human PPO 
sequence, it has been established that the mammalian protein, which is encoded by 
nuclear DNA (Kolarov et aI, 1983), is imported into mitochondria. Import studies 
with recombinant PPOs from human (Nishimura et aI, 1995b) and tobacco plant 
(Lennontova et ai, 1997) showed that these proteins were targeted and translocated 
into these organelles. In plants, in addition to the mitochondria, PPO activity has been 
associated with other subcellular structures such as the plasma membrane (Jacobs et 
ai, 1991; Lee et ai, 1993) and the endoplasmic reticulum (Retzlaff and Boger, 1996). 
The interesting visualisation of significant immunogold labelling within the 
cytoplasm, indicating presence of PPO in this cellular compartment may lend support 
to the suggestion of precursor fonns of the protein which are presumably destined for 
the mitochondria. Previous studies showing little or no -cytoplasmic PPO activity 
could indicate that these precursor fonns of the protein have very little or no activity 
at all. The existence of precursor fonns of PPO would be in keeping with the 
synthesis of other mitochondrial proteins as precursors, which facilitates their 
targeting and translocation into these organelles. Previous findings have indicated that 
synthesis of the mammalian (rat) PPO does not take place on mitochondrial, but 
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Concluding Remarks 
The presence of PPO has been demonstrated in a wide variety of organs. It therefore 
appears that haem synthesis occurs in a variety of tissues, and generally this process 
correlates with a cell's demand for energy production. As haem is an important 
component ofmany proteins involved in energy transfer and redox reactions, it stands 
to reason, that there will be a variable requirement for haem that is tissue/cell 
dependent. This is reflected in the presence/absence of haem synthetic enzymes, of 
which PPO is representative. While our observations are largely descriptive, the 
results imply that there are some significant sites of haem synthesis other than the 
liver and bone marrow which should not be ignored in studies concerned with haem 
dynamics and flux in the human body. 
Our electron microscopy studies demonstrated that human PPO is predominantly 
located in mitochondria in liver cells, confirming previous findings from sub-cel1ular 
fractionation studies. This work has also demonstrated the presence of 
immunologically detectable PPO in the cytosol, which may indicate the existence of 
precursor forms of this protein in this compartment. 
The techniques developed in this study may prove to be a useful tool in understanding 
the pathogenesis ofVP, particularly that due to PPO mutations which may disrupt the 
targeting and translocation of this protein into the mitochondria. 
This study also underlines the possibility that immunocytochemical techniques in 
combination with electron microscopy may allow the study of precursor forms of 












Conclusions and Future Directions 

In this work interspecies characterisation of PPOs from human, B. subtilis and M 
xanthus was carried out. The use ofa rapid single-step purification procedure 
with the recombinant proteins has been a great improvement when compared to 
previous methods which involved multiple steps that often resulted in significant 
protein loss. The ability to produce and work with purified, active recombinant 
PPOs facilitated the characterisation of these enzymes. 
Data from substrate specificity and lipid effects revealed differences and 
similarities in the characteristics ofB. subtilis, M xanthus and human PPOs. 
Similarly, data from the investigation of these PPOs by means of inhibitor studies 
highlighted the differences between B. subtilis, M xanthus and human. Various 
inhibitor substances yielded a competitive mode of inhibition, probably due to 
electronic and structural similarities to the PPO substrate, protoporphyrinogen­
IX. The behavioural differences between different fonns of this protein were 
clearly not a simple reflection of prokaryotic versus eukaryotic diversification, 
nor Gram positivity versus negativity in the case of prokaryotes. 
Primary structural variations clearly affect the ability of the protein to interact 
with different compounds, be it substrates or inhibitors. Investigation of the 
effects ofchanges in protein/gene sequences, arising from both natural and 
engineered mutations, was not the goal of this work but, substrate and inhibitor 
studies on the different fonns of the protein may provide clues to amino acid 
residues involved in catalysis and/or substrate binding. This work has shown that 
such detailed kinetic studies are indeed feasible. 
Phylogenetic analysis based on PPO protein sequences revealed interesting 
divergences, especially, amongst prokaryotic fonns. Generally, grouping of the 
various organisms in the phylogenetic tree was similar to those obtained using 
other methods based on morphology and/or fossil records. This work shows the 
use of protein or gene sequences as highly suitable for establishing phylogenetic 
relationships because of the vast amount ofinfonnation they contain. 
Demonstration ofPPO in human tissues/organs indicates occurrence ofhaem 
synthesis in a variety of tissues. It appears that PPO is more apparent in "active" 
cells where energy demand is greater. Localisation studies using electron 
microscopy confinned the predominant location ofPPO in mitochondria, and a 
cytosolic fonn, which probably represents precursor fonns, was demonstrated by 
immunogold labelling. This methodology may provide yet another useful tool in 











mutations which may disrupt the targeting and translocation of these proteins to 
the mitochondria. 
It is clear that the use ofmolecular biology techniques has facilitated the 
characterisation ofvarious proteins, including the haem synthetic enzymes. This 
has enabled refinement ofpurification procedures resulting in simple rapid steps 
with large yields of native proteins. Detailed characterisations are therefore 
possible, and in some cases protein crystal structures have been determined. As 
more detailed data, such as is presented in this dissertation, becomes available, it 
will be possible to identify and isolate critical elements ofPPO with respect to 
catalysis and structure. Importantly, data emanating from the application of these 
techniques to both naturally occurring and engineered mutant PPOs will assist in 
the elucidation and further understanding of the pathogenesis ofVP. Once this is 




























Transformation, Expression and 
Puri'fication of the Recombinant 
Protoporphyrinogen Oxidases of B. 
subtiiis, M. xanthus and Human 
1.1 Transformation of E. coli JM 109 cells by PPO 
expressing recombinant plasmids 
Reagents and equipment 
1. Luria-Bertani (LB) medium 
109 Tryptone (DIFCO Laboratories, Detroit, Michigan, USA) 
5 g Yeast Extract (DIFCO Laboratories, Detroit, Michigan, USA) 
5 g NaCI 
made up to 1 L with deionised water and autoclaved. 
For antibiotic resistance selective media 100 )lglml ampicillin was added to 
the broth, once cooled to approximately 40°C, and mixed. 
2. LB agar plates with ampicillin (100 pg/mJ) 
2 g Tryptone 
1 g Yeast Extract 
1 g NaCI 
3 g Agar Noble (Difco Laboratories, Detroit, Michigan, USA) 
made up to 200 ml with deionised water and autoclaved. Media was cooled to 
40°C, ampicillin (100 )lglml) added, and quickly poured into sterile petri 











3. Calcium Chloride solution (pH 8.0) 
-50mMCaCh 
-10 mM TrislHCI 
-sterilized by autoclaving. 
4. Sterile 1.5 ml microfuge tubes 
5. Heating block (Techne dri-block DB-2D, Laboratory and Scientific 
equipment Co. Cape Town, South Africa). 
6. Ice bath. 
7. Recombinantplasmid vector (pBsubtPPO-X, pHPPO-X or pMx-PPO). 
Transformation procedure 
-1 ml of an overnight culture (10 ml) ofE. coli JM 109 cells was transferred 
into 100 ml of sterile LB broth in a 500 ml flask. The cells were grown with 
vigorous shaking at 37°C until an O.D.600 of0.5 was achieved. 
-The culture was decanted into pre-chilled sterile 50 ml capped tubes and 
chilled on ice for 10 min. The cell suspension was centrifuged at 4 000 G for 
5 min at 4°C. 
-The cell pellet was resuspended in ice-cold sterile CaCh solution (PH 8.0), 
which was half the original volume of medium used for the culture. This was 
placed in an ice bath for 15 min and then centrifuged at 4 000 G for 5 min at 
4°C.. 
-The cells were resuspended in ice-cold sterile CaCb solution (PH 8.0), which 
was 1115 the original volume of medium used for the culture. 200 J..d aliquots 
were dispensed into pre-chilled sterile Eppendorf tubes. These were stored at 
4°C for 12-24 h to increase competence. 
-Recombinant plasmid DNA (approximately 40 ng in a maximum 100 JlI TE 
buffer) was added to an aliquot ofthe cell suspension, mixed and stored on 
ice for 30 min. 
-The transformation mixture was transferred to a heating block preheated to 
42°C, and left for 2 min. 
-1 ml of sterile LB broth was added, and incubated at 37°C for 1 h without 












-100 J.11, 200 J.1l, and 500 J.11 of transformed cell suspension was spread out 
with a sterile glass spreader over LB plates containing ampicillin (100 J.1g/ml). 
- Once the cell suspension had absorbed into the medium the plates were 
incubated at 37°C for 12-16 h until colonies appeared. Apparent single 
colonies were then replated on fresh plates. After appearance of single 
colonies, 100 ml ofLB broth containing ampicillin (l00 J.1g/ml) was 
inoculated with a single colony. 
-After overnight growth 700 J.11 aliquots of the culture were transferred into 
microfuge tubes with 300 J.11 sterile glycerol, mixed and stored at -80°C as 
stocks. 
1.2 Expression and Purification 
Reagents and equipment 
-Orbital shaker incubator (Yih der LM-510, Taiwan) 

-LB medium with 100 J.1g/ml ampicillin. 

-Ni-NT A agarose (Qiagen, Chatsworth A, USA). 

-Talon resin (Clonotech Laboratories, Palo Alto, USA). 





-Phenyl-methyl-sulfonyl fluoride (PMSF), 1 J.1g/ml fmal concentration. 

-Isopropyl-1-thio-p-D-galactoside (IPTG); 1 M stock. 

-Jouan KR 422 centrifuge (Saint Herblain, France). 















1.2.1 Expression and purification of the B. subtilis PPO 
1.2.1.1 PPO expression 
-100 J.11 of thawed E. coli cells containing the pBsubtPPO-X plasmid, which 
expresses recombinant B. subtilis PPO, was transferred into 10 ml ofsterile 
LB medium containing ampicillin (100 J.1g/ml) and incubated overnight at 
37°C. 
-1 ml of the culture was transferred into 1 L of LB medium (in a 2 L flask) 
and incubated with vigorous shaking at 37°C until an O.D.600 of 0.5-0.6 was 
reached. IPTG (1 mM) was added to induce PPO expression and cellgrowth 
continued for another 4 h. 
-Cells were harvested by centrifugation at 4 000 G for 30 min at 4°C. 
1.2.1.2 Native purification of recombinant B. subtilis PPO: 
-The cell pellet was resuspended in 30 ml of ice-cold sonication buffer (50 
mM NaH2P04, 300 mM NaCI, 1 % Tween-20, pH 8.0). 
-The cell suspension was sonicated 4 X30 sec on ice to produce a lysate. This 
was ultracentrifuged at 40000 G for 30 min at 4°C. 
-Approximately 30 ml ofPPO-containing supernatant was loaded onto a Ni­
NTA agarose column (0.9 X 1 cm), pre-equilibrated with sonication buffer 
(15 ml), and allowed to flow through by gravity. 
-The column was washed with sonication buffer (20 ml), followed by 20 ml 
of the first wash buffer (50 mM NaH2P04, 300 mM NaCI, 0.2% Tween-20, 
pH 8.0) and 20 ml of a second wash buffer (50 mM NaH2P04, 300 mM NaCI, 
0.2% Tween-20, 10% glycerol, pH 6.3) 
-Bound PPO was eluted from the column with 100 mM imidazole in the· 
second wash buffer. 
-PMSF (1 J.1g/ml) was added, immediately before use, throughout the 
purification procedure. 
1.2.1.3 Purification ofB. §ubtilis PPO using denaturing conditions 
-The cell pellet was resuspended in denaturing solubilisation buffer (6 M 
GuHCI, 100 mM Na-phosphate, 10 mM Tris, pH 8.0) at 5 ml per gram wet 
weight and stirred gently for 1 h at room temperature. 
-The lysate was centrifuged at 105 000 G for 30 min at 4°C and the PPO­











-The supernatant was loaded onto a Ni-NTA column (0.9 XI cm) pre­
equilibrated with the solubilisation buffer at a rate of3 column voVh. 
-The column was then washed with solubilisation buffer (15 ml), followed by 
20 ml of a first wash buffer (8 M urea, 100 mM Na-phosphate, 10 mM Tris, 
pH 8.0) and 15 ml ofa second wash buffer (8 M urea, 100 mM Na-phosphate, 
10 mM Tris, pH 6.3). 
-Bound protein was eluted from the column with 250 mM imidazole in the 
second wash buffer. 
-PMSF (1 Jlglml) was added immediately before use throughout the 
purification procedure. 
1.2.2 Expression and purification of M. xanthus PPO 
1.2.2.1 PPO expression 
-1 ml from an overnight culture (10 ml) ofE. coli cells, containing the pMx­
PPO plasmid which expresses recombinant M xanthus PPO (Dailey and 
Dailey, 1996a), was transferred into lL ofLB medium with ampicillin (100 
Jlglml) and incubated at 37°C with vigorous shaking for 20 h. 
- Cells were harvested by centrifugation at 105000 G for 30 min at 4°C. 
1.2.2.2 PPO purification by Talon affinity chromatography using 
native conditions 
-The cell pellet was resuspended in 30 ml of sonication buffer (20 mM 
TrisIHCI, 100mM NaC!, 1 % Tween 20, pH 8.0). 
-The cell suspension was sonicated 4 X 30 sec, and the resulting lysate 
centrifuged at 105 000 G for 30 min at 4°C to produce a PPO-containing 
supernatant. 
-The supernatant was loaded onto a 1 cm Talon resin column pre-equilibrated 
with sonication buffer (IS ml) and allowed to flow through by gravity. 
-The column was washed with 15 ml of sonication buffer, followed by 20 ml 
ofa first wash buffer (20 mM TrisIHCI, 100 mM NaC!, 10% glycerol, 0.5% 
Tween-20, pH 6.3), 20 ml of a second wash buffer (50 mM NaH2P04, 100 
mM NaC!, 0.5% Tween-20, 10% glycerol, pH 6.3) and finally 20 ml wash 
buffer 2 containing 25 mM imidazole, pH 6.3. 
-Bound protein was eluted with 100 mM imidazole in the second wash buffer .. 












1.2.3 Expression and purification ofhuman PPO 
1.2.3.1 PPO expression 
-1 ml ofan overnight culture ofE. coli cells containing the pHPPO-X 
plasmid, from which recombinant human PPO is expressed (Dailey and 
Dailey, 1996b), was inoculated into 1 L ofsterile LB medium with ampicillin 
(l00 /-Lg/ml). 
-The cell culture was incubated at 37°C for 22 h with vigorous shaking after 
which the cells were harvested by centrifugation at 4 000 G for 30 min at 4°C. 
1.2.3.2 Purification of human PPO by Talon affinity 

chromatography using native conditions 

-The cells were resuspended in 30 ml of sonication buffer (20 mM TrisIHCI, 
300 mM NaCI, 1 % n-octyl-~-D-glucopyranoside, pH 8.0) and subjected to 4 
X 30 sec sonication on ice. 
-The lysate was centrifuged at 105000 G for 30 min at 4°C and the PPO­
containing supernatant collected. 
-The supernatant was loaded onto a Talon resin column (approximately 1 cm) 
pre-equilibrated with sonication buffer (IS ml) by gravity. 
-The column was washed with sonication buffer (20 ml) followed by 20 ml of 
wash buffer (20 mM TrisIHCI, 300 mM NaCI, 25 mM imidazole, 0.2% n­
octyl-~-D-glucopyranoside, pH 8.0). 
-Bound protein was eluted from the column in 20 mM TrisIHCI, 300 mM 
NaCI, 0.2% n-octyl-~-D-glucopyranoside 150 mM imidazole, pH 8.0. 













Sodium Oodecyl Sulphate 
Polyacrylamide Gel Electrophoresis 
[50S-PAGE] 
(Laernmli, 1970) 
Reagents and equipment 
1. SE-600 vertical slab gel electrophoresis unit (Hoefer Scientific 
InstrumentslPhannacia Biotech, Cambridge, UK) 
2. PS-1200 DC power pack (Hoefer Scientific InstrumentslPhannacia 
Biotech, Cambridge, UK) 
3.30 ml gradient mixer (Hoefer Scientific InstrumentslPhannacia Biotech, 
Cambridge, UK) 
Electrophoresis gel 
A 3.6% stacking gel in 125 mM TrisIHCI, pH 6.8 on a 7.5%-17.5% linear 
gradient acrylamide gel in 350 mM TrislHCl, pH 8.8 was used for the 
separation of proteins by electrophoresis. 
17.5% Resolving gel solution 
- 7 ml of "high" buffer (1 M TrislHCI, pH 8.8; 30% Glycerol). 

- 12 ml of A-Bis-A solution (30% acrylamide/0.8% bisacrylamide). 

- 0.3 ml of 10% SDS. 

- made up to 20 ml with deionised water. 

7.5% Resolving gel solution 
- 7 ml of "low" buffer (lM TrislHCl, pH 8.8; 7.5% Glycerol) 

- 5 ml of A-Bis-A solution (30% acrylamide/0.8% bisacrylamide). 

- 0.3 ml of 10% SDS 













Spacer solution for stacking gel 
- 8.6 ml Spacer buffer (125 mM TrisIHCI, pH 6.8) 
- 1.2 ml A-Bis-A solution (30% acrylamide/0.8% bisacrylamide). 
- 0.1 ml 10% SDS 
Gel electrophoresis tank buffer 
-25 mM Tris, pH 8.8 






-1 g PAGE-83 

-200 ml 50% TCA 

-300 ml Ethanol 

-500 ml deionised water 

Filtered before use. 













in 0.005 M TrisIHCI pH 6.8. 

Gel destain solution 
















Preparation of SDS Polyacrylamide gel 
-20 ml each of the 17.5% and 7.5% resolving gel solutions were prepared. 
-To each resolving gel solution 100 J.tl of freshly prepared 5% ammonium 
persulphate solution and 10 J.tl ofTEMED were added immediately before 
use, and mixed well. 
-16 ml of the 7.5% resolving solution was poured into the left chamber of the 
gradient mixer allowing a small volume to flow into the channel connecting 
. the right chamber which was positioned on top of a magnetic stirrer. 
-16 ml of the 17.5% resolving solution was poured into the right chamber 
which contained a rotating stirrer bar. 
-Both the connecting tap and the tap leading from the gradient mixer were 
opened, and the mixing solution pumped from the gradient mixer to the gel 
well between the two glass plates mounted vertically on a gel pouring stand). 
The gel well was filled up to a level allowing the spacer comb teeth to be 
entirely within the stacking gel. 
-Approximately 1 ml ofwater was gently layered above the gel using a 
synnge.. 
-Once set, the water was removed. 100 J.tl of 15% ammonium persulphate 
(freshly prepared) and 10 J.tl ofTEMED were added to the spacer solution, 
mixed and poured on top of the gel. Sample bay comb was inserted and the 
gel allowed to set. 
Protein preparation and gel electrophoresis 
-Protein samples were boiled for 5 min with an equal volume ofsample 
solution. 
-The chemically denatured protein and samples containing imidazole were 
mixed with equal volumes ofloading buffer and incubated at 37°C in a water 
bath for 15 min prior to loading onto gel. 
-A buffer tank was assembled with the gel plate component containing the set 
gel. 
-The tank was filled with gel electrophoresis buffer. 
-The samples (maximum 100 J.tl) were loaded into the spacer bays with a 
Hamilton microsyringe. 
-The gel was run at a constant voltage of 65 V for 16 h or until tracker dye 











;.The gel was removed from the plates and stained with gentle shaking for 
approximately 1 h. 
-The gel was transferred to destain solution and agitated until protein bands 
were clearly visible and the background well reduced. 












Molecular Weight Determination of 
Native B.subtilis PPO 
Reagents and equipment 
Isco fraction collector with UV monitor(Anatach Instruments, Johannesburg, 
South Africa. 
Aldolase bovine serum albumin, ovalbumin and cytochrome C from Gel 
filtartion calibration kits, Sephadex G200 (Pharmacia Biotech, Vienna, 
Austria) 
Packing and running of column 
6 g Sephadex G-200 wasswoolen in deionised water at 90°C for 5 h., allowed 
to cool and the gel degassed. 
The gel was packed into a 100 X 1.4 cm column. The column was 
equilibrated with 10 mM phosphate pH 7.4, 100 mM Nacl, 0.2% n-octyl -D­
glucopyranoside at a fixed flow rate of20mllh. 
2 mg of each standard was dissolved in 2 ml of the equilibration buffer and 
loaded onto the G-200 at 20 mllh and identical sized fractions collected. 
A standard curve was constructed by plotting the molecular weight versus the 
fraction number. This was repeated to ensure reproducibility. 
A run was performed in which non-denatured B. subtiUs PPO was included 












Protein Estimation with Bicinchoninic 
Acid 
Sigma Procedure No. TPRO-562 (Kit No. BCA-I), Sigma Chemical Co., St. Louis, 
VSA. 
Reagents and equipment 
Hitachi V-lIDO Spectrophotometer (Hitachi Koki Co. Ltd, Tokyo, Japan). 
Water bath (37°C). 
Bicinchoninic Acid Solution; B-9643 - Reagent-A. 
Copper (II) Sulphate Pentahydrate 4% Solution; C-2284 - Reagent-B. 
Protein Standard Solution- 1.0 mglml bovine serum albumin (BSA). 
Assay procedure 
-The protein determination reagent was prepared by adding 1 part Copper (II) 
Sulphate Pentahydrate 4% Solution (1.5 ml) to 50 parts Bicinchoninic Acid 
Solution (75 ml). 
-A standard curve was constructed as shown below to enable determination of 






















Unknown sample (J.lI) 
100 0 
50 50 
-2 ml of protein detennination reagent were added to each tube. The tubes 
were then vortexed and incubated at 37°C for 30 min. 
-Tubes were cooled to room temperature and the absorbance measured at 562 
run. 
-Blanks of the buffer utilized (100 and 50 J.ll) were also included and a water 
blank was used to zero the machine. 
-Absorbance of both the standards and the unknown sample were read at 562 
run. An appropriate dilution of the unknown sample was prepared to ensure 
that its absorbance was within the range of standards. 
-A standard curve was prepared by plotting the known added BSA 
concentration (J.lg) versus the net absorbance at 562 run. This standard curve 
was used to detennine the amount of unknown protein. 
Calculation of protein concentration (mg/ml) in unknown samples:­












Determination of Protein Molecular 
Weights 
Procedure 
-Unknown molecular weights for the PPO proteins were determined by 
comparison with protein standards ofknown molecular size (Da) RainbowTM 
coloured protein molecular weight markers (Amersham International pic, 
Amersham Place, Little Chalfont), viz. Myosin (220 000); Phosphorylase b 
(97400); Bovine serum albumin (66000); Ovalbumin (46000); Carbonic 
anhydrase (30 OOO);Trypsin inhibitor (21 500); and Lysozyme (14 300). 
-For each protein standard the relative migration values (Rr) was determined 
using the formula:­
Distance protein has migrated from origin! Distance from origin to reference point 
-Using the top of the resolving gel as the origin and the furthest travelled 
distance by any of the protein standards was used as the reference point. 
-The logs of the protein standard molecular sizes were plotted against their 
respective Rrvalues to construct a standard curve which was used to 
determine the unknown molecular weights of the protein (PPO) samples. This 












Determination of Isoelectric Point (Flat 
bed Isoelectric Focusing) 
Reagents and equipment 
-ISOBOX model HE950 (Hoefer Scientific InstrumentslPharmacia Biotech, 
Cambridge, UK). 
-LKB 2197 power supply (LKBlPharmacia Biotech, Cambridge, UK). 
-Arnpholine PAG plates (PH range 3.5-9.5); LKBlPharmacia Biotech, 
Cambridge, UK). 
-Anode electrolyte solution (100 mM H3P04 in double distilled water). 
-Cathode electrode solution (100 mM NaOH in double distilled water). 
Sample preparation 
-The B. subtilis PPO was purified under non-denaturing conditions by the 
method described in "Expression and Purification ofPPOs". Protein samples 
(0.5 mg/ml) were desalted in pure water by gel filtration on a PD 10 column 











Isoe/ectric focusing (pH range 3.5-9.5) 
The isoelectric points (PI) for the unknown proteins were determined by 
comparison with standard proteins of known pIs. The Pharmacia Broad pI 
Calibration kit containing the following standard pI markers was used: 
Protein marker PI (24 +/-1.5 °C) 
Amyloglucosidase 3.50 
Methyl red dye 3.75 
Soybean trypsin inhibitor 4.55 
~-lactoglobulin A 5.20 
Bovine carbonic anhydrase B 5.85 
Human carbonic anhydrase B 6.55 
Horse myoglobin acidic band 6.85 
Horse myoglobin acidic band 7.35 
Lentil lectin acidic band 8.15 
Lentil lectin middle band 8.45 
Lentil lectin basic band 8.65 
Trypsinogen 9.30 
-The P AG plate was slowly lowered onto sufficient liquid paraffin on the 
cooling plate to ensure a complete layer under the gel. The isobox was then 
cooled to 10°C for 20 min. 
-Electrode strips, cut to the correct size, were soaked in the appropriate 
electrode solutions and applied to the long edges of the gel. 
-Sample application wicks were positioned in a row, 5 mm apart on the 
PAGplate approximately 20 mm from the cathode. 
-The electrodes were positioned onto the electrode strips and the 











-The gelwas prefocussed for 10 min using the following conditions:­
Power(W) Voltage (V) Current (mA) Time (min) 
30 1 500 50 10 
-15 I.d of the unknown protein (PPO) and the Broad pI Calibration Kit 
markers (PH 3-10) (reconstituted in 100 J..I.I double distilled water) were 
applied to separate sample wicks. 
-The gel was focussed as shown below :­
Power(W) Voltage (V) Current (mA) Time (min) 
30 1 500 50 90 
-The application wicks were removed 30 min prior to end of focusing. 
Staining ofproteins with Coomasie blue. 
-The gel was incubated for 1 h in fixing solution (11.5% TCA; 3.4% 
Sulphosalicylic acid) with gentle shaking. 
-Washed in destaining solution (25% Ethanol; 8% Acetic acid) for 5 min. 
-Stained for 2 h in staining solution (0.12% Coomasie Brilliant Blue R-250 in 
destaining solution) with gentle shaking. 
-Destained by several washes in destaining solution until background had 
cleared. 
pi determination 
The known pIs of the different markers (Y-axis) were plotted against the 
respective migration distances (X-axis) in the gel from the cathode edge of the 
gel, and draw a calibration curve (PH gradient profile) by connecting the 
points with straight lines. The unknown pIs of the sample proteins were 
determined from the pH gradient profile curve by interpolation, using their 












Flavin Cofactor Analysis 
(Koziol, 1971; Faeder and Siegel, 1973; Cerletti and Giordano, 1971) 
Reagents and equipment 




-Flavin extract preparation. 

-20% Trichloroacetic acid (TCA) (chilled to 4°C). 

-100 mM Na2HPO,JNaH2P04 buffer, 0.1 mM EDTA, pH 7.4. 

-200 mM Na-acetate buffer, pH 3.5. 

-3 M Tris chilled to 4°C. 









Beckman L7-65 Ultracentrifuge, Ti 50 rotor (Beckman Instruments, Inc., Palo 

Alto, California, USA). 

Extraction and determination of PPO flavins 
-Protein samples were mixed with equal volumes of cold 20% TCA and 
placed on ice for 15 min. 
-The mixture was centrifuged at 105 000 G for 20 min. at 4°C. 
-pH of the flavin-containing supernatant was immediately adjusted to 7.4 
using 3 M Tris. 
-Appropriate dilutions of known flavin standards (FAD and FMN), and the 
flavin containing supernatant were prepared with the phosphate buffer pH 7.4. 
(for neutral pH readings), and with acetate buffer pH 3.5 (for acidic pH 
readings). 
- The absorption spectra of the neutral (PH 7.4) solutions were recorded from 











-The maximum fluorescence emission spectra were recorded from 600 to 480 













Protoporphyrinogen Oxidase Assay 
(Meissner et aI, 1986) 
Reagents and equipment 
1. Cuvette Buffer:­




-3 mM Dithiothreitol (DTT) - added immediately before use. 

-pH 8.1 for human and M xanthus PPOs, and 8.7 for B. subtilis PPO. 

2. Assay Buffer:­
-same as cuvette buffer plus 0.1 % Tween-20. 
3. Substrates:­
-ProtopOIphyrin-IX (proto.) (Porphyrin Products, Logan, UT. USA). 
-Mesoporphyrin-IX (meso.) and Coproporphyrin-III (copro.) (Porphyrin 
Products, Logan, UT, USA) were substituted for Protoporphyrin-IX when 
required. 
4.2.7 N HCl for dissolving Protoporphyrin-IX and 0.1 N HC! for 
Mesoporphyrinogen-IX and Coproporphyrinogen-Ill. 
5. 100 JlM FAD solution. 
6. 20% Ethanol in 10 mM KOH. 
7. Sodium (Na) and Mercury (Hg) to prepare the 4% Na-Hg Amalgam for 
reduction of Protoporphyrin-IX. 
8. Round botttomed glass flask with side arm. 












10. Hitachi 650-lOS Fluorescence Spectrophotometer.(Koki Co Ltd, Tokyo, 
Japan. 
11.Hitachi U-l100 UVNIS Spectrophotometer (Koki Co Ltd, Tokyo, Japan). 
12. Bunsen burner. 




The procedure was perfonned in a dark room. 

Preparing protoporphyin-IX stock solution 
-12 mg protoporphyrin-IX was dissolved in 30 milO mM KOH in 20% 
ethanol (v/v),with stirring in the dark (proto. stock). The solution was then 
filtered through a 0.45 JlIll filter. 
-Protoporphyrin-IX concentration was detennined by measuring absorbance 
ofa 11100 dilution of the proto in 2.7 N HCI at 408 nm in a u.v/vis 
spectrophotometer, using the extinction coefficient, 262. 
[Protoporphyrin-IX] IlM = O.D'40S/262 X 105 
-The filtered proto. stock was diluted to a final volume of 12 ml in 10 mM 
KOH (230-250 IlM final concentration). The exact proto. concentration was 
detennined as described above and used to calibrate the fluorimeter .. 
Preparation of reaction and absorbance measurement (time 
point) tubes 
-Assay reaction tubes: -enzyme sample (vol. as required) + FAD (50 Ill) + 
assay buffer ( to give final vol. of 1 ml), were prepared. 

-For each assay tube a corresponding blank was prepared by substituting the 

enzyme sample with equal amount of heated protein (80°C for 10 min). 

-Samples were preincubated in assay tubes for 20 min. 













-Calibration of fluorimeter 
- 1110 dilution of proto. stock (100 JlI) was made in assay buffer (900 JlI) 
followed by a further 11250 dilution (250 JlI) in cuvette buffer (6 mI). A 
standard curve was prepared as follows:­






-The fluorimeter was then calibrated such that the highest proto.concentration 
read approximately 1000 relative fluorescence units (RFU). 
Preparation ofsubstrate 




-1.8 g Na was cut into small pieces and covered with liquid paraffin; 43.2 g 

Hg weighed and both immediately put in a fumehood. 

-The Hg was poured into the round bottom glass flask. 

-Nitrogen gas was introduced through the angled side arm of the flask. 

-The flask was held with a clamp and heated inside the fumehood. 

-The Na was added piece by piece through the top of the vessel. The reaction 

may occur spontaneously, or require some gentle heating over the burner. 

-The vessel was swirled around while heating, till amalgam was completely 

liquid and glass sides clear. 

-Amalgam was immediately transferred into a pre-warmed mortar and 

agitated whilst chopping with a spatula until solidified. Agitation causes 

amalgam to condense into little granUles. 

2. Reduction ofProtoporphyrin-IX to Protoporphyrinogen-IX with 
4% Na-Hg amalgam 
-Approximately half the amalgam was added to the round bottomed glass 











-Fluorescence was monitored under a uv light, and gas allowed to escape from 
time to time. 
-As fluorescence disappeared the remaining amalgam was added and shaking 
continued until reduction was complete ( as indicated by disappearance of 
fluorescence when viewed under uv light). 
·Proto. was filtered through a 0.45 ~ filter and pH adjusted with 2 M MOPS 
to 8.1 for human and M xanthus PPOs, or 8.7 for B. subtilis PPO. 
Experiments involving fluorescence measurements before and after reduction 
showed that the fluorescence was always more than 96% complete.The 
concentration ofprotoporphyrinogen was thus taken as being equal to that of 
the protoporphyrin starting solution. 
PPO assay procedure 
-Substrate was prepared immediately before use. 
-100 !J.I of the proto. substrate was added to each assay tube, mixed and 
incubated for 10 min. 
-At each time point 100 III was transferred from assay tubes into matched 
"cuvette" tubes (final volume = 1.1 ml) and fluorescence measured. 
-Four equivalent time points ranging from 10 min to a maximum of 60 min 
were used. 
-Determination of relative fluorescence units 
A customised spreadsheet (Lotus 123) was used. This subtracts the blanks 
from specimen rates, multiplies by all dilution factors, corrects time to 1 h, 
and multiply by a regression factor to finally yield enzyme activity in RFUs 














Inhibition of Protoporphyrinogen 
Oxidase 
(Corrigall et ai, 1994) 
Reagents and equipment 
PPO Inhibitors 
- Acifluorfen (AF) and Acifluorfen-methyl (AFM)- (Chern Services West 
Chester, PA, USA) 
- Bilirubin-IX (BR) and Biliverdin-IX hydrochloride- (BV) (Porphyrin 
Products, Logan USA) 
- Haemin (HMN)- (Sigma-Aldridge, S1. Louis, MO, USA). 
Solvent: 
All inhibitors were dissolved in dimethylsulfoxide (DMSO) to give a final 
solvent concentration of2.5% in the assay reaction. 
Enzyme preparation 
- B subtilis, M xanthus and Human PPOs were purified by non-denaturing 
conditions as outlined in Appendix 1. 
Inhibition experiments 
- The inhibition assay was performed as previously described in Appendix 7 
except for the following modification: the assay buffer was 100 mM TrisIHCI, 
3 mM DTT, 1 mM EDTA, 0.1% Tween-20, and pH 8.7 for B. subtilis PPO 
and 8.1 for human and M xanthus PPOs. 
ICso values were determined for the different inhibitors (AF, MeAF, BV, BR, 
and HMN) by measuring PPO activity at a range of inhibitor concentrations 
ranging from 0 to 100 j.lM at a substrate concentration of 10 j.lM. The kinetic 
constants Kj, Ks, and ex. were determined by using four different inhibitor 
concentrations within the range 0 to 10 j.lM for each of eight different 












Production of PPO Antibodies and 
Western Blotting 
(Kirsch et aI, 1975) 
10.1 Immunization of rabbits and collection of serum 
Reagents and equipment 
-Immunogen~ pure human or B. subtilis PPOs (Blotted onto Nitrocellulose 

membrane) was used for raising the respective antibodies. 

-Complete and Incomplete Freund's adjuvants. 





-New Zealand white rabbits 

Procedure 
Purified B. subtilis and human PPO was subjected to SDS-PAGE (see 
Appendix 2) followed by blotting onto nitrocellulose paper which was then 
dried and stored at room temperature. When required, membrane containing 
approximately 100 J..1g of PPO was cut into small pieces. 
-1 ml DMSO was added and whirley mixed to dissolve the nitrocellulose, 
after which 1.5 ml complete Freunds adjuvant was added and further mixed. 
-The immunogen was injected into multiple subcutaneous sites on the back of 
a rabbit. 
-After 3 weeks a booster injection was given with Incomplete Freund's 
adjuvant (l00 J..1g PPO). 
-Booster injections were repeated at 10 day intervals. 
-After four inoculations 1 ml of blood was collected from ear vein of rabbit 
for testing for antibody production by Western blotting. Once an adequate 











-The blood was kept at room temperature for I h to allow clotting, then stored 
at 4°C for 2 h before centrifugation at 2 500 G for 30 min. The antibody­
containing serum was collected. 
-Serum or IgG (see below) was stored at -80°C in small aliquots. 
-Specificities ofthe PPO antisera were checked by Western blotting. 
10.2 Isolation of the IgG fraction from antiserum 
(Hebert et aI, 1973) 
Reagents and equipment 
Spiramix IO (Denley, Laboratory and Scientific, Cape Town, S. A.) 
Centrifuge (Sorvall RC-3B, The Scientific Co of SA, Johannesburg, South 
Africa) 
PBS pH 7.4 
0.9% NaCI pH 8.0 (adjusted with NaOH) 
Serum from PPO immunised rabbits 
Saturated ammonium sulphate solution 
Procedure 
-To a given volume of serum, an equal volume of70% saturated ammonium 
sulphate was added dropwise whilst gently stirring. 
-After standing for 4 h (or overnight) centrifugation was at 3000 G for 15 min. 
-The precipitate was resuspended in 0.9% NaCI, pH 8.0; equal to the original 
serum volume and dissolved by rolling. 
-The 70% ammonium sulphate precipitation was repeated, allowing only 30 
min standing time prior to centrifugation. 
- The resuspension was dialysed against PBS, pH 7.4 overnight (3 X 5 L). 
-Absorbance of the solution was read at 280 nm (diluted 5 X) and 
concentration calculated using the formula: 












10.3 Western blotting 
(T owbin et aI, 1979) 
Reagents and equipment 
-Electroblotting apparatus:-GT Series Gel Electrophoresis Unit with 
Transphor Power-Lid, model TE 50 (Hoefer Scientific InstrumentslPharmacia 





-Whatman 3M paper. 

-0.45 flM Nitrocellulose membrane (Schleicher & Schuell, Dassel, W. 

Germany). 
-Glass containers for gel and membrane agitation. 
-Shaker: The Belly Dancer (Stoval Life Sciences, Inc., Greensboro NC, USA). 
Transfer buffer 
-4 L of 192 mM glycine, 25 mM Tris plus 1 L of methanol. Chilled to 4°C. 
Tris-Buffered Saline (TBS) 
-50 mM TrisHCI, 20 mM NaCI, pH 7.4. 
Blockini solution 
-1 % Casein, 0.3% Tween-20 in TBS. 
Washini buffer 
-0.05% Tween-20 in TBS. 
Substrate solution 
(made immediately before use). 
-24 mg ofchloronaphthol was dissolved in 8 ml of methanol, diluted with 40 












Protein transfer onto Nitrocellulose paper 
-3 identical sets of samples of the load, pure PPO and molecular weight 
markers were run on an SDS polyacrylamide geL 
-Tank was surrounded with ice in a polystyrene container and filled with 5 L 
of transfer buffer. 
-Six pieces of Whatman 3M paper (slightly bigger than the gel size) and a 
piece ofNitrocellulose membrane (of similar size to the gel) were cut. 
-A scotch brite fibre pad was soaked in ~'transfer buffer" and placed on half of 
a blotting transfer cassette, followed by three 3 layers of soaked Whatman 3M 
paper, soaked nitrocellulose membrane, the polyacrylamide gel and finally 3 
more layers of Whatman paper. Bubbles between layers were removed with a 
roller, and the other half of the cassette clipped into place. 
-The complete cassette was placed in the tank ensuring that the 
polyacrylamide gel was closest to the anode. Tank lid (containing the 
electrodes) was placed on top ofthe tank in such a way that the cathode faced 
the operator. Protein transfer was allowed towards the anode at 90 V for I h. 
Immunodetection 
-Current was switched off and assembly removed from tank. 
-Nitrocellulose membrane was incubated in blocking solution (200 ml) for Ih. 
-The membrane was cut into the 3 identical sections for different primary 
antibody reactions. 
-Membrane sections were incubated with appropriate primary antibody 
111000 dilution (either IgG or serum) in blocking solution for I h. Non­
immune rabbit serum or IgG was used in the negative control as the 
antibodies were raised in rabbits. 
-The membranes were incubated with "washing buffer" (3 X 10min). 
-Followed by secondary antibody incubation (1/500 dil. goat anti-rabbit 
peroxidase conjugate) for 1 h. 
-Incubation with "wash buffer" (3 X 10 min) was followed by TBS for 10 
min. 
-The membrane was exposed to substrate solution, with gentle mixing, until 














11.1 Immunohistological Localisation of PPO in 
Different Human Organs 
Organ specimens and antibodies 
-For light microscopy, surgically removed specimens of human liver, kidney, 
lung, testis, placenta, ovary, stomach, small and large intestine were fixed in 
buffered formalin, embedded in paraffin wax and sections cut at 5 microns. 
Five specimens of each organ were studied. 
- Antibody to human PPO was raised as described in Appendix 9. Antibody to 
Glutathione S-transferase pi was used as a positive control and normal rabbit 
serum as the negative control. A positive control was included in every 
experiment and a negative control included for every specimen examined in 
order to control for nonspecific staining. 
Detailed procedure for immunoperoxidase staining 
The paraffin sections were brought to absolute alcohol by immersing in 
- xylol I (2 min) 
- xylol II (2 min) 
- absolute alcohol (2 min) 
Sections were then: 
Incubated with 0.3% H202 in methanol for 30 min to block endogenous 
peroxidase, followed by a wash in PBS for 30 min with gentle stirring. 
Exposed to normal swine serum (1/20 dilution in PBS) in a humidity chamber 
for 15 min, after which the swine serum was carefully blotted off. 
Exposed to 11100 dilution in PBS of rabbit anti-PPO (primary antibody) for 
30 min at room temperature. A similar dilution ofnormal rabbit serum was 
used for the non-immune control, and a 11500 dilution of Glutathione S­
transferase pi antibody was used as a positive control. Sections were washed 












Exposed to 11250 dilution in PBS ofbiotinylated swine anti-rabbit 
immunoglobulins (secondary antibody) for 30 min at room temperature, 
followed by a wash with PBS for 15 min. 
Exposed to 11500 dilution in PBS of horseradish peroxidase streptavidin for 
30 min at RT, followed by a 15 min wash with PBS. 
Colour reaction was developed with a solution of 5 mg of 3-3' 
diaminobenzidine in 10 ml PBS containing 100 III of 1% H202 for 
approximately 5 min. This was followed by a wash in running tap water for 
approximately 5 min. 
Counter staining ofsections was with Meyer's haematoxylin for 10 min 
followed by a brief rinsing with running tap water, after which section were 
blued with Scott's tap water for 2 min. 
Sections were dehydrated as follows: 
- 70% alcohol (2 min) 
- 95% alcohol (2 min) 
- xylol III (2 min) 
- xylol IV (2 min) 
and then mounted with Entellen mounting medium. The sections were then 
viewed under the light microscope. 
11.2 Electron Microscopy: Cryoultramicrotomy and 
Immunogold Labelling 
(Monaghan and Atherton, 1992) 
Reagents and equipment 
1. Reichart Ultracut-S microtome with a Cryochamber 
2. KF-80 Rapid Freezing apparatus 
3. Aluminium stubs 
4. Carbon-coated Formvar-covered Nickel grids 
5. Zeiss EM 109 Electron Microscope 















-0.1 % glutaraldehyde 

-100 mM phosphate buffer 

8. 2.3 M Sucrose solution 
9. Phosphate buffered saline (PBS) XI0, pH 7.4: 
10. Bovine Serum Albumin (BSA) 

1 L Goat anti-rabbit gold complex (5 nm particles) 

12. 2% GelatinJPBS 
13.20 mM GlycinelPBS sterile solution 
14. Non-immune nonnal rabbit serum 

15.25% Glutaraldehyde stock solution 

16. Neutral Uranyl Acetate 
17. 2% Aqueous Uranyl Acetate 

18.2% Methyl cellulose 

Procedure 
-Small (0.5-1.0 mm3) tissue specimens were fixed in fixative for 
approximately 6 h. 
-The tissue was gradually infused with sucrose overnight until a final 
concentration of2.3 M is reached. 
-Tissues were placed in sucrose on aluminium stubs and frozen rapidly in 
liquid propane at -180oe using the KF-80 rapid freezing apparatus. 
-Ultra-thin sections (120 nm) were cut from the frozen tissue with a Reichart 
Ultracut-S microtome, which has a cryochamber maintained at -120oe, and 
the sections collected on sucrose droplets. 
-The sections were transferred onto carbon-coated fonnvar-covered nickel 











-The grids were incubated with 2% gelatinIPBS (3 X 2 min) to reduce non­
specific labelling followed by incubation with 20 mM glycinelPBS (1 X 10 
min) to quench residual aldehydes. 
-The grids were washed 1 % BSAlPBS (5 X 1 min). 

-The sections were then incubated overnight at room temperature with 

primary antibody(1I50 dilution ofPPO polyclonal antibody raised in rabbits). 





-Grids were rinsed with 1 % BSAlPBS (lOX 2 min). 

-Sections were incubated with goat anti-rabbit gold complex, 5 nm particles, 

1/30-1160 dilution in 1 % BSAlPBS at room temperature for 1 h. 









-Grids were rinsed with distilled water (5 X 2 m~n). 

-The sections were incubated with neutral uranyl acetate (l X 10 min). 

-Grids were rinsed with distilled water (2 X 1 min). 

-The grids were coated with a mixture of 1:9 of2% uranyl acetate and 2% 

methyl cellulose at 4°C (UA/MC) (2 X 2.5 min), picked up with wire loops 
and the excess UAfMC removed by scraping over blotting paper. 
-Air-drying at room temperature followed. 
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